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Abstract 
Inborn errors of metabolism (IEMs) constitute a major class of genetic disorder. Most of 
IEMs  are  transmitted  recessively,  so  consanguinity  has  a  huge  impact  on  disease 
prevalence, particularly in societies like Saudi Arabia, where consanguineous marriage is 
common. Understanding and treatment are very important in genetic diseases, and simple 
models  would  be  helpful.  Thus,  the  feasibility  of  applying  the  fruit  fly,  Drosophila 
melanogaster, as a model for a human renal genetic disease - xanthinuria - was investigated. 
Xanthinuria is a rare human genetic disease, caused by mutations in xanthine oxidase or 
molybdenum cofactor sulphurase; in Drosophila, the homologous genes are rosy (ry) and 
maroon-like (mal), respectively. 
The new Orbitrap technology of mass spectrometry has the potential to determine levels of 
many metabolites simultaneously by exact mass, and a major part of this thesis was to 
investigate  the  utility  of  Orbitrap  technology  in  metabolomics  of  both  wild-type  and 
Drosophila mutant. Repeatable significant differences were identified between ry and wild-
type  flies,  which  recapitulated  painstaking  analytical  biochemical  determinations  of  the 
1950s, but with greater precision. Additionally, completely novel impacts of the ry mutation 
(on pyrimidine metabolism, the urea cycle and osmolyte biosynthesis) were identified. 
As  expected  mal  mutants  showed  more  similar  changes  as  ry,  but  with  widespread 
metabolic perturbations.. 
The online resource, FlyAtlas.org, provides detailed microarray-based expression data for 
multiple tissues and life-stages of Drosophila. Downstream genes, such as urate oxidase, 
are utterly tubule-specific. Accordingly, the utility of Orbitrap technology in elucidating 
tissue-specific metabolomes was also investigated. Additionally, genetic interventions using 
designed RNAi constructs were also made and validated by QPCR and metabolomics. As 
urate is a potent antioxidant, survival of urate oxidase knockdowns was tested in vivo, and a 
significant impact on survival identified. 
An Affymetrix microarray was performed, comparing ry506 mutant flies against wild-type 
and differences were identified in a second experiment, the anti-gout drug allopurinol was 
used to phenocopy the effects of ry. 
Overall, the thesis showed that Orbitrap technology was highly suitable for metabolomic 
analysis of  both  wild-type and mutant  Drosophila,  and  had potential in the  analysis  of 
metabolomes of  single tissues. The possibility of using Orbitrap-based metabolomics in 
human diagnosis is discussed.   IV 
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Chapter 1  Introduction   2 
1.1  Human genetic disease 
Many human diseases are either genetic or have a genetic contribution (Goh et al., 
2007).  Scientists  have  classified  genetic  diseases  into  subcategories,  namely;  multi-
factorial,  chromosomal,  mitochondrial  and  single  gene  disorders.    Multi-factorial 
diseases  are  caused  by  a  mixture  of  environmental  factors  and  mutations  (or 
polymorphisms)  in  multiple  genes.  Some  examples  include  diabetes,  cancer,  and 
obesity.  Because  of  their  nature,  management  of  multifactorial  diseases  is  more 
complicated than the other types. Chromosomal diseases are caused by abnormalities in 
chromosomal number or structure. Usually several or many genes are defective, for 
example  in  Down  syndrome  (trisomy  21).  In  mitochondrial  diseases,  chromosomal 
DNA is intact but rather the mitochondrial DNA carries mutations. Each mitochondrion 
contains 5 to 10 circular pieces of maternally-inherited DNA. An example is Leber’s 
hereditary optic neuropathy (LHON), caused by defects in genes encoding subunits of 
mitochondrial complex I.  The fourth category (single gene disorder) is of particular 
relevance  to  this  thesis.  Single  gene  disorders  are  classified  into  further  groups 
according to mode of inheritance, into autosomal, dominant or recessive, or X-linked 
recessive.  
Diseases  of  dominant  or  mitochondrial  inheritance  are  rarely  found  in  the  neonatal 
period; however, autosomal or X-lined recessive inheritance constitute the major causes 
of disease development (Ellaway et al., 2002).  
As  previously  mentioned,  all  categories  of  genetic  disease  are  found  worldwide; 
however,  the  autosomal  recessive  mode  of  inheritance  is  particularly  favoured  by 
factors (for example, geographical isolation, close tribal affiliations, large family size 
and a culture of consanguineous marriage (Al-Gazali et al., 2006)) that are common in 
the Arab countries (Figure   1-1). 
In Saudi Arabia, for example, certain inborn errors of metabolism (IEM) are far more 
common than in the western world (Table   1-1), and neonatal screening must thus be 
more comprehensive. These unique inborn errors of metabolism are attributed to the 
consanguineous  marriages  practiced  in  the  Arab  world,  especially  in  a  country  like 
Saudi Arabia (Al-Odaib et al., 2003).    3 
 
Figure    1-1.  Distribution  of  consanguineous  (second  cousin  or  closer)  marriages 
worldwide. (Tadmouri et al., 2009). 
 
Table   1-1. Incidence of selected IEMs in Saudi Arabia compared to Europe and USA.  
Personal communication from Dr. Hazem Ghneim: (Ghneim, 2010) 
Disease   KSA  Germany  USA 
PKU  1: 10,528  1:10,400  1: 19,000 
MSUD  1: 6,016  1: 250,000  1: 940,000 
ASL  1: 8,423  1: 250,000  1: 940,000 
ADSL  1: 16,845  No cases  1: 190,000 
HMG  1: 42,113  No cases  No cases 
IVA  1: 42,113  1: 62,500  1: 130,000 
MMA  1: 5,615  1: 125,000  1: 90,000 
PA  1: 42,113  1: 250,000  1:300,000 
BKT  1:84,226  No cases  1: 470,000 
GA-I  1: 42,113  1: 83,300  1:190,000 
MCAD  1:1:12,032  1: 20,800  1:13,000 
3MCC  1:10,528  1: 125,000  1:36,000 
       
Total screened  84,226  250,000  940,000 
Overall incidence  1: 732  1: 2,400  1: 4,300 
PKU;  Phenylketonuria;  MSUD,  Maple  syrup  urine  disease;  ASL,  Argininosuccinate 
lyase; ADSL, Adenylosuccinate Lyase deficiency; HMG, 3-hydroxy-3-methylglutaryl-
coenzyme  A  lyase  deficiency  (also  known  as  HMG-CoA  lyase  deficiency);  IVA,  
Isovaleric Acidemia; MMA, Methylmalonic Acidemia; PA, Propionic Acidemia; BKT, 
Ketothiolase  Deficiency;  GA-I,  Glutaric  Acidemia    Type  1;  MCAD,  Medium-chain 
acyl-coenzyme  A  dehydrogenase  deficiency;  3MCC,  3-methylcrotonyl-coenzyme  A 
carboxylase deficiency.   4 
1.2  Consanguinity in the Arab world 
All humans are heterozygous for several lethal recessive mutations (Consortium, 2010). 
In an outbred genetic system this is not a severe problem. However, in societies with 
high  levels  of  consanguineous  marriage,  the  impact  will  be  severe.  In  Arabic 
communities for example, first or second cousin marriages are very common (Figure 
  1-2).  Consequently,  autosomal  recessive  disorders,  when  present,  are  unsurprisingly 
going to spread in this community. So when parents are both heterozygous for a given 
mutation,  any  child  has  a  25%  likelihood  of  being  affected.  In  Saudi  Arabia,  in 
particular, consanguinity rates are about 50%, of which 60% are at a first-cousin level of 
consanguinity (El Mouzan et al., 2008); furthermore, the Kingdom is considered to have 
one  of  the  highest  birth  rates  in  the  Middle  East  and  North  Africa  (Saadallah  and 
Rashed, 2007).  
 
Figure    1-2. High level of consanguinity among Arabs (Al-Gazali et al., 2006). Two 
Arab family pedigrees, showing intermarriages over several generations. 
So premarital screening programmes for congenital diseases could help significantly to 
limit the incidence and impact of inborn errors of metabolism. In the Jewish population, 
for example, Tay-Sachs disease incidence is ten times higher when compared with other 
races (Myerowitz and Costigan, 1988). Thus, an effective premarital screening program 
(Kaback et  al.,  1993)  and  carrier  detection  (Kronn  et  al.,  1998)  are  very  important 
(Kaback et al., 1993). At the same time, global population screening-based programs are 
also indicated (Kaback, 2000) and (Bach et al., 2001).    5 
Although  premarital  screening  is  an  ideal  solution,  it  is  not  always  practical  or 
economic; so in practice both diagnosis and treatment must also be researched. In order 
to have better understanding, and to improve management of human genetic disorders, 
good  animal  models  are  desirable.  The  requirements  of  such  models  are  discussed 
further in section   1.5. 
 
1.3  Inborn errors of metabolism (IEMs) 
This term was coined by Sir Archibald Garrod, the British physician, to describe a 
group of disorders which result from failure of steps in a biochemical pathway (Houten, 
2009). Inborn errors of metabolism (IEMs) consist of a group of largely monogenic 
disorders. The clinical manifestations appear as results of an enzyme malfunction a few 
examples can be seen in Table   1-2 and Figure   1-3.  
Table   1-2. Possible impacts of inborn errors of metabolism. 
No.  Type of disease  Example  Defective enzyme 
1  Lack of immediate product  GSD-I  G6P  
2  Accumulation of immediate precursor  Galactosemia   GALT 
3  Accumulation of remote precursor  G6PD, PKU  G6PDH, PAH 
4  Failure of feedback inhibition  LNS  HGPRT 
GSD-I;   Glycogen storage disease type I , G6P; Glucose-6-phosphatase, GALT; galactose-1- phosphate 
uridyl transferase, G6PD; Glucose-6-phosphate dehydrogenase deficiency, G6PDH; Glucose-6-phosphate 
dehydrogenase, PKU; Phenylketonuria, PAH; phenylalanine hydroxylase, LNS; Lesch-Nyhan syndrome, 
HGPRT; Hypoxanthine-guanine phosphoribosyltransferase. (Pinksy, 1972).  
 
 
Figure   1-3. Possible impacts of biochemical inhibition (Pinksy, 1972) 
In some inborn errors of metabolism, one or more of these biochemical effects produce 
the final metabolic and pathological picture. For example, in glycogen storage disease 
type I (GSD-I), glycogen is accumulated in different tissues, namely liver, intestinal 
mucosa and kidney. This happens as a remote effect of the absence of G6P, the enzyme   6 
responsible for converting glucose-1-phosphate (G1P) to glucose, as shown (number 3) 
in  Figure    1-3.  Furthermore,  the  same  enzyme  is  also  responsible  from  producing 
glucose from its precursor G3P, which then will be taken into erythrocytes.  Absence of 
the enzyme G6PDH reduces the glucose supply to erythrocytes. This makes the RBCs 
susceptible to haemolytic anaemia; this is represented as number 1 in Figure   1-3. The 
GSD disease pathway is summarized in Figure   1-4. 
 
Figure   1-4. Glycogen storage disease type I. 
Another example of a metabolic disease that arises as a result of accumulation of an 
immediate  precursor  (number  2  in  Figure    1-3),  is  galactosemia.  It  is  an  autosomal 
recessive monogenic metabolic disorder, in which it is not possible to convert galactose 
to glucose because of the absence of galactose-1-phosphate uridyltransferase (GALT). 
If not functioning, accumulation of the immediate precursor, which is Gal-1-P, will be 
obvious. The later, when precipitated within tissues, becomes toxic.  
Also, accumulation of chemical compound as a result of a mutated enzyme sometime 
leads  to  toxicity.  For  example,  in  phenylketonuria,  the  absence  of  phenylalanine 
hydroxylase enzyme leads to accumulation of phenylalanine, which leads to progressive 
mental retardation.  
Metabolic diseases can also result from defects in feedback inhibition Figure   1-5, for 
example  in  Lesch-Nyhan  syndrome.  The  defective  enzyme  is  hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), which is part of the purine salvage pathway. It 
inhibits the biosynthesis of purine from hypoxanthine and guanine. Thus in the absence 
of this inhibition feedback mechanism, excessive uric acid production takes place. This 
can lead to disorders such as gout.  
 
   7 
  
Figure   1-5. Purine biosynthesis -Salvage pathway.    
 
1.3.1  Clinical classification of IEMs 
IEMs can be clinically classified into two main categories; I and II (Martins, 1999). 
Diseases which affect the functional or anatomical system are categorized as category I. 
The  symptoms  are  clearer  and  less  complicated  than  category  II.  Diseases  in  this 
category  usually  affect  a  specific  functional  or  anatomical  system  for  example  the 
endocrine system, immune system or coagulation factors. The symptoms are consistent 
and can easily direct the physician to the defective biochemical pathway. For example, a 
prolonged coagulation time can be a clear indicator of a defect in one of the coagulation 
factors (Martins, 1999).  
On the other hand, category II diseases need careful and thorough investigation. This 
occurs  when  the  affected  metabolic  pathway  is  responsible  for  a  common  job  in 
multiple  different  cells  and  organs.  Diseases  from  this  category  have  wide  clinical 
diversity, and the disease can manifest as either primary or even as secondary effect of a 
metabolic pathway. They can be divided into three groups (Figure 1-6). Disturbance of 
biosynthesis or catabolism constitute the first group.  As a result of this disturbance, 
complex molecules accumulate in some vital sites, such as lysosomes. Thus they are 
called lysosomal disorders, such as Gaucher disease.  Diseases from group two, lead to 
acute or chronic intoxication. Amino acids related-disorders are the main cause of this   8 
group. Examples are: cystinuria, phenylketonuria and Maple syrup urine disease. The 
last,  group three, is related to energy deficiency or  production diseases. This  group 
includes disturbance in the glycolysis and gluconeogenesis defects (Martins, 1999).  
 
Figure   1-6. Clinical classification of IEMs according to Martins, 1999. 
 
1.3.2  Sample selection for diagnosis  
Sample selection varies differently according the metabolic diseases being investigated. 
Samples could be of whole blood, serum, plasma and even urine. Samples are typically 
collected into a collection tube with or without anticoagulant. Recently, Guthrie card 
blood spots for sample collection for inborn errors of metabolism have formed the basis 
for neonatal screening programs.  
The analysis principles and application, later on, varied widely using different detection 
methods;  spectrophotometric,  radiochemical,  or  mass-spectrometric  methods.  These 
detection methods provided a powerful selective screening tool for different inherited 
disorders. However, the above methods for neonatal screening of metabolic disorders 
have  common  disadvantages:  limited  diseases  covered  by  each  method,  high  false-
positive rates, and low specificity or sensitivity (Rashed et al., 1997).  
All  of  those  and  others  disorders  are  nowadays  are  mostly  diagnosed  using  mass 
spectrometry. This method is increasingly updated and new analyzers being discovered 
in order to have better and early diagnosis.  
   9 
1.4  Congenital kidney disease 
Most of the genetic renal diseases in human are related to polycystic kidney disease 
(PKD). The frequency was estimated to be between 1 in 500 and 1 in 1,000 live births 
(Rossetti et al., 2007). It is characterized by accumulation of fluids containing cysts in 
the renal parenchyma. This diseases can be inherited either as dominant or recessive 
autosomal forms. The dominant form of the disease mainly affects adults and is caused 
by defective proteins polycystin 1 or polycystin 2, which are encoded by the PKD1 and 
PKD2  genes respectively  (Figure 1-7). However, the onset of the  recessive form  is 
earlier, either in infancy or in early childhood. It is mainly caused by a defective protein 
called fibrocytin, which is encoded by polycystic kidney and hepatic disease  (PKHD) 
gene (Patel et al., 2009).  
Recently, a study suggested that a cellular organelle, the cilium, has a major role in the 
cause of the PKD in all previously mentioned forms of inheritance (Yoder, 2007). It is 
located in the top of most body cells and it is hair-like structure. It has an important role 
in  cell  proliferation  and  growth  by  transducing  mechanosensory  signals.  Thus,  any 
mutation in the genes which are involved in ciliary function will lead to PKD (Figure 
  1-8). As a result, fluid transport will also affected; and with time, cells become full with 
fluids.  Consequently,  with  gradual  swollen  cells  become  full  with  fluids  and  cyst. 
Finally the whole kidney becomes enlarged and end-stage polycystic diseases arises 
(Patel  et  al.,  2009).  This  particular  disorder  is  an  example  of  one  that  cannot  be 
modelled in Drosophila MT, as Drosophila cells (with the exceptions of sperm and 
some sensory cells) lack primary cilia (Zhang et al., 2004). 
 
Figure   1-7. Structure of PKD 1and 2 after (Stayner and Zhou, 2001).   10 
 
Figure   1-8. Signal transduction by cilium. The function of the cilia is to sense fluid 
movement. PC1, acts as a sensory molecule for fluid that transmits the signal from the 
extracellular  to  PC2,  it  also  produces  sufficient  Ca
2+  influx  to  activate  intracellular 
ryanodine  receptors  (RyR).  This  leading  to  local  increase  in  the  cytosolic  Ca
2+ 
concentration.  This  increase  in  the  cystolic  Ca
2+,  regulates  numerous  molecular 
activities inside the cell that contribute to tissue development (Nauli et al., 2003). 
 
Figure   1-9. Mechanism of progression of PKD. Mutation in PKD 1 & 2 genes which 
encoding the proteins polycystin 1 and 2 leads to abnormalities in tubular fluid secretion 
(A), cell proliferation (B) and tubular basement membranes (C), all of these are give 
rises in renal cysts  (Bennett, 2009). 
 
However, many IEMs also have renal consequences. This can be because the kidney is 
unable  to  clear  sufficient  quantities  of  accumulating  metabolite;  this  can  typically 
precipitate to form concretions called kidney stones, and so block the kidney. The term 
nephrolithiasis refers to stone formation within the kidney itself, and urolithiasis to 
formation within the broader urinary tract; both are possible consequences. An example 
of a congenital inherited disorder which affects the kidneys is Xanthinuria type I. It is an 
autosomal recessive genetic disease where the enzyme xanthine oxidase is absent. This 
enzyme is responsible for converting hypoxanthine to xanthine and then to uric acid. In 
the absence of this enzyme, uric acid production is reduced sharply; and as a result the   11 
substrates, hypoxanthine and xanthine, accumulate. The consequences of this disorder is 
explained in detail in (Dent and Philpot, 1954).  
 
1.5  Animal models for IEMs 
When the human genome project started, it was  thought that answers about human 
hereditary diseases would emerge rapidly (Collins and Mansoura, 2001). However, this 
massive effort mostly produced the sequence of the genome, and did not of itself cure 
any human disease (Sachidanandam et al., 2001). It became clear around a third of all 
genes were entirely novel. How could their function be elucidated?  
So  for  this  reason  the  approach  of  reverse  genetics  has  emerged. Reverse  genetics, 
unlike  forward  genetics,  is  moving  from  the  genotype  to  phenotype  (Lewin,  1986; 
Orkin, 1986; Ruddle, 1982). This means selecting a target gene, then mutating it either 
by knockdown or overexpression, then looking for a phenotype. If a suitable model is 
available,  it  is  possible  to  perform  physiological,  behavioural  or  metabolomic 
experiments.  
 
1.5.1  Mouse 
The mouse is the closest related genetically tractable model to human. It is a mammal, 
and it has defined body organs such as kidneys, heart, lungs and blood. Transgenic lines 
are available in several genomic centres around the world (Dow, 2007). All of these 
characteristics  make  it  a  very  useful  animal  model.  Furthermore,  the  whole  mouse 
genome has been sequenced. However, can all of these features make it the exclusive 
candidate  for  all  research  purposes  including  genetic  studies?  The  answer  is  not 
necessarily “yes”.  
Different models have different advantages depending on the question to be addressed. 
For example, when studying DNA replication, E. coli is the best model, as it reproduces 
every 20 minutes. Thus, it is not surprising that the Nobel prize for the study of DNA 
replication was awarded for work on bacteria (Berg and Lehman, 2007) (Dow, 2007).  
Furthermore, in the genetic study, transgenic technique is crucially important to produce 
mutations of specific genes and to intervene in a tissue-specific way. In mouse, this 
procedure  it  must  be  planned  carefully  in  terms  of  cost  and  time.  Constructing  a 
transgenic mouse needs several years. There is a huge financial outlay that can reach   12 
$100,000 and continuing cost of $10,000 per year to maintain a single line (Dow, 2007). 
Therefore, mouse is not automatically always the best choice as an animal model for 
genetic diseases.  
 
1.5.2  Drosophila  
So  we  argue  that  Drosophila  melanogaster  has  clear advantages  for  studying  some 
human disease genes, applying the reverse genetic approach. This is based on the rich 
information  available  for  researchers.  For  example,  availability  of  the  completed 
Drosophila genome sequence (Adams MD, 2000), the tens of thousands of available 
classical mutants in stock centres, RNAi stocks for nearly every gene (Dietzl et al., 
2007), and  the  FlyAtlas.org  (Chintapalli et al., 2007)  and Homophila (Reiter et al., 
2001)  websites.  The  last  two  web  sites are for  finding  the  best tissue  to  select  for 
studying, and the fly gene homologues to human disease genes respectively. 
In contrast with mouse, a transgenic fruit-fly line can be made for approximately $500 
in only three months and costs $30 per year to maintain (Dow, 2007). Further details of 
Drosophila melanogaster as genetic model are discussed in section (1.6 Droso. As a 
genetic model)   1.6.    
On  the  other  hand,  Drosophila  as  an  invertebrate,  suffers  from  some  limitations 
particularly when trying to model genes involved in specifying specifically vertebrate or 
mammalian  characteristics,  for  example  creating  the  four-chambered  heart,  ducts  of 
mammary glands or bone calcification  diseases (Bier, 2005). 
    
1.5.3  When to choose Drosophila vs. mouse 
Despite all of this, all experimentally animal models are vitally important for research. 
However,  answering  some  specific  biological  questions  which  will  persuade  an 
individual  to  select  one  over  the  other  (Figure    1-10).  For  example,  some  inherited 
metabolic disorders, like Xanthinuria type I, cannot be studied in mouse. The reason 
behind  that  is  the  defective  xanthine  oxidase  enzyme,  which  is  responsible  for 
xanthinuria, also interferes with milk production in mouse (Wu et al., 1994), (Vorbach 
et al., 2002). Thus, mutated female lines are unable to produce the necessary milk to 
their  progenies.  While,  in  Drosophila,  it  is  not  only  easy  to  find  a  mutant,  but   13 
constructing a transgenic line and targeting the effect specifically to Malpighian tubules 
can be done relatively easily. 
 
Figure   1-10. Trade-off between genetic power and biochemical relevance (Dow, 2007). 
 
1.6  Drosophila as a genetic model 
Drosophila melanogaster has drawn scientists’ attention for approximately 100 years, 
since T.H. Morgan described the first ever discovered white mutant. Since that time, 
Drosophila  melanogaster  has  been  extensively  used  to  research  biological  status  in 
health and disease conditions.   
Drosophila, or fruit fly as others call it, is one of the best and powerful genetic animal 
models being used; this is due to its short life cycle, which allows multiple generations 
to be screened quickly. The availability of full Drosophila genome sequence is another 
advantage. The small size of the insect makes it better than many other animal models 
in terms of space in the lab and food requirements.  
At the molecular level, balancers and P-elements provide powerful genetic tools for 
gene  transformation  and  phenotype  selection.    Interfering  RNA  is  also  one  of  the 
important  molecular  genetic  tools  which  helps  in  field  of  functional  genomics, 
specifically reverse genetics. 
 
1.6.1  P-elements  
There are many transposon families naturally found in the Drosophila genome, the best 
known of which is the P-element. They are important because they are extensively used 
in constructing and generating transgenic flies. The P-element normally contains one 
gene, which encodes the transposase enzyme, required for transposition to take place.    14 
This transposable element is autonomous, and is 2.9 kb in size, so they have the ability 
to jump from plasmids into the germlines of the fly. At the same time in the genome, 
smaller incomplete P-elements are present and it is believed that they were generated as 
a  result  of  deletions  in  the  original  P-element.  The  difference  between  the  two  P-
elements apart from the size is that the smaller ones are non-autonomous (Rubin and 
Spradling, 1983). 
 
1.6.2  Enhancer trapping 
Enhancer trapping provides a powerful method to map patterns of gene expression in a 
fly or embryo. It also allows the identification of genes that are expressed in a particular 
pattern (O'Hare and Rubin, 1983) (Brand and Perrimon, 1993).  
In most engineered P-elements, the transposase gene is substituted with a genetic cargo 
of  choice,  together  with  a  reporter  gene,  mini-white,  downstream  or  a  ubiquitous 
promoter,  allowing  the  presence  of  a  P-element  to  be  scored  visually  in  a  w
- 
background. So this line has a non-motile or trapped P-element. These flies are then 
crossed  with  another  line  carrying  germline-expressed  transposase,  mostly  from  the 
∆2,3 line which contains an incompletely excised (and thus immotile) P-element. So in 
such a cross, the P-element is going to jump only in the germline of the progeny. In 
subsequent  generations,  flies  with  red  eyed  colour  are  selected  for  further 
experimentation (Guo, 1996).    15 
 
Figure   1-11 Schematic diagram of first generation enhancer trap. A) The main features of the Drosophila 
transposons. B) Transposon could be inserted between the gene regulatory elements and a gene. C)The 
gene specific regulatory elements can drive the expression of LacZ.  
 
 
1.6.3  GAL4-UAS system 
Using P-elements with a marker gene like white, the transgenes are introduced into the 
flies with the help of a helper plasmid encoding transposase into w
- flies to visibly 
identify transgenesis. However, some random insertions show lethality when they were 
made homozygous. This is because of the insertion of the P-element into an essential 
place  in  the  genome. 
In  this  case  these  flies  will  be  made  heterozygous  using  the  help  of  balancer 
chromosomes that do not allow recombination. 
 
GAL4 is a transcription factor that is naturally found in yeast ((O'Kane and Gehring, 
1987)). It has been applied to be used in activating the gene transcription in Drosophila. 
By  itself,  GAL4  has  no  target  gene  in  the  Drosophila  but  will  specifically  drive 
expression of the transgenes under the control of upstream activating sequence (UAS). 
Both GAL4 and UAS comes in a bipatriate system developed by brand and perrimon   16 
(1993).  The  GAL4  is  either  randomly  inserted  in  the  genome  of  the  fly  or  fused 
downstream  of  a  promoter  sequence  which  constitute  one  component.  The  other 
component is the transgene of interest cloned under the control of UAS. 
 
When these two systems or in other words flies are mated they will give rise to the 
progeny that have both components. This in turn activate the transgene under the control 
of UAS by the GAL4-specific expression manner. As the GAL4 expression depend on 
the upstream elements it was inserted or fused with, this system is useful in elucidating 
tissue- and cell-specific functions. For example, GAL4 can be placed under the control 
of  the  urate  oxidase  gene  promoter  as  this  gene  is  expressed  exclusively  in  the 
Malpighian  tubules,  the  Uro-GAL4  line  drives  transgene  expression  with  exquisite 
precision  in these tissues (Terhzaz et al., 2010).  This is not as easy as it sounds, it have 
some problems and do not always work because some gene’s promoters not necessarily 
at the start of the gene    , so enhancer trap do not always reflect expression of the gene. 
Another possibility, inserts may unintentntially disrupt a gene. Also, RNAi may not be 
effective, or may have off-target effects.  
 
 
Figure   1-12. The GAL4 UAS system. This diagram showing the GAL4-UAS system in 
gene expression. The expressed gene in  this case is an inverted  repeat that  gives a 
hairpin-like dsRNA which silences a targeted gene (Brand and Perrimon, 1993).  
 
1.6.4  Balancer chromosomes 
   17 
As recessive lethal mutations must be kept alive by providing a functional gene in trans, 
in most species it is necessary to select for the mutant gene in every generation, so 
adding  hugely  to  the  cost  and  complexity  of  genetic  research.  A  key  advantage  of 
Drosophila is the relative ease of keeping recessive lethal alleles alive, so allowing large 
stock  centres  to  be  built.  Here  comes  the  usefulness  of  balancer  chromosomes.  A 
balancer is a region which prevents recombination between homologous chromosomes 
during meiosis. This feature is gained from the presence of an inverted region or a series 
of inversions on it. 
 
Typically,  balancer  chromosomes  in  the  Drosophila  melanogaster  contain  three 
important  features:  (i)  multiple  inversions  to  suppress  the  recovery  of  viable 
recombination  products over  the  length  of  the  chromosome;  (ii)  a  dominant  visible 
phenotype  that  enables  the  inheritance  of  the  chromosome  to  be  tracked  easily  in 
progenies; and (iii) a recessive lethal mutation that eliminates the homozygous balancer 
from the population of breeding flies. 
 
The inverted regions entirely prevent crossover. The markers also make it very clear 
where the balancer is, even if it is visually indistinguishable from wild-type. This makes 
genetic crosses with balancers totally predictable. 
 
Even though mutations are often detrimental, if left in a stock of flies with a wild-type 
counterpart, after a number of generations they will be lost. Some can be kept on their 
own, if they are viable enough, but some mutations are poorly viable, or totally lethal. 
In this case, in order for the stock of flies to persist, a wild-type copy of the gene must 
be present to rescue the lethality. If present on a wild-type chromosome, the mutation 
will be lost from the stock as the wild-type chromosome takes over. However, if the 
wild-type  copy  is  present  on  a  balancer,  the  balancer  cannot  take  over  as  they  are 
homozygous lethal.  
 
In the case of a recessive lethal mutation, only files containing the lethal chromosome 
and the balancer can survive. 
   18 
1.6.5  Heritable RNAi 
The complete sequencing of Drosophila melanogaster has encouraged researchers to 
investigate the function of each gene (Adams MD, 2000).  The reverse genetic approach 
is  considered  as  the  best  choice  of  elucidating  gene  function  by  generating  loss  of 
function phenotype. To cause a gene malfunction, RNA interference (RNAi) technique 
may be the best choice,  because it  tends to produce viable  hypomorph,  rather than 
(possibly lethal) nulls. This then allows physiological studies. Double-stranded RNAi is 
widely used to inactivate genes of interest and provide a powerful tool for gene function 
studies (Fire et al., 1998).  
However, gene silencing by injected dsRNA is transient and consequently is not going 
to be heritable. So heritable dsRNA is highly desirable as an experimental tool. So more 
advanced methods were developed to construct plasmids that are able to express dsRNA 
into transgenic fly. Furthermore, those plasmids or vectors after transcription produce 
inverted repeats or hairpin RNA loops that are substrates for the RISC complex, so 
generating dsRNA (Kennerdell and Carthew, 2000).  
However, cloning long inverted repeats into a plasmid is known to be problematic. This 
is because of the internal deletions that happened as a result of bacterial culturing. To 
solve this problem, a short linker (like a functional intron) must be introduced between 
the repeated sequence (Lee and Carthew, 2003).  
A contemporary vector for the efficient construction of RNAi lines is pRISE (Kondo et 
al., 2006), with the characteristic repeat of the Gateway recombination cassette (Akbari 
et al., 2009) and (Boy et al., 2010). This vector enables the gene silencing effect to be 
achieved more easily and with great efficiency (Kondo et al., 2006).  Further details are 
found in (2.7.6 The pRISE vector for RNAi ) 
 
1.6.6  Malpighian tubules 
Renal function in Drosophila is performed by the Malpighian tubules. Part of this thesis 
is devoted to testing their suitability as a model of mammalian renal dysfunction.    
 
1.6.6.1 History 
The tubules are named after Marcelo Malpighi, who was a physician of the Pope, 500 
years ago. Beside his work as comparative anatomist, he was a pioneer in the use of   19 
microscopy. This interest allowed him to apply his skills in microscopy to investigate 
insect  anatomy.  As  a  result  of  this  interest  he  discovered  the  Malpighian  tubules. 
However, it was not demonstrated until the 20th century, that they can produce urine 
(reviewed in Dow and Davies, 2003). Since then, tubules have been extensively studied 
for their excretory and osmoregulatory functions. 
 
1.6.6.2 The Drosophila Malpighian tubules 
The Malpighian tubules are simple, cylinders, closed at one end. They connect to the 
junction  of  mid-gut  and  hindgut  by  the  ureters.  They  are  two  pairs,  anterior  and 
posterior and each contribute equally to the function  (Figure   1-13) (Dow and Davies, 
2003).  They  are  among  the  smallest  insects  tubules  to  be  studied.  They  measure 
approximately 2 mm long, 35 µm in diameter and consist of nearly 150 cells. Each 
tubule  is  divided  into  multiple  segments,  namely;  initial,  transitional  and  main 
segments, and lower tubule and upper and lower ureter (Sozen et al., 1997).  
 
Each  segment  in  this  simple  epithelial  tube  does  a  specialised  function.  The  initial 
segment of the anterior tubule absorbs calcium and stores it. The main segment is a 
secretory segment heavily involved in fluid transport and other key funcitons of redox 
homeostasis. The lower tubule involved in the reabsorption of the fluid. The ureter joins 
two tubules and opens up into the hindgut.  
 
The main segment of the tubules is composed of two cell types; the columnar epithelial 
principal cells and the star-shaped stellate cells. The principal cells have deep basal 
infoldings  and  long  apical  microvilli,  and  are  more  abundant  than  the  stellate  cells  
(Cabrero et al., 2004). The stellate cells are comparatively small and thin, with shallow 
basal infoldings and short apical microvilli (Wessing, 1978; Wessing and Eichelberg, 
1978).  Enhancer  trapping  has  been  used  to  investigate  the  Malpighian  tubule’s 
morphology with great insights identifying a distinct lower segment in both the anterior 
and posterior tubules. Bar-shaped cells and tiny cells in the tubule were discovered by 
Sozen et al., in 1997. The bar-shaped cells are thought to be the equivalent of stellate 
cells in the initial segment, and the tiny cells may be stem cells (Sozen et al., 1997).   20 
1.6.6.3 Physiology 
The Malpighian tubules perform various  physiological roles in Drosophila, from the 
expected renal and hepatic roles, to a surprising role in immune response as well as 
osmoregulation.  Active cation transport by the tubules is described by the Wieczorek 
model (Wieczorek et al., 1991). The model suggests that the principal cells use the 
apical  proton-pumping  activity  of  the  Vacuolar  ATPase  (V-ATPase)  to  build  a 
favourable transport gradient. Apical alkali metal-proton exchangers are then able to 
drive potassium into the tubule lumen, with water following the potassium due to the 
osmotic gradient. The Wieczorek model seems to fit the tubule experimental data in 
Drosophila, as V-ATPase inhibitors prevent fluid secretion (Dow et al., 1994), and the 
V-ATPase subunits are highly enriched and expressed in the principal cells (Wang et 
al., 2004). The principal cells are also involved in the active transport of cations and 
anions (O'Donnell et al., 1996; Torrie et al., 2004).  
The stellate cells appear to be the site of transcellular chloride shunt and therefore water 
movement  (Dow  and  Davies,  2003).  Chloride  shunt  is  controlled  by  the  hormone 
Drosokinin and the second messenger intracellular Ca2+, which increase transcellular 
conductance through chloride channels (O'Donnell et al., 1998). 
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Figure    1-13.  Regional  differentiation  of  adult  Drosophila  Malpighian  tubules.  After 
(Wessing and Eichelberg, 1978)  and (Singh et al., 2007). 
 
1.7  The human kidney 
 
1.7.1  Introduction  
The kidneys play a dominant role in regulating the composition and volume of the 
extracellular  ﬂuid  (ECF).  They  normally  maintain  a  stable  internal  environment  by 
generating the urine and excreting many solutes. These substances include not only 
waste products and foreign compounds, but also many useful substances that are present 
in excess as a result of eating, drinking, or metabolism.  
 
The kidneys perform a variety of important functions: 
1.  They  regulate  the  osmotic  pressure  (osmolality)  of  the  body  fluids  by  excreting 
osmotically dilute or concentrated urine, as appropriate, under hormonal control.   
 
2. They regulate the concentrations of numerous ions in blood plasma, including Na
+, 
K
+, Ca
2+, Mg
2+, Cl
- , bicarbonate (HCO3
−), phosphate, and sulphate. 
 
3. They play an  essential role in acid–base  balance, by excreting H
+ when there  is 
excess acid, or HCO3
− when there is excess base, to protect against acidosis or alkalosis, 
respectively. 
 
4. They regulate the volume of the ECF by controlling Na
+ and water excretion. 
5. They help regulate arterial blood pressure by adjusting Na
+ excretion and producing 
various substances (e.g., renin) that can affect blood pressure. 
 
6. They eliminate the waste products of metabolism, including urea (the main nitrogen-
containing end product of protein metabolism in humans), uric acid (an end product of 
purine metabolism), and creatinine (an end product of muscle metabolism). 
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7. They remove many drugs (e.g., penicillin) and foreign or toxic compounds. 
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1.7.2  Functional renal anatomy 
Each kidney in an adult weighs about 150 g and is roughly the size of a ﬁst. If the 
kidney is sectioned, two regions are seen: an outer part, called the cortex (1), and an 
inner part, called the medulla (2).  
All the glomeruli, convoluted tubules, and cortical collecting ducts are located in the 
cortex.  
The medulla has  a striated appearance that  results from the parallel arrangement  of 
loops of Henle, medullary collecting ducts, and blood vessels of the medulla.  
The medulla can be further subdivided into an outer medulla (a), which is closer to the 
cortex, and an inner medulla (b). 
 
 
 
Figure  1-14 Mammalian kidney. 
(Modiﬁed from Smith HW. Principles of Renal Physiology. New York: Oxford University Press, 
1956.   24 
1.7.3  The nephron is the basic unit of renal  structure and function 
 
Each human kidney contains about one million nephrons, each of which consists of a 
renal corpuscle (1) and a renal tubule (2). The renal corpuscle consists of a tuft of 
capillaries,  the  glomerulus  (a),  surrounded  by  Bowman’s  capsule  (b).    The  renal 
tubule is divided into several segments. The part of the tubule nearest the glomerulus is 
the proximal tubule (2a). This is subdivided into a proximal convoluted tubule (2a1) 
and proximal straight tubule (2a2). The straight portion heads toward the medulla, 
away from  the  surface of  the  kidney. The loop  of Henle includes (3) the proximal 
straight tubule, thin limb, and thick ascending limb. Connecting tubules (4) connect the 
next segment, the short distal convoluted tubule, to the collecting duct system. Several 
nephrons drain into a cortical collecting duct, which passes into an outer medullary 
collecting duct. In the inner medulla, inner medullary collecting ducts unite to form 
large papillary ducts. 
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Figure   1-15 Components of the nephron and the collecting duct system. (Modiﬁed from 
Kriz  W,  Bankir  L.  A  standard  nomenclature  for  structures  of  the  kidney.  Am  J  Physiol 
1988;254:F1–F8.) 
 
The glomerulus of the nephron (Figure   1-16a) in the mammalian kidney is responsible 
for blood filtration.   The filtration barrier is constituted by specialized epithelial cells 
called podocytes, which surround the glomerular capillaries. These cells are paved on a 
basement membrane, and arranged closely to each other with 30-50nm spaces or slits 
(Figure    1-16b).    Theses  slits  together  with  the  basement  membrane  control  and 
constitute  the  filtration  barrier.  Disruption  of  this  barrier  leads  to  leakage  of  blood 
proteins into the urinary space (proteinuria), and is diagnostic of kidney dysfunction. 
Insects’  excretory  systems  lack  nephrons;  however,  nephron-like  components  such 
filtration cells (nephrocytes) and ducts (MT) are present (Figure   1-16c). On the other 
side, insect nephrocytes (Figure   1-16d), which absorb potentially harmful substances. It 
has been found by  (Weavers et al., 2009), infoldings in the plasma membranes forming 
small cavities. Similar to the situation in podocytes, the cavities’ entrances are narrow 
gaps, 30 nm width, that are bridged by cell surface proteins forming the nephrocyte 
diaphragm.  The  nephrocyte  diaphragm  and  basement  membrane  both  behave  as  a 
selectively permeable barrier (Figure   1-16d), and filtrate is endocytosed from the sides   26 
of the lacunae. Significantly, the anatomies of the nephrocyte and podocyte filtration 
barriers are remarkably similar, because both contain neprhrin, the characteristic protein 
of the slit diaphragm. Weavers et al. 2009 have thus postulated that the insect excretory 
system is an intermediate step towards the formation of  a glomerular filtration system. 
It  is  not  that  the  insect  system  is  more  primitive  (both  insects  and  vertebrates  are 
successful classes of organism); it is that the small size of insects has rendered the 
formation of an elaborate vascular system, and a glomerular kidney, unnecessary. 
 
 
Figure   1-16  The  glomerular  and  nephrocyte  filteration  barriers.  a–d,  Diagram  of  the 
vertebrate  nephron  (a),  glomerular  filtration  barrier  (b),  insect  excretory  system  (c) 
nephrocyte filtration barrier (d). bm, basement membrane; nd, nephrocyte diaphragm; 
sd, slit diaphragm.  
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1.8  Metabolomics 
1.8.1  Introduction 
Clearly, understanding the impacts of inborn errors of metabolism invites the study of 
the broader metabolism of an organism or tissue. As a global technique, metabolomics 
is  a  new  emerging  part  of  the  ‘omics’  approach  (Dettmer  and  Hammock,  2004). 
Genomics deals with genes, transcriptomics deals with mRNA and proteomics deals 
with the proteins. The crucial advantage of the metabolome is that it can potentially 
provide a ‘fingerprint’ of the entire metabolic status of a cell or tissue and so help in 
closing  the  gap  between  genotype  and  phenotype.  Metabolomics  is  the  “systematic 
study of the unique chemical fingerprints that specific cellular processes leave behind - 
specifically, the study of their small-molecule metabolite profiles” (Daviss, 2005).  
 
Figure   1-17. The 'Omics' Cascade.  (Dettmer et al., 2007) 
 
The metabolome can be considered as the end-point of the OMICS cascade (Figure 
  1-17). In view of its importance, metabolomics has rapidly developed in the last few 
years (Figure   1-18) (Oldiges et al., 2007).  
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Increasing number of publication in  metabolomics 
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Figure    1-18.  This  graph    shows  the  rapid  increase  in  publications  in  the  field  of 
metabolomics (Oldiges et al., 2007).  
 
1.8.2  The basic MS principle 
Metabolomic analysis can potentially be performed with almost any analytical 
technique, but the power of mass spectroscopy (MS), means that this has rapidly 
become the standard for such studies. The basic principle of MS is thus covered here 
Figure   1-19. 
 
Figure   1-19 Operation of a spectrometer mass analyzer (Revesz et al., 2002). 
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Consider a sample contains two metabolites A and B that are introduced into the high 
vacuum of an MS instrument on a “target”. Firstly, in the ion source, the sample is 
converted from the liquid status into gas status i.e. vaporized, for example by heat or 
laser.  Then, with the ionization step, each metabolite becomes electrically charged, and 
may be fragmented into smaller charged molecules.  
In the analyser part of the spectrometer, electrical and magnetic fields are applied as 
each samples passes through. When an electrical or magnetic current is applied, each 
metabolite behaves differently from other metabolites according to its mass to charge 
(m/z) ratio. Thus the electrical force accelerates the particles through the machine, and 
particles and  the  magnetic field  will  affect  the  ion  direction.  Finally,  the  arrival  of 
charged  molecules  is  measured  in  a  detector.  There  is  thus  the  potential  to  resolve 
multiple molecular species from a single specimen. 
Metabolomic experiments, utilizing MS, were first performed in 1971 (Horning and 
Horning, 1971) and (Mamer et al., 1971). Although the first papers did not mention the 
word  “metabolomics”,  more  than  250  metabolites    were  measured  in  a  single 
experiment in the same year  (Pauling et al., 1971). However, the term metabolomics 
started to appear in the literature after Oliver and colleagues conducted a systematic 
functional analysis of the yeast genome (Oliver et al., 1998).  
Metabolomics can be applied in many research and diagnostics fields and the analytical 
samples vary widely depending on the biological question researchers want to address.  
The  samples  studied  in  metabolomics  include  dried  blood  specimens  (Chace  et  al., 
2003),  serum (Brindle et al., 2002), urine (Salek et al., 2007), wide range of fluids, like 
seminal fluid, amniotic fluid, cerebrospinal fluid (Lindon et al., 2006), tissue extracts 
(Kamleh et al., 2008) or microorganisms (Mashego et al., 2007).  
In the field of agriculture, plants have been modified genetically or environmentally in 
order to improve diet, health and nutrition. This leads to alteration in the genomic and 
metabolomic levels, thus newly produced metabolites should precisely and effectively 
monitored by metabolomic study (Fiehn et al., 2001). 
In  the  pharmaceutical field, metabolomics  has been used in  the application of  drug 
discovery, development, toxicology and pathophysiology of diseases (Wishart, 2008).  
In  bacteriology,  the  application  of  metabolomics  focuses  on  the  understanding  of 
genetics and physiology of the bacterium to improve human health, drug effectiveness 
and resistance and bacterial effects on the environmental health (Mashego et al., 2007).    30 
Also these bacteria could be engineered to ordered them to make new compounds or 
enzymes  that  are  not  normally  produced  by  them,  this  is  an  emerging  field  called 
synthetic biology. It is a relatively new field of study, combining biological science and 
engineering. A good example for this approach is the bacteria that produce different 
light in specific  status and so called the Escherichia coli that can see light (Levskaya et 
al., 2005). 
In the diagnosis of inborn errors of metabolism, metabolic analysis was used many 
years ago by Sir Archibald Garrod (Lanpher et al., 2006). With the recent technological 
advances,  metabolomic  profiling  has  long  been  applied  with  high  success  in  all 
previously mentioned fields. However, issues like accuracy and reproducibility are still 
waiting to be addressed. 
Metabolic analysis was first used for simple detection of changes in black urine from 
alkaptonuric patients (Houten 2009). After this and after further advances in sensitivity, 
it  was  used  to  detect  more  smaller  and  specific  metabolites,  such  as  glucose, from 
different human biological fluids like serum and plasma samples.  
As more metabolites are studied simultaneously, it becomes harder to separate them and 
resolve them from each other, so it was important to find a method for separating those 
metabolites.  So  liquid  chromatography  was  developed  and  coupled  to  a  range  of 
analyzers  in  order  to  improve  separation  and  detection.  Coupling  the  liquid 
chromatographic column will be explained in detailed later. 
 
1.8.3  Technologies available for metabolomic studies  
1.8.3.1 Gas chromatography MS (GC-MS) 
GC-MS  is  a  common  type  of  chromatographic  detection,  applied  in  the  field  of 
analytical chemistry, for volatile metabolites. The basic principle of the technique relies 
on  the  mobile  phase  which  in  this  case  is  the  gas  to  carry  the  molecules  over  the 
stationary phase, which is the inner side of the glass tube. Helium or nitrogen are the 
most widely gases used in this method. The inner side of the column is sometimes 
coated with different materials that interact differently with other metabolites and may 
delay or increase the retention time for molecules. Molecules are typically ionised by 
electrospray ionization (ESI). 
   31 
1.8.3.2 Liquid chromatography MS (LC-MS) 
This is another technique for metabolic detection branching from analytical chemistry. 
Separation  principle  is  based  on  the  physical  and  molecular  mass  properties  of  the 
molecules being separated. Interfacing the output of this liquid chromatographic column 
with the MS is usually accomplished by ESI.   
LC-MS has been considered as a powerful metabolic technique, and is widely used in 
field of analytical chemistry. It offers a reasonable extent of sensitivity and specificity 
for targeted detection molecules.  
In the LC-MS the diameter of the separation column, usually 1 mm and the flow rate are 
both small. This is considered a limitation of this technique, as it thus permits only a 
limited injection into the MS instrument, and so limits sensitivity.  
 
1.8.3.3 Fourier transform ion cyclotron resonance (FT-ICR) 
FT-ICR offers the best resolving power and the best accuracy among all MS analysers 
(McLuckey and Wells, 2001). In this type of detection, the principle is based on the 
measuring the frequency of oscillating ions in a spindle-shaped detector. The Orbitrap 
mass analyser is one of the best of this type, with the potential to measure mass to better 
than 1 part in 1 million, and will be used extensively in this thesis.   
 
1.8.4  Mass spectrometry technology  
1.8.4.1 Ion generation, positive mode electrospray ionization (PIESI)  
Samples are to be analysed should be first dissolved into a polar volatile solvent before 
it can be transported into a high potential electrospray needle. Due to the very high 
voltage inside the needle, all molecules become charged with the addition of 1 H
+ ion or 
more; to calculate these adducts, calculations such as those  shown in Table   1-3 are 
used. This additive has the mass of 1.0073, thus adding this mass number to the total 
mass  expected  to  each  molecular  species.  At  the  point  where  the  liquid  leaves  the 
needle, a cone shape is formed which is called Taylor cone as shown in Figure   1-20 . 
This Taylor cone slowly bursts into smaller fine sprays due to solvent evaporations 
under the effect of heat. These smaller sprays droplets, which contain metabolites shrink 
until they reach the gas phase, with ions moving individually through the mass analyser.    32 
Positive ion electrospray ionisation (PIESI) is the most common ionisation technique, 
and generally works well for both low and high molecular weights molecules. Although 
the technique has been improving and developing since its discovery, the basic working 
principles have remained the same. 
The PIESI is the widely method applied and is considered very sensitive for compounds 
separation containing an amine group, amides, etc. On the contrary, PIESI does not 
work well for polar acids such as Krebs cycle acids or for neutral sugars. 
 
 
Figure   1-20. Taylor cone. In this diagram a spraying needle tip is shown. Due to the 
high voltage all molecules are charged. As the sprayed liquid leaving the needle and at 
just where the liquid leaves the needle a cone shape is formed which is called Taylor 
cone (Gates, 2004).  
 
1.8.4.2 Ion generation, negative mode electrospray ionization (NIESI)  
On  the  opposite  to  PIESI,  negative  ion  electrospray  ionisation  (NIESI)  is  generally 
somewhat less sensitive than PIESI and consequently detects fewer compounds. The 
main groups of compounds which can be detected exclusively in negative ion mode are 
neutral sugars and organic acids such as the Krebs cycle acids. Table   1-3 is useful table 
to help in accurately deduce metabolites.   33 
Table    1-3.  Expected  adducts  generated  as  a  result  of  ionization.  Where  M  =  any 
metabolites detected  (Kind, 2010). 
Ion name  Ion mass 
C
h
a
r
g
e
 
 
Ion name  Ion mass 
C
h
a
r
g
e
 
1. Positive ion mode    2. Negative ion mode 
M+3H   M/3 + 1.0073  3+    M-3H   M/3 - 1.0073  3- 
M+2H+Na   M/3 + 8.3346  3+    M-2H   M/2 - 1.0073  2- 
M+H+2Na   M/3 + 15.7662  3+    M-H2O-H  M- 19.0184  1- 
M+3Na   M/3 + 22.9893  3+    M-H   M - 1.0073  1- 
M+2H   M/2 + 1.0073  2+    M+Na-2H   M + 20.9747  1- 
M+H+NH4   M/2 + 9.5206  2+    M+Cl   M + 34.9694  1- 
M+H+Na   M/2 + 11.9983  2+    M+K-2H   M + 36.9486  1- 
M+H+K   M/2 + 19.9852  2+    M+FA-H   M + 44.9982  1- 
M+ACN+2H  M/2 + 21.5205  2+    M+Hac-H   M + 59.0139  1- 
M+2Na   M/2 + 22.9892  2+    M+Br   M + 78.91889  1- 
M+2ACN+2H  M/2 + 42.0338  2+    M+TFA-H   M + 112.9856  1- 
M+3ACN+2H  M/2 + 62.5471  2+    2M-H   2M - 1.0073  1- 
M+H   M + 1.0073  1+    2M+FA-H   2M + 44.9982  1- 
M+NH4   M + 18.0338  1+    2M+Hac-H   2M + 59.014  1- 
M+Na   M + 22.9892  1+    3M-H   3M - 1.0073  1- 
M+CH3OH+H   M + 33.0335  1+         
M+K   M + 38.9632  1+         
M+ACN+H   M + 42.0338  1+         
M+2Na-H   M + 44.9712  1+         
M+Propanol+H  M + 61.0653  1+         
M+ACN+Na   M + 64.0158  1+         
M+2K-H   M + 76.9190  1+         
M+DMSO+H   M + 79.0212  1+         
M+2ACN+H   M + 83.0604  1+         
2M+H   2M + 1.0073  1+         
2M+NH4   2M + 18.0338  1+         
2M+Na   2M + 22.9892  1+         
2M+K   2M + 38.9632  1+         
2M+ACN+H   2M + 42.0338  1+         
2M+ACN+Na   2M + 64.0158  1+         
1.8.5  Ion separation methods 
A very wide range of mass analysers can be used to separate the ions generated by ESI. 
In this thesis particular attention will be given to the Orbitrap analyser.  
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1.8.5.1 The Orbitrap mass spectrometer 
The Orbitrap analyser was invented in 2005 by Makarov and then was available in the 
markets by Thermo Electron Corporation  (Hu et al., 2005). The detection principle is 
based on the trapping  the injected  ions into the trap between the inner spindle-like 
electrode and the outer barrel like electrode Figure   1-21 (Bateman et al., 2009).  
The analyser is consists of an outer barrel-like shape electrode divided into two exact 
halves, and an inner spindle-like shape electrode.   
As group of ions enters the trap, the electric field is switched ON and then attracts the 
ions between the barrel-like and the spindle-like central electrodes, then the ions will 
start moving in a circular movement around the spindle-like electrode. This shape of the 
electrodes give advantages of giving a modified electric field which permits to the ions 
to move into angular, radial and axial oscillation movements regularly (Makarov et al., 
2006).  The frequency of this oscillation movement is proportional to the mass over 
charge  ratio  (m/z).  Then  the  readings  are  output  as  chromatograms  (electrographs) 
(Breitling et al., 2006; Makarov et al., 2006). 
 
Figure   1-21. The LTQ-Orbitrap working mechanism. A, transfer octopole; B, curved 
RF-only quadrupole (c-trap); C, gate electrode; D, trap electrode; E; ion optics, F; inner 
orbitrap electrode (centeral electrode), G; outer orbitrap electrode. In ESI, the analytes 
is pumped into the source in solution via the eluent flow LC that interfaced with mass 
spectrometer.  The  analyte  solution  flowing  through  the  electrospray  needle  to  form 
droplets. These droplets travel between needle tip and counter electrode to evaporate 
solvents before sample injected into mass spectrometer. When a high voltage is applied, 
Taylor cone is produced and spray charged droplet is formed. Then charged ions pass 
through stages of differential pumping through RF only multipoles into a curved RF 
only quadruple then to the C-trap. Ions in the C-trap accumulate and their energy is 
dampened using nitrogen gas. They are then injected by a curved lens system which 
provides  further  areas  of  differential  pumping  before  being  passed  into  Orbitrap 
detector. Then mass spectra are acquired by image current detection. The Orbitrap mass 
spectrometer consists of : ESI ionization source, (I) heated capillary, followed by (II)   35 
multi-pole focusing devices, (III) a gating lens, followed by a focusing octapole, linear 
ion  trap  (LTQ)  following  by  focusing  multi-pole  (IV)  which  leads  to  new  bent 
quadrupole (C-trap), and finally the Orbitrap mass analyser (Makarov et al., 2006).  
 
Because  of  this  working  principle,  this  Orbitrap  analyser  ensures  vary  high  mass 
accuracy; with internal lock mass, it can resolve to better than 2 parts in 1,000,000. This 
makes it the most precise mass spectrometry currently available (Olsen et al., 2005).    
The  Orbitrap  has  several  advantages,  when  compared  with  other  analysers,  as  it  is 
relatively  cheaper  and  with  lower  maintenance  cost.  It  also,  does  not  have  a  huge 
magnetic sector and consequently a complicated cooling system is not required.  
To explain this high mass accuracy, molecules having the same integer mass but with 
different molecular formulae will have  slightly different exact masses. For example 
ethanol (C2H4O) and methyl hydrazine (CH4N2) both have the same mass of 44, but the 
exact masses are 44.02622 and 44.03744 respectively (Figure 1-19). The Orbitrap, but 
not the other analysers, has sufficient precision to differentiate between them (Breitling 
et al., 2006). 
 
     Figure    1-22.  Ultra-high  accuracy  and  resolution  are  required  to  discriminate 
metabolites of near-identical mass. The masses of metabolite A (blue) and metabolite B 
(green) differ by only 0.004 Da (1 ppm). This is one of the most extreme cases observed 
in small-molecule databases. No other organic chemical has a similar mass; therefore, 
accurate mass measurement enables unambiguous assignment of a molecular formula. If 
the Orbitrap analyzer was set at high enough resolution (around 1 000 000 full-width 
half-maximum resolution), the two compounds could even be distinguished in the same 
mixture.   36 
 
 
1.8.6  Further separation methods 
In  order  to  have  accurate  metabolite  detection,  and  isomers  to  be  accurately 
distinguished, an efficient chromatographic separation is highly recommended. 
Generally, a chromatographic step minimizes the risk of ion suppression effects and can 
help distinguish between isomers. Thus, an extra separation method at the beginning of 
the process, can decrease of interfering compounds, and can help in identifying a larger 
number of metabolites. 
 
1.8.6.1 Hydrophilic Interaction Chromatography (HILIC) 
HILIC provides an excellent separation chromatographic method. On the zwitterionic 
(ZIC-HILIC) column, the water layer associated with column surface acts as a pseudo 
stationary phase Figure   1-23. The zwitterion coating in theory is charge neutral thus 
minimising ion exchange interactions with the analyte and the chain length separating 
the positive and negative charges of the ZICHILIC column is optimised so that the 
charges on the column surface can fold round and interact to neutralise each other. The 
column is used with a high organic solvent content in the mobile phase which favours 
ionisation under ESI conditions (Watson, 2010) and (Alpert, 1990). 
 
 
Figure   1-23 The chemistry of the ZIC-HILIC column. A) HILIC is a high-performance 
liquid  chromatographic  (HPLC)  technique  for  separation  of  polar  and  hydrophilic 
compounds. It is based on the HILIC retention, which is based on partitioning of the   37 
injected analyte solute molecules between the mobile phase eluent and a water-enriched 
layer in the hydrophilic HILIC stationary phase. The more hydrophilic the analyte is, 
the more is the partitioning equilibrium shifted towards the immobilized water layer in 
the stationary phase, thus the more is the analyte retained. The hydrophilic surface holds 
water when exposed to mixtures of organic solvent and water. Compounds such as, 
acids, bases, ions, sugars, and other charged and neutral hydrophilic compounds that are 
annoying to separate in ordinary separation techniques. They are much easier to be 
separated in HILIC due to the different separation selectivity. Some compounds are 
possible to separate by more than one chromatographic technique, and HILIC does them 
all.  B) HILIC partly overlap with RPLC (reverse phase liquid chromatography), NPLC 
(Normal Phase Liquid Chromatography) and IC (Ion Chromatography) and it fills the 
gap  in  the  chromatographic  toolbox  and  perfectly  fits  in-between  other  separation 
techniques (Appelblad et al., 2008).   
 
 
Figure   1-24 Comparison of advantages and disadvantages for different MS techniques  
(Shulaev, 2006).   38 
1.8.7   Data Processing  
The greatest amount of time in metabolomic experiments is devoted to data processing.  
 
1.8.7.1 Sieve Software 
Most commercial data processing software aims to plot extracted ion chromatograms 
across  the  full  scan  range  of  the  mass  spectrometer.  In  order  to  do  this  the  Sieve 
software is widely used. Sieve  is a software developed by a collaboration between Vast 
Scientific  and  Thermo  Scientific  (Vast_Scientific_Inc.,  2010).  It  takes  the  data 
generated by the Orbitrap mass spectrometers and aligns it, extracts the relative ion 
chromatograms (RICs) and tabulates them. Further details of the software analysis used 
in this thesis are provided in chapter 2.  
 
1.8.8  Microarray 
The function of a cell depends on the genes which it expresses. Measurement of gene 
expression, for example by Northern blot, is a cornerstone of molecular biology. Most 
recently, microarray technology has allowed the simultaneous measurement of tens of 
thousands  of  genes  from  a  single  sample.  The  reconciliation  of  microarray  and 
metabolomic data is thus potentially extremely powerful. 
 
1.8.8.1 Technology 
Microarray principle is highly dependent in its work on the principle of hybridization 
following the reverse Northern blot principle. In other words, oligonucleotide probes, 
corresponding to every gene or transcript that is to be measured, are arrayed on a solid 
substratum in a known pattern. Labelled mRNA is hybridised to the slide, and the signal 
attached to each probe is measured- typically by confocal microscopy or some variant 
thereof. This will tell researchers which genes are being expressed in each sample, and 
at  what levels  the  transcripts are  found.  A  typical  microarray  chip  contains  tens  of 
thousands of probes attached to the glass slide. In the Affymetrix system (Figure   1-25), 
each gene has multiple probes, each of approximately 28 nt length. Half the probes are 
perfect matches to the known sequence (PM probes), and half (MM probes) have single 
base changes from the corresponding PM probes. The proprietary analysis software uses   39 
the difference between PM and MM signals to control for nonspecific hybridisation, and 
so potentially yield more quantitative results (Wu and Irizarry, 2004) 
 
 
Figure    1-25.  Probe  distribution  on  an  Affymetrix  gene  chip.  From  
http://www.mun.ca/biology/scarr/Human_mtDNA_re-sequencing_microarray.html    40 
 
Figure    1-26.  A  typical  microarray  workflow  for  the  identification  of  clusters  of 
differentially  expressed  genes.  http://www.stathis.co.uk/art/infographics/infographics-
gallery/?pid=96  
 
The  availability  of  Affymetrix  microarrays  has  helped  the  Drosophila  community 
hugely. Among applications of the technology, the FlyAtlas.org resource has clearly 
helped  in  closing  the  phenotype  gap  between  human  diseases  and  Drosophila 
(Chintapalli et al., 2007) by directing researchers to the specific Drosophila tissues in 
which their genes of interest are mostly expressed. This is particularly useful when 
looking for the best fly tissues to start investigating for human disease homology.  
Microarrays are widely employed to explore differences between samples (healthy vs. 
diseased, experimental vs. control, etc.), as shown in Figure   1-26. In this work, we will 
be using microarrays to analyse the differences between rosy and wild type flies, and 
additionally to perform a time-course gene expression analysis of drug action. 
   41 
1.8.8.2 Validation of microarray results 
Although Affymetrix arrays are considered to be highly reliable, it is considered prudent 
to validate changed expression of genes of particular interest before publication. This 
could be by several techniques (for example Northern blotting, or Western blotting for 
protein levels); but is usually performed by quantitative reverse transcriptase PCR (Q-
RT-PCR). 
 
1.8.9  Aims of the thesis 
The main aims of this thesis is to  
•  Test the feasibility of Drosophila melanogaster ‘kidney’ (Malpighian tubules) as 
genetic model. 
•  Applying the Drosophila to give insights informative information about inborn 
errors of metabolism.  
•  Test the Drosophila as a model for disease related to congenital renal diseases. 
•  How beneficial this would be to the field resulting from the powerful genetic 
tools that Drosophila acquired over the years.  
•  Integrating  the  omics  approach;  genomics,  transcriptomics  and  maybe 
metabolomics  may  provide  novel  insights  into  the  disease  state  or  even  its 
amelioration. 
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Chapter 2  Materials and Methods   43 
2.1  Drosophila melanogaster 
2.1.1  Drosophila stocks 
Name  From  Used for  Phenotype 
Oregon R  Bloomington stock 
center (BSC) 
Control for all 
studies 
 
wild type 
Canton S  BSC  control for all 
studies 
 
wild type 
w
1118  (Hazelrigg et al., 
1984) 
background for P-
element insertions 
 
white eyes 
mal 
37  BSC  Metabolomics  brown eyes 
cho   BSC  Metabolomics  brown inclusions 
in tubules 
ry 
506  BSC  Metabolomics 
 
brownish eyes 
w
1  BSC  Alternative white 
allele 
 
white eyes 
w
93  BSC  Alternative white 
allele 
 
white eyes 
5’ HIUH  VDRC  UAS-RNA line 
 
Carries mini-w
+ 
uro- GAL 4  Made in lab, 
(Terhzaz et al., 
2010) 
Drives expression 
in principal cells 
Carries mini-w
+ 
Actin-GAL 4/CyO  BSC  Drives ubiquitous 
expression 
 
Carries mini-w
+ 
and CyO balancer 
TM3, Sb, (Ser)  BSC  Balancer for 
Chromosome 3 
Stubbly bristles; 
(some variants 
have serrate 
wings) 
w
1118; {w
+mC=WH}PBac 
uro
f04888 
 
Bloomington  Survival assay  Normal 
CyO  Bloomington  Balancer for 
Chromosome 2 
Curly wings   44 
 
2.1.2  Drosophila rearing 
All flies were kept in small ventilated plastic vials on standard Drosophila medium  (at 
section   8.1) (Ashburner, 1989). The room temperature was between 20 – 22 ºC in a 
12:12 light: dark cycle and between 35 – 40 % relative humidity. When large quantities 
of Drosophila were needed, large bottles were used under the same conditions. Flies 
were tipped as required on to new medium, approximately every two weeks. 
 
2.1.3  Dissection of Drosophila  
Adult flies, usually 5 to 7 days old, were first anaesthetized on ice before they were 
transferred to a Petri dish containing an appropriate volume of Schneider’s medium. Fly 
Malpighian tubules can be easily dissected intact without complicated equipment (Dow 
et al., 1994). For dissecting Malpighian tubules, a fly is firmly held by a forceps from 
the thorax region and with the other hand, forceps pulling the very end part of the fly 
gently and slowly. At this point the Malpighian tubules will start to appear - attached, 
however, to the midgut (MG). Then they need to be freed by using the forceps with 
great care, gently hold the tubules from the ureter by separating them from the MG at 
the ureter (Figure   2-1). In case of head sampling, the head was separated from the body 
by applying two forceps on the neck and pulling in opposite directions. The number of 
flies dissected varied depending on each experiment. This method was adopted after 
(Dow et al., 1994; Sullivan and Sullivan, 1975). 
 
Figure   2-1 Malpighian tubule dissection method  (Dow et al., 1994). 
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2.1.4  Generation of transgenic flies 
After constructing appropriate plasmids and providing the required amount of at least 50 
µg,  DNA  samples  were  sent  to  Bestgene  Drosophila  Injection  Services,  USA.  for 
microinjection into white background (w
1118) flies along with a helper plasmid supplied 
by Bestgene. The newly generated flies (G0) were crossed with w
1118 again. This service 
included microinjection, transfomant identification and –optionally- balancing.  
 
2.1.5  Characterization of transgenic flies 
 
Figure   2-2. Germline transformation of Drosophila. 
The germline transformation process is conducted by injecting embryos from the w
1118 
strains with a P-element shuttle vector that contains the gene of interest and a marker 
mini-white gene, along with a ∆2-3 helper plasmid. Emerged flies from these embryos 
are crossed with w
1118. Progeny of this cross are then screened for red eyes, implying   46 
that  they  carry  mini-white,  and  thus  transgenes.  Only  those  red-eyed  adult  flies  are 
backcrossed again to w
1118, and selected to produce a stably transformed line. Figure is 
after (Guo, 1996).  
 
2.1.6  Crossing and rearing crosses 
The  GAL4/UAS  system  provides  a  powerful  tool  for  cell-specific  expression  of 
transgenic payloads (Sentry and Kaiser, 1992). Typically, a UAS-RNAi line was tested 
for effectiveness by crossing to the Actin-GAL4 driver, to determine whether ubiquitous 
expression of the construct has an effect on fly development, survival, or any other 
detectable phenotype.  For finer spatial control, UAS lines were also crossed to the uro-
GAL4 driver, which directs expression to only tubule principal cells of only third instar 
and adult flies (Terhzaz et al., 2010). This was achieved by collecting between 20 to 30 
virgin flies of the uro-GAL4 into small vials. Each vial contained one virgin fly and was 
kept  for  2  to  3  days,  to  ensure  that  fertilized  eggs  were  not  being  laid.  Any  vial 
containing fertilized eggs was discarded. After making sure only virgins were present, 
each was crossed to uro or ry RNAi lines males. The reciprocal crosses were also made, 
to test for sex-specificity of expression, though this was not observed in this project. 
 
  Example: UAS line on Chromosome III 
 
 
 
X 
 
  Uro GAL4 expression driver 
 
 
Use for experiments 
 
 
↓ 
& 
Flies  carrying  the  designed  content  (P) 
with red eyes, short bristles phenotype. 
 
 
  Flies with long bristles were only selected from this cross. 
 
  Example: UAS line on Chromosome II   47 
 
 
 
 
 
X 
   
Flies from constructed lines UAS-uro 
with red eyes and curly wings phenotype 
curly wings. 
 
 
Use for experiments 
 
and 
 
 
  Flies with straight wings were only selected from this cross.  
Figure    2-3  Some  typical  examples  of  GAL4-UAS  crosses  and  selection  of 
appropriate progeny. 
 
After mating took place and sufficient eggs were laid, adults were transferred into new 
fly food bottles leaving the first bottles with only larvae. The newly transferred flies 
were  left  for  several  days  until  sufficient  eggs  were  laid  then  again  transferred  as 
desired. This process took approximately between five to ten days.  
 
2.1.7  Survival food preparation 
To  test  for  survival  under  oxidative  stress  conditions,  a  special  peroxide  diet  was 
prepared. The food contained 1% agarose, 1% sucrose and 1% H2O2 into a final volume 
of 10 ml per vial. 
 
2.1.8  Oxidative stress survival assays 
Freshly emerged adults were placed in mixed-sex groups of 20 flies on normal diet in 
tubes,  until  egg-laying  was  established,  then  transferred  to  vials  with H2O2,  freshly 
prepared as described above. To ensure that the oxidative challenge was maintained, 
flies were transferred to fresh H2O2 vials every 2 days. The time to emergence of adult 
progeny was carefully noted. Then the percentage of survivors were calculated using the   48 
(GraphPad) using the Kaplan-Meier survival curve as means ± SEM. Experiments were 
always performed in which progeny of a cross (typically a GAL4/UAS cross) were 
compared with each parental line,  i.e. two different parents and the progeny. 
 
2.2  RNA extraction 
Messenger RNAs (mRNAs) were extracted using the Qiagen RNeasy Mini extraction 
kits  following  the  manufacturer’s  instructions.  For  Malpighian  tubules,  mRNA  was 
extracted from 25 to 35 flies, depending on the experiment. Tubules were then collected 
into  2.0  ml  eppendorf  tubes  with  350  µl  lysis  (RLT)  buffer  containing  10%  β-
mercaptoethanol,  prepared  freshly.  For  long-term  storage,  lysates  were  immediately 
frozen in liquid nitrogen and then transferred to a -80 ºC freezer, where it could be 
stored for several months until needed.  Once extracted according the manufacturer’s 
protocol, mRNA concentration and purity were checked using the Nanodrop
TM 1000 
spectrophotometer. First strand cDNA synthesis 
Complementary  DNA  (cDNA)  was  prepared  from  mRNA  with  the  help  of  the 
Superscript  II  reverse  transcriptase  (Invitrogen)  according  to  the  manufacturer’s 
protocol. Then the DNA concentration and purity were checked using the Nanodrop
TM 
1000 spectrophotometer. 
 
2.3  Quantification of nucleic acid 
Quantification of mRNA and DNA are important steps in any molecular experiment. 
This was carried out using the Nanodrop
TM 1000 analyzer. At the same time sample 
purity was also monitored. The measurements were based on the assumption that an OD 
of 1 at 260 nm corresponds to 50 µg/ ml for DNA and 40 µg/ ml for RNA. The analyzer 
was zeroed by the same elution solution used in the samples. 
The purity was calculated by the ratio of A260/280. Values of 1.8 for DNA and 2.0 for 
RNA were considered pure.  
2.4  Oligonucleotide synthesis 
All primers in this thesis were designed using MacVector 10.0 software. The selected 
pairs were then sent to the MWG Biotech where they were synthesized. Primer quality 
was  controlled  and  assessed  by  MWG  Biotech  using  Trityl  monitoring,  OD   49 
measurement and MALDI-TOF MS. Primers were supplied as lyophilized pellets, and 
reconstituted with the appropriate volume of ultrapure sterile water to produce a stock 
of  100  pmol/µl.  Further  dilution  was  needed  to  produce  a  working  PCR  primer 
concentration of 6.6 µM. When not in use, primer stocks were stored at -20 ºC.     
 
2.5  Polymerase chain reaction (PCR) 
2.5.1  Standard PCR using Taq DNA polymerase 
Volumes (in µl) for a typical PCR reaction are shown below: 
10 x PCR buffer  5 
MgCl2   1.5 
dNTPs  2 
Forward primer  1 
Reverse primer  1 
Taq DNA polymerase  0.4 
cDNA  2 (or as needed to yield 50-100 ng template) 
H2O  To 20 µl 
 
2.5.2  Reverse-transcription (RT) PCR 
Reverse  transcription  PCR  (RT-PCR)  is  a  technique  to  measure  abundance  of 
expression.  It  is a  two-step  process,  in  which mRNA  is  first  reverse  transcribed  to 
cDNA, then amplified with gene-specific primers. Reverse transcription was carried out 
using  Superscript II reverse transcriptase kit (Invitrogen), dNTPs and oligo-dT. The 
reaction  volumes  were  20  µl  following  the  company  instruction’s  protocol.  Then 
appropriate aliquots were made and stored at – 20 ºC for further use. 
 
2.5.3  Quantitative (Q)-PCR 
Quantitative PCR technique is a powerful  tool for gene expression  analysis. In this 
thesis the analysis was carried out into a 96 well plate. Each tube contains mixture 
solution of 12 µl of Sybr green, 1 µl of each forward and reverse primers. Water was   50 
added  to  a  final  volume  of  24  µl/  sample.  Then  in  each  qPCR  tube  an  equal 
concentration  of  cDNA  template  was  added.  A  no-template  blank  was  included  to 
ensure the integrity of the master mix. 
The  absolute  quantitation  of  gene  expression  method  used  to  measure  the  gene 
expression. For this method, a standard curve was generated to estimate the sample 
copy  number.  This  led  to  make  a  serial  dilution  of  the  corresponding  gene  being 
analyzed. At the same time, an internal quality checking was also analysed using  the α- 
tubulin  housekeeping  gene  (Chintapalli  et  al.,  2007)  with  specific  primer  set.  After 
aliquotting the master mix and the addition of samples, tubes were carefully covered 
with special caps. To ensure the content is completely mixed together and it is at bottom 
of the tubes, centrifugation for each strip was necessary .  
The protocol used was the following: 
Denaturation   95 ºC   10 min 
Denaturation   95 ºC   10 s 
Annealing  50-60 ºC   30 s (according to primers) 
Extension   72 ºC   30 s 
Absorption reading   76 ºC   10 s 
Incubation   72 ºC   5 min 
Melting curve   63 - 90 ºC   read every 0.2 ºC   
 
2.5.4  Agarose gel electrophoresis 
Agarose gel electrophoresis is historically the method of choice for DNA detection in 
research labs. The principle of DNA separation relies on the negative charge that DNA 
possesses and its size. Small DNA fragments migrate faster towards the positive anode.  
The mixture prepared in 1% agarose in 0.5x TBE and ethidium bromide. After certain 
period of time the visualization took place under the UV light, the gel was photographed 
and the fragment sizes were compared with 1kb ladder (Sambrook and Russell, 2001).   
 
2.5.5  PCR purification 
When the DNA generated from a PCR run is needed for further experiments (such as 
cloning), it is necessary to remove any unutilized dNTPs, primers or Taq enzyme to 
leave only pure DNA fragments. For this task, the Qiagen DNA purification kit was 
used according the manufacturer’s instructions. 
30-40 x   51 
 
2.5.6  Gel purification 
After running a gel and observing a DNA fragment of the desired size, it is sometimes 
necessary to select that particular fragment for further analysis. For such needs, one 
specific  band  was  excised  using  a  scalpel  blade  under  UV  illumination  on  the 
transilluminator, taking care to protect the eyes from UV.  This fragment would be 
transferred to an eppendorf tube, weighed, then processed according to the Qiagen Gel 
Extraction Kit manufacturer’s instructions. 
 
2.6  DNA cloning 
2.6.1  E. coli strains and plasmids 
One Shot
® Top 10 chemically competent E. coli were used for the pENTR directional 
TOPO cloning.  
The DH5α 
TM were used for general transformation, for example with  the pRISE2 
dsRNA  vector. 
E.coli 
Strain  Genotype 
One Shot
® Top10  ( F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacΧ74 recA1 
araD139 ∆(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG λ- ) 
DH5α
TM subcloning efficiency 
competent cells (Invitrogen) 
(F
- φ80dlacZ ∆M15, ∆(lacZYA-argF), U169, deoR, recA1, endA1, 
hsdR17 (rK-,m
K+), phoA, supE44,λ
-, thi-1, gyrA96, relA1). 
Plasmids 
Name  Purpose 
pRISE 
(Invitrogen) 
Used to clone DNA fragment of interest downstream of the UAS 
sequence, to generate RNAi. Also contains the Amp
R gene to confer 
ampicillin resistance when transformed into E.coli. 
pENTR Gateway cloning system 
 (Invitrogen) 
Plasmid used to express the effects of RNA interfering. Also 
contains the Amp
R gene to confer ampicillin resistance when 
transformed into E.coli. 
 
2.6.2  Topo cloning of PCR products 
The Invitrogen Topo-Directional cloning kit was used. It allows efficient directional 
cloning into a vector. Many issues should be taken into account. This starts with the 
primers design, where CACC bases at the 5’ end of the forward primer should be added. 
Then the blunt-end  PCR  product  generated  should be used freshly, and  cloned into   52 
Topo-D  vector in  1:1 molar ratio. To complete the cloning, this then needed  to be 
transformed into One Shot Top 10 chemically competent E. coli and incubated with 
SOC  medium  for  an  a  hour  then  plated  overnight  onto  L-amp  X-GAL  IPTG  agar  
(Katzen, 2007).  
 
2.6.3  Restriction digests 
New England Biolab restriction enzymes were used in this project. Generally 1-10 µg of 
DNA was digested with 1 µl of a particular enzyme in 20 µl of the corresponding buffer 
for  1  h  at  37  ºC.  If  purification  of  the  resulting  DNA  was  required,  this  was 
accomplished either by DNA pruficaton (2.5.5.) or gel excision (2.5.6). 
 
2.6.4  DNA ligation 
DNA ligation was required when cloning a DNA fragment into a vector was needed. 
Before  this,  both  vector  and  insert  had  to  digested  with  appropriate  compatible 
restriction enzymes, and the resulting DNAs purified and quantified. To prevent the 
vector from religating to itself, a treatment with alkaline phosphatase at the end of the 
restriction digest incubation period was occasionally performed; this need was reduced 
by  designing  directional  cloning  strategies  with  two  enzymes  that  produced 
incompatible  sticky  ends.  Then  a  specific  molar  ratio  of  insert  to  vector  was  used 
according to the instruction’s manual according to Roche rapid DNA kit ligation kit.  
 
2.6.5  Transformation into E. coli 
Two µl of plasmids were transformed into E. coli competent cells by incubating on ice 
for 5 to 30 min. The mixture was then heat-shocked for 30 sec at 42 ºC then placed on 
ice immediately. The reaction volume then added into 250 µl of SOC medium before 
incubated  at  37ºC  for  one  hour  with  shaking  at  250  rpm.  The  final  step  of 
transformation  100  µl  was  spread  on  selective  bacterial  plates  containing  50  µg/ml 
kanamycin or 60 µg/ml ampicillin, as appropriate.   
   53 
2.6.6  The pRISE vector for RNAi 
Several “RNAi” vectors for constructing RNA inverted repeat sequence are available, 
and some are designed for germline transformation into Drosophila. One of them is 
pRISE II. The pRISE II vector contains two attR1-ccdB-attR2 recombination cassettes 
in inverted orientation separated by a functional intron from the ftz gene. So this will 
help to insert any DNA sequence into two different orientations with the help of another 
vector  contains  the  recombination  sites  like  the  pENTR/D  from  Invitrogen.    This 
pENTR/D contains attL1 and attL2 recombination sequence. So when we clone our 
DNA into the pENTR vector, between the attL1 and attL2 positions, it can be easily 
transferred into the pRISE vector by an enzyme called LR Clonase Figure   2-4. This 
enzyme recognizes the attL and attR target sites (Kondo et al., 2006).  
The pRISE also contains the UAS promoter region which allows the cell-type specific 
expression of dsRNA under the control of appropriate GAL4 drivers.    54 
 
Figure   2-4 The pRISE  plasmid vector and principle of generating an inverted repeat for 
gene silencing construct generation.  a) The pRISE vector. b) Steps of constructing an 
inverted repeat using pENTR and pRISE vectors with the help of LR Clonase enzyme. 
After (Kondo et al., 2006). 
 
2.6.7  Gateway
TM cloning 
The  first  step  in  gene  cloning  for  gene  silencing  with  the  Gateway  kit,  the  DNA 
fragment of interest must me first cloned into an entry clone. This enter clone will   55 
contain  the  gene  of  interest  flacked  by  attL  sequences,  which  later  can  be  easily 
recombine with the destination victor particularly in the attR sequences.  
This technology insures fast, efficient directional cloning that ligates the DNA fragment 
with desired orientation for gene expression (Figure   2-5).  
 
 
Figure   2-5 The pENTR vector  (Invitrogen, 2002). 
 
2.6.8  LR Clonase 
The Gateway LR Clonase enzyme mix is an enzyme responsible for the facilitating the 
recombination between an entry clone into a destination vector. In this thesis it was 
responsible to transfer the DNA sequence in the pENTR to the destination vector pRISE 
to constructing an inverted repeat to produce RNAi effects when driven by GAL4. 
This based on the site recombination between the attL and attR site in each vector. 
An equal molar ratio (1:1) of the insect entry clone was added to the destination vector 
with LR Clonase buffer. TE buffer (pH 8), was added to a final volume of 16 µl.  Then 
4 µl LR Clonase
TM enzyme was added to the reaction and mixed by brief vortexing.  All 
previous  steps  were  carried  out  at  room  temperature.  Then  the  reaction  tube  was 
incubated at room temperature for 60 min before the Proteinase K was added. This was 
incubated for further 10 min at 37 ºC.  The next step was transform it to DH5α  as in 
section   2.6.1 .  
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Figure   2-6 The Gateway LR in vitro recombination reaction (Invitrogen, 2010). 
 
2.6.9  Colony screening and selection 
2.6.9.1 Plasmid selection 
The  DNA  plasmids  utilised  during  this  study  contained  either  the  ampicillin  or 
kanamycin  resistance  genes,  which  were  used  as  transformation  selection  factors. 
Colonies transformed with the plasmid were selected by the addition of ampicillin (100 
µg  ml
-1)  or  kanamycin  (50  µg  ml
-1)  to  the  L-Agar  or  L-Broth  growth  medium. 
Ampicillin was stored as a 100 mg ml
-1 stock solution (w/v) in 50% H2O, 50% ethanol, 
at -20 °C. Kanamycin was purchased in a 50 mg ml
-1 solution (Sigma-Aldrich, UK) and 
stored at 4 °C. 
 
2.6.9.2 Diagnostic PCR for plasmid selection 
To identify the presence and orientation of a DNA insert in a vector, bacterial colonies 
on a plate were tested using PCR (before overnight cultures were set up). PCR reactions 
were sat up with one primer that bound to the insert and one primer that bound to the 
vector (facing into the cloning site). The colony was touched with a sterilised tip and 
then the tip was used to pipette the PCR solution up and down several times. 
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2.6.9.3 Preservation of selected  bacterial cultures  
Equal  amounts  of  bacterial  cultures  and  30  %  glycerol  were  added  to  a  screw-top 
cryovial tube with gentle stirring with the pipette tip. This was immediately snap- frozen 
in liquid nitrogen before the stocks were stored in the – 70 °C freezer.  
 
2.7  Affymetrix microarray experiments 
2.7.1  Fly preparation and Allopurinol treatment scheme 
Fly food used in this experiment was freshly prepared and all vials used were from the 
same fly food stock. Allopurinol was added in the concentration of 110 µg/ml as it was 
found in pilot experiments that this concentration can phenocopy the ry mutant. The 
drug  was  added  on  the  surface  of  the  fly  food.  To  prevent  evaporation,  vials  was 
immediately closed with cotton and left for overnight to dry. Four different time course 
samples were prepared as zero, 6, 24 and 48 hours along with the ry
506 mutant.  
 
Figure    2-7  Schematic  diagram  for  preparation  of  fly  food  with  Allopurinol.  In  this 
sample preparation, allopurinol was added to fly food. The drug concentration  was 110 
µg/ml (Keller and Glassman, 1965) . After adding the drug, vials were left for 24 hours 
to make sure that all was absorbed by the food and that no residue remained to cause the 
fly to stick to the diet, and thus die. Was drawn by me.  
 
2.7.2  Sample preparation  
Malpighian tubules were dissected from flies aged between 5 to 7 days after emergence. 
Tubules from between 25 to 30 flies were used for each sample. Malpighian tubule 
dissection was followed as described in section   2.1.3 and as in Figure   2-1. In order to 
minimize  the  chance  of  RNA  degradations,  each  dissected  MT  were  immediately   58 
transferred into the RLT buffer that was kept on ice. For total-RNA extractions the 
Qiagen-RNeasy Mini Kit was used following the manufacturer protocol. The goal of 
this experiment was to test the transcriptomic changes elicited on the MT by allopurinol, 
and to compare with the authentic rosy mutation. For reasons of cost, the experiment 
was designed as a time course, with samples taken in triplicate at 0 h (control), and at 
six,  twenty  four  and  forty  eight  hours,  together  with  a  t=0  h  rosy
506  mutant  for 
comparison.  
 
2.7.3  RNA target preparation 
Total RNA was extracted with Qiagen minicolumns according to the manufacturer’s 
protocols,  and  quality  verified  using  the  Agilent  Bioanalyzer,  which  is  a  computer 
assisted nanogel electrophoresis for total or complementary RNA. A GeneChip
® IVT 
Expression  Kit,  based  on  linear  RNA  amplification  and  T7  in  vitro  transcription 
technology, was used to prepare cRNA for microarray. 
In this process, the total RNA undergoes reverse transcription to synthesize the first 
strand cDNA, this then converted into a double strand DNA template for transcription. 
In vitro transcription synthesis an amplified RNA (aRNA) and incorporates a biotin-
conjugated nucleotide, washing step taken place to remove unconjugated NTPs , salt 
and  enzymes.  Next  is  fragmentation  of  the  biotin-labelled  aRNA  in  preparation  for 
hybridization onto the array chip.   
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2.8  Metabolomics 
2.8.1  The control animal model strains 
An Oregon R wild type strain was used as a control in these experiments. These flies 
were  cultured  on  standard  food  at  25  C°  and  55%  r.h.  on  a  12:12  photoperiod  as 
described in the section on Drosophila rearing   2.1.2. 
 
2.8.2  Chemicals  
The allopurinol used for this study was purchased from Sigma Chemical Co. (St Louis, 
MO, USA). Acetonitrile was from Fisher Scientific (Leicestershire, UK), formic acid 
(UWR, Pool, UK) and methanol. All chemicals used were analytical reagent grade. A 
Direct Q-3 water purification system (Millipore, Watford, UK) was used to produce the 
HPLC water that was in all of the analyses. All other chemicals used were obtained 
from Sigma Chemicals (Poole, Dorset), or Fisher Scientific Co. 
 
2.8.3  Dissection and sample preparation 
Different  fly  tissues  were  dissected  the  same  way  as  in  section    2.1.3  except  where 
otherwise mentioned. Then all following steps were carried out on ice. Next in order to 
homogenize the contents, each sample were then sonicated very well for 2-3 s for three 
times.  
Samples  then  were  centrifuged  at  10,000  rpm  at  4ºC  for  10  min  in  a  cooled 
microcentrifuge, and the supernatants were collected into new 2.0 ml eppendorf tubes 
and kept at – 80 ºC (Figure   2-8).     60 
 
Figure   2-8 Metabolite sample preparation methodology. Was drawn by me. 
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2.8.4  Operation of the Orbitrap 
 
Figure   2-9 Diagram showing the steps taken for metabolomic investigation. Was drawn 
by me.   62 
2.9  Metabolite extraction strategies  
2.9.1  Methanol-water (MW) solvent 
Solvent used in this experiment was a mixture of methanol and water in the ratio (1:1), 
which was suggested by (Kamleh et al., 2008). Ten whole flies (male and female) were 
added into 500 µl of the mixture solvent in eppendorf tubes and then homogenized by 
sonication for 2-3 seconds for three times; the mixtures tubes were then spun in a cooled 
microcentrifuge at 10 000 rpm at 4 ˚C. The filtered extracts were then kept in the freezer 
at  -80  ˚C  prior  to  analysis.  On  the  day  of  analysis,  samples  were  brought  to  RT 
temperature and placed into chromatograph glass vials. 
 
2.9.2  Chloroform-methanol-water (MCW) solvent 
An alternative method method of extraction was also tested. Methanol/chloroform/water 
solvents were also used in the sample extraction method in the ratio was 3:1:1. Ten 
adult flies from both genders were collected and anesthetized under CO2, they were then 
transferred into the mixed solvents and well homogenized for 2-3 seconds by sonication 
for  three  times.  The  sample  was  then  centrifuged  for  10  minutes  at  4˚C,  and 
supernatants were then transferred into new eppendorf tubes and then were stored in the 
freezer at -80˚C until required. Prior to analysis, samples were kept at room temperature 
and were placed into chromatograph glass vials. 
 
2.10 Allopurinol containing-fly food preparation 
This was prepared as described for the microarray experiments, to allow comparison 
between corresponding transcriptomes and metabolomes of the tubule.   63 
 
2.11 Software and applied libraries used 
In the following, all software used and applied libraries are listed in table 4 
Software      Description 
Excel 2007                    Microsoft spreadsheet 
Xcalibur v. 2.0              Analysis of LC/MS data 
Sieve software v.1.2             Converts raw data to appropriate format 
Sieve Extractor                         Automates metabolites identification 
SIMCA-P+11                   Evaluates and displays LC/MS data 
KEGG Encyclopaedia             Works as identifier to  provide  metabolite  names 
(http://www.genome.jp/kegg/)     Works as identifier to provide  metabolite  names 
PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed       
Works  as  identifier  to  provide  literature  for 
metabolite  names 
Metlin (http://metlin.scripps.edu/) database             Works as identifier to provide metabolite  names 
Human  Metabolome  Database 
(http://www.hmdb.ca/)     
Works as identifier to provide  metabolite  names 
                 
 
Figure   2-10 Workflow of metabolic software used.   64 
2.12 High resolution mass spectrometry adjustments  
LC-MS  data  were  obtained  from  experiments  that  were  carried  out  at  Strathclyde 
University (Department of Pharmaceutical Analysis) using a Finnegan LTQ Orbitrap 
(Thermo Fisher, Hempstead, UK). Orbitrap analyser resolution was set up at 30000.  
Samples was analysed in positive mode with a capillary temperature of 250˚C, Sheath 
gas flow 40ml/min and auxiliary gas was 10, while the mass scanning range was (50-
1250)  m/z.  The  whole  instrument  was  controlled  by  Xcalibur  software  version  2.0 
(copyright
© Thermo Fisher Co).  
ZIC–HILIC column 5µm (150 × 4.6mm) was used in all analyses and a method was 
developed which produced good separation for a broad spectrum of metabolites. Solvent 
A was 0.1 % formic acid in HPLC grade water, and solvent B was 0.1 % formic acid in 
acetonitrile. A flow rate of 300 µl/min was used and the injection volume was 10 µl. 
Samples were in a vial tray which was set at constant temperature at 3 ˚C to avoid any 
possible degradation of samples. 
2.13 Metabolite identification 
Samples within an experimental set were analysed on the same day and in a single run. 
This  means  that  the  differences  in  instrument  response  from  run  to  run  due  to 
independent manual tunings were limited.  
LC-MS data obtained from Xcalibur software version 2.0 composed of retention time 
and the mass/charge ratio of metabolite. Several steps of the metabolite identification 
and data analysis were carried out in this thesis and are worth describing here. 
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2.14  Step by step data analysis 
2.14.1  Xcalibur  
Firstly, the Xcalibur sample files were loaded into Sieve software 1.2 (Thermo Fisher 
Co) to convert raw data obtained from Xcalibur software to a common format that 
allows use for further data processing.  
The software shows only 2 dimensions. 
 
Figure   2-11 Typical raw data produced by the Xcalibur software. The upper trace shows 
total current chromatograms, and the lower trace,  mass spectrogram peaks from 50 – 
1200 dalton. Was captured by me. 
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2.14.2  Sieve software 
Secondly, samples are uploaded to the Sieve program as two groups: control and test 
samples. Sieve software was tasked with the alignment and framing of chromatograms. 
The software shows retention time, observed mass, ratio for the mean peak areas, mass 
intensity and P-value or t-test between ion chromatograms of the control group (normal 
wild type) and those of the test group.  
The importance of this program is mainly to align data obtained from the Xcalibur. Data 
alignment is important to bring peaks widths within the limit of reading range, and to 
minimise the analyser’s reading errors. 
 
 
Figure    2-12  Typical  screenshot  of  the  alignment  step  in  Sieve.  The  control  and 
experimental traces are coloured blue and red. Was captured by me. 
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The second step of the Sieve software is to analyse the aligned peaks Figure   2-13. 
 
Figure    2-13  Detail  of  aligned  peaks  in  Sieve.  Each  trace  represents  an  individual 
experimental  sample.  In  this  case,  the  record  is  for  the  metabolite  kynurenine  its 
molecular  weight,  compared  with  the  m/z  ratio,  retention  time  ,  P-value.  (Five 
dimensions). 
 
2.14.3  Sieve Extractor  
Thirdly, a large number of extracted mass results from the Sieve program were not 
annotated automatically with the name of the metabolite. Sieve Extractor software can 
help in naming metabolites. Following classification by Sieve software, data obtained 
were copied and pasted into Sieve Extractor (SE), a programme designed by Strathclyde 
University – Pharmaceutical Analysis Department in-house for automated metabolite 
identification.  Briefly,  Sieve  data  were  manipulated  by  SE  according  to  ion 
chromatogram mass width and R.T Width. Two chemical structure databases, Metlin 
and  KEGG  were  searched  to  establish  identity  for  peaks  by  exact  mass.  New 
identifications  were  manually  curated  for  specificity  and  plausibility  before  being 
accepted (discussed below). 
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Figure   2-14 Sample output from Sieve Extractor (SE) Programme. Was captured by me. 
 
In a few cases some metabolites suggested by the software make no sense, thus manual 
checking is always required. In most cases several formula are possible but one or more 
of these do not make sense in biological classification and can be rejected. Chemical 
databases such as PubChem, Human Metabolome and Metlin database were associated 
with  metabolite  naming  when  the  possible  formula  within  mass  accuracy  limit  was 
used.  
Misidentification or incomplete identification of metabolites was occurring during data 
analysis for several different reasons. In such cases, MS
2 fragmentation is one of the 
metabolite  identification  approaches  that  can  help  in  confirming  the  identity  of 
compounds  especially  when  distinguishing  structurally  similar  constituents  such  as 
isomers. Loss of the lower mass range occurs during the fragmentation mechanism. An 
additional  approach  for  distinguishing  isomer  ions  is  possible  on  the  basis  of  the 
retention time of metabolites in the ZIC-HILIC column stationary phase. Metabolite 
identification  based  on  retention  time  depends  on  understanding  of  the  chemical 
properties of a metabolite which reacts with  ZIC-HILIC column. In HILIC columns, 
metabolites which are classified as cations are retained more than anions.   69 
In  this  thesis,  hypoxanthine  and  allopurinol  are  isomer  compounds.  Although  the 
Orbitrap  and  Xcalibur  showed  no  difference  in  mass  and  elemental  composition 
between  hypoxanthine and allopurinol, a separation between  them was observed  by 
chromatographic  column  according  to  physicochemical  properties.  An  example  is 
shown in Figure   2-15. 
 
 
Figure    2-15  Extraction  chromatograms  from  TIC  of  isomeric  compounds  using  the 
HILIC-column. 
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Sometimes differences  in retention times do  not tell the whole  story. Thus  MS/MS 
fragmentation is mandatory to get an informative answer for some isomeric compounds, 
for  example  hypoxanthine  and  allopurinol  or  oxypurinol.  Another  step  is  using 
standards  to  differentiate  between  metabolites  which  produce  the  same  observed 
molecular mass in the analyzer.  
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2.15 Microscopy 
2.15.1  Polarizing microscope  
Is  a  simple  bright  field  microscope  equipped  with  polarizer,  located  between  light 
source and specimen, and analyzer, placed in the optical pathway before the eyepieces. 
Although polarizing microscopy has a range of uses, it was particularly useful in this 
thesis for the visualization of uric acid crystals in situ. Uric acid is a metabolite of 
Xanthine,  and  so  presence  of  urate  crystals  implies  a  functional  purine  metabolism 
pathway. Uric acid crystals are brightly birefringent (that is, they appear bright under 
crossed polaroizing filters). 
See the chapter 5 on uro 5.4.1 for more details. 
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Chapter 3  The rosy  (ry)   73 
3.1  History 
The mutant rosy (ry) is the second Drosophila mutant ever identified, just after the 
white mutant was discovered by T.H. Morgan in 1910. Although the exact date is not 
clear, it is likely that rosy was first isolated in 1912 (Dow, 2007). The rosy mutant is 
characterized by a red-dull eye colour (Figure   3-1), due to the absence of the enzyme 
Xanthine dehydrogenase  (XDH) (Hadorn and Schwinck, 1956). This enzyme has an 
important role in the eye pigmentation reaction in Drosophila. Chemically, flies lacking 
this enzyme possess high levels of 2-amino-4-hydroxypteridine, which is a precursor of 
isoxanthopterin (Glassman and Mitchell, 1959). Moreover, ry flies show high levels of 
hypoxanthine and xanthine, which are precursors of uric acid, so rosy clearly affects the 
purine metabolism pathway. The ry mutants are sensitive to purine-rich diet; ry mutants’ 
life span is shown to be directly reduced by a purine enriched diet when compared to 
wild type flies (Collins et al., 1970).   
Strikingly, this phenotype is not found only in ry. Several other mutants, like mal, cin, 
lxd, are described having the same eye colour defects, and subsequent investigation has 
shown that they encode other genes which impinge on the purine metabolism pathway 
(Table   3-1). 
  
Table   3-1. Comparison between selected Drosophila mutants with defective eye-colour.  
Gene  sym  chr  Eye colour  Enzyme activity  References  
rosy  ry  3  Brown, Red dull  Absent or low XDH  (Hadorn and Schwinck, 
1956) 
maroon-like  mal  1  Brown red dull  Present, inactive Co-F. 
 
(Forrest et al., 1956) 
(Wahl et al., 1982) 
cinnamon  cin   1  Reddish-brown  AO, PO, XDH, SO.   (Baker, 1973) 
chocolate   cho  1  Brown  2-amino-4-hydroxypteridine 
absent 
(Sturtevant, 1955) 
(McKay, 1972) 
AO;  Aldehyde  oxidase,  PO;  pyridoxal  oxidase,  XDH;  xanthine  dehydrogenase,  SO; 
sulfite oxidase.  
 
There is also a renal phenotype; in the ry mutants: as an result of XDH absence, the 
enzyme’s substrates, xanthine and hypoxanthine are found at much higher levels than   74 
normal. Consequently, xanthine calculi form in the Malpighian tubules (MT), which 
become enlarged and malformed (Figure   3-2).  
 
 
Figure   3-1. Showing the characteristic red-
dull eye colour of ry mutant against white-
eyed  flies  (w
1118)  and  Canton  S  wildtype 
(WT). 
 
 
 
Figure    3-2.  Inflated  MT  in  ry  and 
compared with WT (Wang et al., 2004). 
A; MT from  a wild type fly, B;  shows 
inflated MT from homozygous ry mutant 
blocked with xanthine orange particles. 
   
As the mutant is best known for its dull-red eye colour (Figure   3-1), one might expect 
that the main location of the XDH enzyme is in the eyes. Reaume et al (1989) stated that 
XDH enzyme is transported to the eye but not expressed; however by looking at the 
Flyatlas.org one can see the gene is expressed almost everywhere in the fly, including 
the eyes, but mainly in the MT.  Also, XDH is mainly cytoplasmic, so transportation is 
unlikely.  
3.2  Xanthine dehydrogenase vs. oxidase 
Xanthine  oxidoreductase  is  the  generic  name  for  the  house  keeping  gene  enzyme; 
namely Xanthine dehydrogenase (XDH) and Xanthine oxidase (XO) (Meneshian and 
Bulkley, 2002). 
WT 
ry 
506 
W
1118   75 
 
 
Figure   3-3. Xanthine Oxidoreductase (XOR ) structure and interchangable mechanism 
(Meneshian and Bulkley, 2002). 
 
Both the dehydrogenase and oxidase use hypoxanthine and xanthine as substrates to 
produce  uric  acid;  however,  different  cofactors  are  utilized  in  each  reaction.  The 
dehydrogenase uses NAD
+ as an electron acceptor and produces NADH. However, the 
oxidase utilizes O2 as a cofactor and produces more reactive oxygen species (ROS), 
namely H2O2 and O2
-. These in turn can form further radicals. So the XO is known to be 
a source of free radicals as seen in the reaction (A) in (Figure   3-4). 
 
 
 
A) 
 
   
 
B) 
 
 
Figure   3-4. Xanthine dehydrogenase and oxidase reactions. 
Xanthine dehydrogenase 
Xanthine oxidase   76 
 
Furthermore, both enzymes are encoded by the same gene and exist as interchangeable 
forms.  Usually  it  is  found  in  the  dehydrogenase  form;  however  under  some 
pathophysiological conditions or in injuries such as ischemic reperfusion, it is converted 
into the oxidase form, using the excessive O2 present as a cofactor and thus producing 
ROS as a result of the oxidative stress. This switch could thus be thought of as a defence 
mechanism in ischemia, where the body suffers from severe O2 loss; on recovery, the 
body is trying to provide an immediate supply of O2 to the affected tissue. This huge 
supply  of  O2  gained  into  cells,  from  increased  blood  flow,  can  causes  sometimes 
unwanted effects like cellular damage of proteins, DNA and plasma membrane (Martin 
et al., 2004). Thus, in order to prevent cell death, conversion of XDH to XO helps to 
utilize the excessive O2 present. However, although this mechanism rescues the body 
from oxidative stress, it is at the cost of generating high levels of ROS.  
This interconversion can also be either reversible  when sulfhydrylated; or irreversible, 
when proteolysed (Figure   3-5)   (Chung et al., 1997).  
Thus, the enzyme XDH/OX has an important role in cellular defence against oxidative 
stress. 
 
 
Figure    3-5.  Interconversion  between  XDH  and  XO  (Modified  from    Chung  et  al., 
1997).This figure shows the interconversion between XDH and XO. The original form 
is  the  dehydrogenase  form,  which  can  be  converted  to  the  oxidised  form  by 
sulfoxidation and converted back to the dehydrogenase form by reduction. However, 
conversion to XO by proteolysis is irreversible.  
 
Furthermore, XO plays an important role against free radicals, because its main product 
is uric acid, a very well known reducing agent (electron donor). Urate can thus act as a 
free radical scavenger by donating electrons to be coupled to ROS. Moreover, XDH/XO 
could modulate the immune response, as ROS, in the form of O2
-, OH
- and H2O2; and   77 
RNS,  in  the  form  of  NO,  in  the  presence  of  bacteria,  can  act  as  antibacterial  and 
cytotoxic agents against various pathogens and tumour cells (Vorbach et al., 2003).  
In humans, the interconversion between XDH and XO is known to occur, leading to its 
naming as XOR. Such interconversion has not been demonstrated in Drosophila, where 
the gene product has been called XDH since 1956. Thus, to avoid misunderstanding, in 
this thesis I am going to call the enzyme XDH in Drosophila and XOR when discussing 
in mammal particularly humans.  
3.2.1  Basic biochemistry  
Both enzymes are composed of two identical subunits with a total size of 300 kDa. Each 
subunit consists of one molybdenum (85kDa), two non-identical Fe2S2 centres (20kDa) 
and flavin adenine dinucleotide (FAD) (40kDa), producing a total molecular weight of 
150kDa (Chung et al., 1997).  
3.3  Results 
3.3.1  Tissue-specific knockdown of XDH activity 
Although  a  wide  range  of  rosy  alleles  have  been  characterised,  and  many  are  still 
available in stock centres, we wished to investigate the role of rosy in further detail, 
dissecting  its  enzymic  and  defence  roles  in  individual  tissues  –  for  example,  the 
Malpighian tubules, the tissue in which ry is most abundantly expressed. As both rosy 
and the corresponding human disease (Xanthinuria type I) both show similar defects, 
this would allow a more detailed modelling of the human condition in flies, and so test 
the  implicit  hypothesis  of  the  thesis  (that  human  renal  disease  could  usefully  be 
modelled in Drosophila). Accordingly, we tried to develop new alleles of rosy, and new 
analytical techniques to study their impact.  
3.3.2  RNA interference (RNAi)  
RNAi is a method widely used as a powerful tool for reverse genetics in gene silencing. 
The  method  first  was  used  in  C.  elegans,  then  was  adapted  into  Drosophila 
melanogaster for gene silencing (Kennerdell  and Carthew,  2000).  Since then, many 
elegant  RNAi  vectors  have  been  developed.  For  our  purposes,  the  RNAi  inducing 
silencing vector (pRISE) is an effective tool to generate constructs that can be used in 
Drosophila RNA silencing technique (Kondo et al., 2006).    78 
This approach is based on constructing a plasmid including an inverted repeat of the ry 
target sequence separated by a functional intron to form double stranded RNA (Figure 
2-4  B).  This  plasmid  also  uses  a  characteristic  repeat  sequence  of  the  Gateway 
recombination cassette which helps in avoiding multiple restriction digest and ligation 
steps. To accomplish the ry gene silencing, our DNA fragment has first to be cloned 
into an appropriate entry vector, which is the pENTR/D-TOPO from Invitrogen. Once 
the cloning is done then this will be transferred or subcloned easily into the pRISE by 
the help of an enzyme recognising the Gateway cassette site by recombination reaction 
(Figure 2.6 LR clonase). This enzyme is the LR Clonase, also from Invitrogen.   
In principle, the use of clonase rather than ligase offers very high frequency of ligation, 
and  the  approach  was  successful  elsewhere  in  this  project.  However,  after  several 
attempts, it proved impossible to clone the open reading frame for ry into pENTR in-
house (Figure   3-6).    79 
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uro screening. Lane 
4,5 & 7 showed 
success insertion 
for uro. 
 
In this particular gel 
picture only the 
positive control was 
shown. 
       
New primer set.    
B 
     
   The newly ry  
primer set tested on 
both lanes 3 &5. 
 
Upper lane 1 
ladder, 2 to 12 
samples. 
Lowe lane 1 ladder, 
2-10 samples, 11 
+ve cont 
 
Restriction digest. 
Lane 1 ladder, 2-5 
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Figure   3-6 Gel pictures showing ry cloning. 
All column 1 gel pictures are for primer testing. A1 ry and uro primer testing. 
While in B1 a new ry primer set was used. Column 2 gel pictures were for direct 
colony screening. Same steps in row B were repeated several times.  
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During  the  course  of  the  project,  comprehensive  libraries  of  transgenic  Drosophila 
containing RNAi constructs downstream of UAS, have become available from several 
stock  centres.  Accordingly,  the  transformant  25172  was  also  ordered  from  the 
Drosophila Genomic Resource Centre in Vienna. 
3.3.2.1 Validation by qPCR.  
Flies  were  crossed  with  urate  oxidase-GAL4  line,  which  drives  RNAi  expression 
exclusively in the principal cells of the main segment of the tubules of third instar larvae 
and adults (Terhzaz et al., 2010). Then week-old adult progeny were selected, tubules 
were dissected, total mRNA were extracted, cDNA were also generated and then gene 
expression validation of the knockdown took place.  
QPCR method is considered the method of choice for gene expression validation. So 
primers were designed to amplify a DNA fragment of 196 bp (primers qPCR ry II F and 
R see appendix 9.5) in the ry gene. Then the annealing temperature was optimised. 
Results were normalized against the housekeeping gene, α-tubulin (Chintapalli et al., 
2007). 
Malpighian tubules were dissected from both parents and progeny then total mRNAs 
were checked for quality as well as for quantity. Then cDNA was generated and then 
checked  for  quality  and  quantity,  next  this  was  used  as  a  template  for  the  gene 
expression validation reaction. It was found that the RNAi line, when driven by the 
tubule-specific  driver  uro-GAL4,  reduced  expression  of  the  ry  in  the  tubules 
significantly, by 70 %  compared to parental lines (Figure   3-7). 
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Figure   3-7. The ry RNAi knockdown validated by qPCR 
The ry gene knockdown expression is compared to uro-GAL4 and ry RNAi parents. 
Data mean ± SEM, N=4. Significance of changes was assessed by Student’s t-test (two 
tailed) taking P=0.05 as the critical level: significant changes are marked with *.   
 
Accordingly, it was concluded that the Vienna UAS-ry(RNAi) line provided a suitable 
resource – a strong, cell-specific hypomorphic allele of ry – and in-house cloning efforts 
were discontinued. 
3.3.3  Metabolomics 
The metabolomic approach has emerged as a new branch of the omics era. With the 
advances  in  bioinformatics and  unparalleled  sensitivity  in  detection,  it has  potential 
applications for simple model organisms like Drosophila.  
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The Orbitrap was known to be able to detect relevant metabolites, from manufacturer 
standards. However, we set out to establish whether they could be resolved with 
sufficient sensitivity in real extracts of flies.  
Thus we tried to use the Drosophila rosy mutant to find out whether metabolomics, and 
specifically the Orbitrap, are useful tools in flies. Oregon R also was used as a control. 
In a brief pilot study 10 flies were grind up and run. As it can be seen in (Figure   3-8) the 
desired peaks of purine metabolism related metabolites were seen.  
 
 
 
Figure    3-8  Narrow-range  extracted  ion  traces  extracted  across  a  range  of  0.02 amu 
showing  the  metabolites  related  to  uric  acid  biosynthesis  from  female  wild-type 
Drosophila. Along with their retention time as well as mass/charge ratio.   83 
3.3.3.1 Validation by Orbitrap 
For further validation, and as a new method for gene knockdown validation, we tried to 
apply metabolomics to measure relevant metabolites that should be directly affected by 
ry gene silencing.  
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Figure   3-9. RNAi knockdown of rosy phenotypically validated by Orbitrap. It shows 
comparisons between the major metabolites involved in the absence of XDH in different 
lines. Uro-GAL4 drivers parents, ry RNAi parents and progenies. Data are shown as 
mean ±SEM for N=3 independent experiments. Data that differ significantly are marked 
with asterisks are analyzed by Student’s t-test two tailed.  
 
So  from  the  data  presented,  the  RNAi  line  produces  a  useful  knockdown  of  rosy, 
assessed  both  by  gene  expression  and  metabolomic  pathway  disruption;  and  the 
Orbitrap technology provides a useful screen for knockdown of a metabolic enzyme. 
 
3.3.4  Whole fly metabolomics 
Could this technology also be useful for classical mutations (of which there are many 
thousands in stock centres worldwide)? A pilot experiment was performed on extracts   84 
pooled  from  10  flies.  Male  and  females  were  kept  separate  using  the  ry
506  mutant, 
known for as XDH enzyme deficient and Oregon R wild type as a control. Initially we 
were  looking  for  key  metabolite  changes  like  xanthine,  hypoxanthine  and  urate,  a 
targeted rather than global metabolomic approach (Figure   3-10). 
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Figure   3-10 A pilot study for male and female rosy mutant. It shows no differences 
between  male  and  female  involved  the  two  main  metabolites  in  purine  metabolism  
pathway. Data are shown as mean ±SEM for N=5 independent experiments. Data that 
differ significantly analyzed by Student’s t-test two tailed are marked with asterisks. 
 
 
From  classical  biochemistry,  it  was  expected  to  find  that  both  xanthine  and 
hypoxanthine  are  elevated  in  the  ry
506  mutant  (Hadorn  and  Schwinck,  1956)  and 
(Glassman and Mitchell, 1959). This was clearly observed in both males and females, 
with both producing similar results. These results both confirm the classical data, and 
validate the accuracy of the Orbitrap in reproducing similar results with a fundamental 
technology. The Orbitrap is thus a useful tool for targeted metabolomics in Drosophila. 
Having obtained the expected results, the analyzer was challenged further, to see to 
what extent that it would be useful in specific fly tissues. This experiment is much more 
demanding in terms of low metabolite concentrations. Consequently, we carried out 
another  experiment  using  different  fly  tissues,  like  heads  and  Malpighian  tubules.   85 
Empirically, 15-20 heads and tubules for 20-30 flies were found to give good results 
(Figure   3-11). 
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Figure   3-11. Comparison in the rosy mutant between heads and MT. Uric acid levels in 
both head and tubule were too low to be measured. Data are shown as mean ±SEM for 
N=5 independent experiments. Data that differ significantly are marked with asterisks 
are analyzed by Student’s t-test two tailed. This graph shows that xanthine is much 
more significantly higher than hypoxanthine in the MT. While in the heads samples, 
although hypoxanthine level is higher than xanthine, it is not statistically significantly.  
 
Accordingly,  tissue-specific  differences  were  analysed  in  more  detail,  as  shown  in 
(Figure   3-12) and (Figure   3-13).  In both heads and tubules, hypoxanthine and xanthine 
levels were strongly elevated, and uric acid and allantoin depleted; but these effects 
were much more marked in the tubules. This is consistent with microarray expression 
data, as ry is expressed in the whole fly, with higher levels particularly in MT. The 
metabolites  viewed  in  different  tissues  thus  reflect  gene  expression  level  in  those 
individual tissues (Chintapalli et al., 2007), suggesting that it may ultimately be possible 
to build models linking transcriptome and metabolome. 
The results were encouraging, as they showed that the Orbitrap is very useful tool not 
only  in  fly  metabolomics  but  also  in  small  tissues  as  well.  Very  clear  metabolite 
differences were seen between ry and WT in tubules as well as in the heads (Figure   86 
  3-11). Thus metabolomics of individual tissues can provide more detailed insights than 
whole-organism  studies,  in  a  manner  exactly  analogous  with    the  single-tissue 
microarrays that underpin the FlyAtlas.org resource (Chintapalli et al., 2007). 
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Figure   3-12. Wild type vs. rosy heads. Comparisons between key metabolites in purine 
metabolism  pathway  to  their  counterpart  in  WT  in  heads  samples.  Data  for  each 
metabolite are expressed as a percentage relative to the wild-type levels. Data are shown 
as  mean  ±SEM  for  N=5  independent  experiments.  Data  that  differ  significantly  are 
marked with asterisks are analyzed by Student’s t-test two tailed.  
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Figure   3-13. Wild type vs. rosy Malpighian tubules. This graph shows the comparisons 
between key metabolites in purine metabolism pathway to their counterpart in WT in 
MT samples. Data for each metabolite are expressed as a percentage relative to the 
wild-type levels. Data are shown as mean ±SEM for N=5 independent experiments. 
Data that differ significantly are marked with asterisks are analyzed by Student’s t-test 
two tailed.. 
 
3.3.5  Global metabolomics of rosy and wild-type flies 
After validating the technology, by looking for specific metabolites in ry, (so called 
‘targeted’ analysis,) and by comparison with historical data, the approach was extended 
to  all  metabolites  that  could  be  resolved  in  the  Orbitrap,  the  so-called  ‘global 
metabolomic analysis’. 
Initially  we  broadened  our  analysis  to  those  metabolites  associated  with  purine 
metabolism  biosynthesis  and  metabolism  (Table    3-2).  This  confirmed  the  classical 
findings for rosy, but also extended it to several further metabolites.  
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Table   3-2. A broader view of the purine metabolism pathway.  
Metabolite 
P Value 
(Paired t-Test) 
Ratio 
ROSY/WT 
Remarks 
Allantoin  0.00  0.002   
Uric acid  0.00  0.0041   
Leucylarginine  0.00  0.1107   
Thymine  0.12  0.2296  NS 
Uridine  0.02  0.2996   
Aspartic acid  0.02  0.5576   
Valineyl valine   0.41  0.5734  NS 
Uracil  0.00  0.7721   
Guanine  0.01  0.8169   
Guanosine  0.07  0.8713  NS 
Glutamine  0.75  1.0403  NS 
Inosine  0.59  1.0565  NS 
Glutamic acid  0.41  1.0895  NS 
Cytosine  0.14  1.4403  NS 
Adenosine  0.00  2.1464   
Deoxyguanosine  0.00  2.1464   
Cytidine  0.18  2.2857  NS 
Amp  0.00  2.3137   
Xanthine  0.00  19.870   
Hypoxanthine  0.00  36.006   
NS, non significant. P-value less than 0.05  is significant.   89 
 
3.3.6  The main study (male and female) 
As the approach was clearly working well, the analysis was extended globally. Table 
  3-3  shows  all  significantly  changed  metabolites  detected,  arranged  into  putative 
metabolic pathways. 
 
Table   3-3 Significantly changed metabolites seen in ry
506  males and females. Analyzed 
by Student’s t-test two tailed. 
Female  Male 
Metabolite/Metabolic 
pathway  Formula 
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  ratio 
ry/WT 
P.value 
ratio 
ry/WT 
P.value 
Purine / uric Acid related   
Uric Acid  C5H4N4O3  169.0356  1  5.65E-04  7.62E-04  2.5E-09  5.96E-04 
Allantoin  C4H6N4O3  159.013  1  0.047  1.19E-04  0.018  0.002 
Hypoxanthine   C5H4N4O  137.0458  1  15.66  1.92E-04  10.844  4.90E-05 
Xanthine  C5H4N4O2  153.0407  1  25.2  3.19E-04  20.665  5.5E-07 
Guanine  C5H5N5O  152.0567  3  2.83  0.001  1.325  0.073 
Guanosine  C10H13N5O5  284.0989  1  2.89  0.003  1.119  0.527 
6-pyruvoyltetrahydropterin 
(6-PTP) , biopterin  C9H11N5O3  238.0935  5  3.03  4.10E-09  1.576  5.18E-04 
Dihydrobiopterin  C9H13N5O3  240.1091  3  5.47  1.20E-06  5.188  1.2E-07 
Dihydropterin   C7H9N5O2  196.0829  1  0.13  0.013  0.214  0.006 
Inosine  C10H12N4O5  269.088  2  4.69  0.005  2.023  0.011 
AMP  C10H14N5O7P  348.0704  2  1.46  0.055  1.075  0.43 
Tryptophan pathway Metabolites    
Tryptophan   C11H12N2O2  205.09715  2  0.53  0.005  0.36  6.4E-07 
Hydroxytryptophan  C11H12N2O3  221.0921  1  1.87  0.028  0.509  0.004 
Kynurenine  C10H12N2O3  209.921  1  3.35  5.5E-08  0.64  0.004 
Hydroxykynurenine  C10H12N2O4  225.0921  1  0.405  2.5E-07  0.345  7.1E-07 
Osmolytes   
Choline glycerophosphate   C8H21NO6P  258.1101  1  14.57  4E-11  9.56  1.8E-11 
Glycerophosphoethanolamine   C5H14NO6P  216.1101  1  16.16  2E-10  9.672  8.7E-08   90 
Choline  C5H14NO  104.107  1  1.33  0.006  0.792  0.09 
Pyrimidines                  
Cytosine  C4H5N3O  112.0505  1  14.31  0.002  2.571  0.016 
Uracil  C4H4N2O2  113.0346  1  0.921  0.6  0.402  0.002 
Uridine  C9H12N2O6  245.0768  2  0.9  0.617  0.5  0.209 
Arginine Pathway Metabolites  
Citrulline  C6H13N3O3  176.103  1  0.299  0.004  0.348  0.042 
Ornithine   C5H12N2O2  133.0972  1  0.376  0.147  0.128  0.036 
L-Homocitrulline  C7H15N3O3  190.11862  1  0.011  1.9E-07  0.00009  0.00031 
Misc Metabolites 
Alanine  C3H7NO2  90.055  2  1.93  8.4 X 10-8  1.259  0.075 
Glutamic acid  C5H9NO4  148.0604  4  1.75  3.14E-04  0.871  0.094 
Glutamine   C5H10N2O3  147.0764  5  1.32  5.66E-04  1.11  0.233 
Threonine  C4H9NO3  120.0655  2  0.526  0.000032  0.578  2.21 E-04 
Nicotinamide  C6H6N2O  123.0553  1  1.55  1.60E-04  0.732  0.081 
Valine  C5H11NO2  118.08613  5  1.06  0.494  0.76  0.016 
As well as finding what was expected from metabolomic studies in the rosy mutant, 
many  further  changes  in  metabolites  were  obtained,  some  of  which  were  quite 
unexpected, and not known from the extensive classical literature on rosy. I will now 
focus on each affected pathway in detail. Red colour readings indicate conflict between 
male and female.  
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3.3.7  Purine metabolism pathway 
As can be seen in (Figure   3-14), the changes shown in (Table   3-3) are very sensible. 
Significantly, changes in metabolite levels can be detected several metabolites further 
from the genetic lesion than had been detected by classical analytical biochemistry. This 
means that the Orbitrap technology can provide more information in a single experiment 
than can be obtained by classical techniques. 
 
 
Figure   3-14. Part of purine metabolism pathway in Drosophila, with significant changes 
in whole-fly metabolite levels shown (Kamleh et al., 2008). 
 
3.3.8  Tryptophan pathway metabolites 
It was, also found that 3-hydroxykynurenine levels were lower in ry (Table   3-2) and 
(Table   3-3), while kynurenine was elevated. This suggests that the enzyme responsible 
for  converting  3-hydroxykynurenine  to  kynurenine  is  reduced  in  activity;  and  so 
explains how the ry eye red-dull colour is generated. Generally, the Drosophila eye 
colour is constituted as a result of a mixture of two pigment colours, namely, brown 
(xanthommatin or ommochrome) and red (drosopterin). Each colour is generated from a 
distinct pathway (Figure   3-15). Thus, any disruptions in either pathway will impact on 
the Drosophila eye colour. The ommochromes are metabolites of tryptophan pathway, 
via kynurenine and 3-hydroxykynurenine.   92 
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Figure   3-15 (A) Overview of eye pigment formation in insects. (B) Detailed view of 
conversion of tryptophan to xanthommatin. 
 
 
How could Xanthine dehydrogenase impact on the tryptophan metabolism pathway? 
One possibility is through a reduction in cofactors necessary for enzymatic metabolism 
of tryptophan. The structure of flavin adenine dinucleotide (FAD) is shown in (Figure 
  3-16). Adenosine is linked through two phosphate units to a riboflavin; so the idea here 
is that flavin is very important part in the FAD; so when it is defective, vital metabolic 
biosynthesis, like hydroxylation of kynurenine will be disrupted. It was observed that 
levels of riboflavin (vitamin B2), which is necessary for the biosynthesis of the FAD co-
factor required for hydroxylation of kynurenine, were much lower in ry. This may be 
due to malabsorption of the vitamin in ry and could provide an explanation for the 
important of XO on the kynurinine pathway.    93 
 
 
 
Figure   3-16 Chemical structure of FAD. 
The black molecule is adenosine dinucleotide, The red is ribitol, and the blue flavin.  
 
3.3.9   Osmolyte biosynthesis 
Changes  were  also  observed  in  the  glycerophospholipid  pathway.  Both  choline 
glycerophosphate (CGP) and glycerophosphoethanolamine (GPEA) -related to osmolyte 
biosynthesis- were elevated.  
In other organisms, this pathway is triggered or activated when excessive amounts of 
NaCl or nitrogenous wastes (urea) accumulate in the mammalian renal medullary cells. 
This occurs as a result of the animal trying to maintain the osmotic balance. How are 
these  metabolites  changing  in  rosy?  Rather  than  a  direct  enzymatic  effect  on 
phospholipids, it is possible that defective purine metabolism may result in osmotic 
stress – as outlined below – and so induce osmolyte biosynthesis. 
Nitrogenous waste products are highly toxic and need to be eliminated immediately 
from insects. To do so these wastes are must be metabolized to lesser toxic products, 
like uric acid in Drosophila. Uric acid is water insoluble so its excretion is sparing of 
organismal  water  (Chapman  and  Chapman,  1998).  However,  if  urate  formation  is 
blocked,  purine  metabolism  may  result  in  the  accumulation  of  water-soluble 
metabolites, thus they must be diluted to reduce its toxicity until they excreted. As ry   94 
mutants are unable to make uric acid in the absence of XDH, they excrete the nitrogen 
waste in other forms, perhaps as water-soluble xanthine. This process would be wasteful 
of water, leading to osmotic stress. This could explain the observation of CGP and 
GPEA in higher levels in comparison to WT fly in the osmolyte biosynthesis (Figure 
  3-17).  
 
 
 
 
Figure   3-17. Osmolyte biosynthesis: extract from the KEGG pathway map, with fold 
changes superimposed. 
 
Thus all previous effects of on the osmolyte pathway are not directly an effects of ry, it 
is rather a secondary impact of the XDH enzyme on phospholipid synthesis.  
A corollary of this model is that rosy flies might be under baseline osmotic stress, and 
so might be more susceptible to external stress – for example – hyperosmotic diets. It 
would be interesting to test this model experimentally, if time allowed. 
 
3.3.10  Arginine metabolism  
Arginine metabolism (the urea cycle) is also affected in ry, with significantly lower 
levels of ornithine, citrulline and L-homocitrulline (Table   3-2). L-homocitrulline does 
not actually feature on a KEGG map; but it is synthesised from carbamoyl phosphate (a 
precursor  of  citrulline),  and  lysine.  So  its  depression  could  link  to  the  observed 
reduction  in  levels  for  citrulline  (Figure    3-19).    One  explanation  could  be  that  an 
observed  accumulation  of  dihydrobiopterin  (DHBT)  causes  an  inhibition  of 
tetrahydrobiopterin (THBT) recycling (Figure   3-18). One of the isomers of DHBT is 
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known to be an inhibitor of THBT regeneration (Thony et al., 2000) and THBT is 
required as a co-factor in arginine oxidation which results in the formation of NO and 
citrulline.  Accumulation  of  DHBT  in  vascular  tissue  may  have  a  role  in  insulin 
resistance where it inhibits vasodilation through inhibiting NO production (Shinozaki et 
al., 1999). 
 
 
Figure   3-18 Impact of rosy mutation on the purine and biopterin metabolic pathway. 
Although the primary lesion is a disruption of xanthine dehydrogenase, the impact on 
the dehydrobiopterin pathway might be explained by the increase in guanosine levels. 
Red arrows denote significantly changed metabolites; fold changes are shown alongside 
each arrow. After (Kamleh et al., 2008).    96 
 
More simply, a lesion in purine metabolism increases the pressure on other routes for 
nitrogen excretion, and urea production is a key by-product of the arginine (urea) cycle 
(Figure   3-19). Even if rosy exerted a relatively focused effect on purine metabolism, it 
could still perturb this remote part of the metabolic map. 
 
 
 
Figure    3-19.  Arginine  pathway:  extract  from  the  KEGG  pathway  map,  with  fold 
changes superimposed. 
 
3.3.11  Pyrimidine metabolism 
Cytosine is  strongly increased, and uracil  decreased in rosy compared to wild-type, 
although the uracil depression was male specific (Table   3-2). Cytosine and uracil are 
neighbouring  metabolites  in  the  pyrimidine  metabolic  pathway  (Figure    3-20).  By 
contrast,  their  neighbours  (cytidine  and  uridine)  are  not  significantly  changed.  The 
pyrimidine compounds can also be degraded into urea. For example cytosine can be 
catabolized into uracil and then catabolized further to β-Alanine.  
The reason why cytosine is the only metabolite elevated is not clear, however – as for 
the arginine explanation above-  this could be possibly as a secondary effect of the fly 
x 0.004 
x 0.15   97 
trying to compensate for a shortfall in nitrogenous compound excretion through the 
purine metabolism pathway. 
 
Figure    3-20.  Pyrimidine  pathway:  extract  from  the  KEGG  pathway  map,  with  fold 
changes superimposed. 
 
3.4  The mutant rosy, allopurinol and gout 
3.4.1  Introduction 
Gout  is  an  inflammatory  disease  condition  characterized  by  a  recurrent  attacks  of 
inflammatory arthritis, redness, tenderness and swollen joints, as a result of sodium 
urate  or  uric  acid  crystals  precipitating  in  joints  and  soft  tissues  (Figure    3-21)  and 
(Figure   3-22).   
For example, in the UK it is estimated 1.4 % of the adult population are affected with 
gout. The disease is mainly seen in the elderly people over 65 years (Patel et al., 2010).  
Gout can be caused by either dietary habits; high sugar and protein intake, or could be 
happens as a result of secondary effects of metabolic syndrome. It may also result from 
renal failure.  
The exquisitely painful nature of gout has been described by several prominent writers: 
“People wish their enemies dead, but I do not; I say give them the gout, give them the 
stone!” (Mary Worley Montagu) 
x 0.4 
x 14   98 
“Be temperate in wine, in eating, girls, and sloth; Or the gout will seize you and plague 
you both” (Benjamin Franklin) 
 
 
Figure   3-21. A cartoon illustrating the painful inflammatory effects of gout in man can be.  
(From: The Gout, James Gillray, 1799.)  
(A)  (B) 
 
 
Figure   3-22 (A) Diagram of disruption of the big toe (the most common locus for gout) by 
urate  crystals.  (From  medicinenet.com)  (B)  an  affected  joint,  with  a  tophus  of  urate 
crystals clearly visible through the distended skin. (From news.bbc.co.uk). 
 
At first sight, therefore, it would seem that urate formation is undesirable, and that 
circulating levels of urate should be kept as low as possible (Figure   3-23). However, 
(Hilliker et al., 1992) suggested that urate is an important antioxidant agent; as urate-
null mutants, like ry, are extremely sensitive to oxidative stress agents like paraquat and 
die quicker than wild types. Thus they suggested that urate is playing an important role 
in longevity (this will be discussed further in the uro chapter). The human body is thus   99 
likely actively maintain a preferred level of circulating urate, and gout can be seen as an 
unfortunate long-term side-effect of setting this level too high.  
 
Figure    3-23.  Part  of  purine  metabolism  showing  the  key  role  of  Xanthine 
oxidoreductase in urate formation, and thus in gout. 
   
Nonetheless, treatments for gout have been found, and revolve around reducing urate 
levels, by reduced nitrogen in the diet (low protein), higher fluid intake, and allopurinol, 
a pseudosubstrate inhibitor of XOR. 
Hypoxanthine 
 
Allopurinol 
 
Figure   3-24 Hypoxanthine vs. allopurinol chemical structures. 
 Its chemical structure is very similar to hypoxanthine with a slight difference in the 
carbon and nitrogen atoms arrangement (Figure   3-24). Furthermore, the enzyme does 
not differentiate between the two chemically similar compounds: allopurinol is rapidly 
metabolized  byxanthine  oxidase,  to  its  active  metabolite  oxypurinol  (Figure    3-25), 
which  is  also  an  inhibitor  of  xanthine  oxidase.  Allopurinol  is  almost  completely 
metabolized to oxypurinol within two hours of oral administration, whereas oxypurinol 
is  slowly  excreted  by  the  kidneys  over  18-30  hours.  For  this  reason,  oxypurinol  is 
believed to be responsible for the majority of allopurinol's effect.   100 
Oxypurinol  
 
Xanthine  
 
Figure   3-25 Xanthine vs. oxypurinol chemical structure. 
 
 
Crucially, however, oxypurinol can interact with XOR to block urate production from 
xanthine (Spector, 1988).  
Guanosine Inosine
Guanine Adenine Hypoxanthine
Xanthine
Uric Acid
XDH
XDH
Allopurinol
 
Figure   3-26. Allopurinol drug effect. 
 
Consequently,  free  hypoxanthine  concentration  will  feedback  inhibit  the  XOR 
production and oxypurinol prevent urate production. Consequentially producing lesser 
amount of uric acid and accumulating of the precursors, hypoxanthine and xanthine. 
The accumulation of these two metabolites will lead to accumulation of adenine and 
guanine,  precursors  of  hypoxanthine  and  xanthine  respectively.  Increased  levels  of 
adenine and guanine have an inhibitory feedback effect on a rate-limiting enzyme in the 
purine biosynthesis pathway. So allopurinol not only reduces uric acid by inhibiting its 
conversion from its precursor, xanthine, but also by inhibiting the purine biosynthesis 
(Figure   3-26). Allopurinol is also used with cancer patients as prophylaxis treatment 
with chemotherapy as a treatment for stomatitis (mouth ulceration), though its mode of 
action is unclear (Yokomizo et al., 2004). 
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The effect of allopurinol is not only to reduce urate formation, but it could also lead to 
accumulation of the urate precursors, xanthine and hypoxanthine to high levels. It might 
thus be predicted that high levels of, or sustained treatment with, allopurinol could lead 
to xanthinuria; and indeed, xanthinuria type I can arise as a secondary effect of therapy 
with allopurinol. In Drosophila, allopurinol was reported to phenocopy the rosy mutant 
(Keller  and  Glassman,  1965).  So  we  wanted  to  validate  this  concept  by  using  the 
Orbitrap  (Figure   3-27).  Importantly,  allopurinol  has  the  potential  to allow  the  acute 
effects of XDH inhibition to be studied over time; by contrast studies of ry mutants can 
only follow relatively long-term adaptations to the lesion in XDH.   
3.4.2   Experimental procedure 
 
 
Figure   3-27. Allopurinol experiment overview. Was drawn by me. 
 
Allopurinol-treated flies were tested in a time-course experiment. Keller and Glassman, 
(1965) found that 110 µg/ml allopurinol was sufficient to give ry phenotype. Three 
different  times  were  selected  to  conduct  the  experiment;  zero,  6,  24  or  72  hours. 
Replicate samples were taken for microarray analysis.  
3.4.3  Results 
Initially, the treatment of Oregon (WT) with allopurinol led to dramatic changes in 
metabolite concentration of hypoxanthine, xanthine, allantoin, uric acid and oxypurinol 
when  compared  with  the  control  group  (Table    3-4).  Expressed  graphically    (Figure   102 
  3-28), it can be seen that levels of hypoxanthine and xanthine increase immediately 
upon  exposure to allopurinol, but build steadily  to maximum levels over two days. 
Urate, however, declines only very slowly. This is probably because the tubules, fat 
body and eyes of the fly contain major deposits of urate as insoluble uric acid crystals. 
Accordingly, these deposits are likely to have very long half-lives and so deplete very 
slowly. By contrast, allantoin decreases quickly and rather erratically, perhaps reflecting 
that its major pool is as soluble allantoin in the tubules. Accordingly, there is a dynamic 
sub-pool of urate and allantoin in tubules (independent from the insoluble urate pool) 
which is more sensitive to the activity of XDH, and thus the instantaneous metabolism 
of xanthine. 
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Figure   3-28 Timecourse of major metabolites in the purine metabolism pathway after 
feeding allopurinol to Oregon R (WT) flies at t=0. In this log scale graph, dramatic 
changes in metabolite concentration of hypoxanthine, xanthine uric acid and allantoin 
are  visible.  Hypoxanthine  and  xanthine  levels  were  increased  immediately  upon 
exposure to allopurinol and then were built steadily to maximum levels over two days 
(blue lines).  By contrast,  urate and allantoin (red  lines)  were both decreased. Urate 
declined very slowly. This is probably because the tubules, fat body and eyes of the fly   103 
contain  major  deposits  of  urate  as  insoluble  uric  acid  crystals.  Accordingly,  these 
deposits are likely to have very long half-lives and so deplete very slowly. By contrast, 
allantoin decreases quickly. Data are shown as mean ±SEM for N=5. Metabolites that 
differ significantly from t=0 are marked with asterisks are analyzed by Student’s t-test 
two tailed. 
 
 
Other pathways are impacted by allopurinol (Table   3-4), though in general the changes 
are  less  marked  than  for  the  purine  metabolism  pathway.  As  with  the  previous 
metabolomic  analysis  of  rosy  mutants,  there  is  impact  on  the  pigment  precursor 
(kynurinene  and  typtophan)  metabolism  pathways,  serving  to  confirm  the  broad 
accuracy with which allopurinol phenocopies the rosy mutation.   104 
Table   3-4. Metabolic pathways significantly affected by allopurinol. (F.C.; Fold change, 
P.V.;  P  value).  Red  means  down  regulated,  blue  means  up  regulated.  Analyzed  by 
Student’s t-test two tailed. 
  6 h  24 h  48 h  72 h 
 
Mr  Elution 
time 
F.C.  P.V.  F.C.  P.V.  F.C.  P.V.  F.C.  P.V. 
Purines/pterins 
Hypoxanthine  137.0460  11.5  2.3  0.0036  5.2  0.012  3.1  0.0035  6.0  0.0025 
Xanthine  153.0407  10.9  3.2  0.0077  7.8  0.0082  12  0.010  12.3  0.0001 
Urate  169.0357  14.04  1.1  0.38  1.1  0.085  0.85  0.14  0.72  0.002 
Allantoin  159.0514  15.1  0.25  0.00073  0.52  0.007  0.10  0.0011  0.40  0.0028 
Pterin  164.0568  12.7  1.3  0.035  1.7  0.000006  1.6  0.0024  1.4  0.0016 
Isoxanthopterin  180.0517  13.0  1.1  0.32  1.0  0.9  1.2  0.64  1.0  0.70 
Inosine  269.0882  12.7  0.84  0.19  1.0  0.91  0.74  0.0012  0.67  0.0026 
Drosopterin  369.1534  19.2  1.1  0.26  1.1  0.13  1.3  0.012  1.0  0.43 
Oxidative stress 
Methionine S-
oxide 
166.0532  19.1  0.99  0.98  2.77  0.00072  1.5  0.0019  1.4  0.83 
Ascorbic acid  175.0248  13.7  ND  -  ND  -  ND  -  ND  - 
GSH  308.91  17.0  0.51  0.0054  0.40  0.01  0.52  0.0077  0.45  0.0059 
Riboflavin  377.1458  10.2  1.0  0.84  0.47  0.0067  0.31  0.0084  0.26  0.0048 
GSSG  613.1592  21.5  1.4  0.12  2.9  0.011  1.8  0.022  1.4  0.06 
Pentose phosphate pathway 
Deoxyribose  133.0506  8.4  0.42  0.033  0.30  0.11  0.6  0.087  0.36   
Sedoheptulose 7-
phosphate 
289.0331  20.3  0.73  0.022  1.0  0.33  0.75  0.0031  0.71  0.0075 
Aldose reductase 
Gulonolactone  177.0405  12.2  0.30  0.029  0.32  0.034  0.26  0.026  0.52  0.090 
glucitol  181.0718  16.3  0.29  0.031  0.50  0.073  0.42  0.048  0.43  0.048 
Gulonic acid  195.0511  16.9  0.46  0.020  0.44  0.020  0.36  0.012  0.42  0.021 
Kynurenine pathway 
Niacin/Nicotinate  124.0393  8.2  0.72  0.029  0.79  0.034  0.44  0.0016  0.44  0.002 
Oxoadipic acid  159.0300  12.2  0.28  0.003  0.31  0.029  0.24  0.0027  0.54  0.1 
dihydroxyquinoline  162.0548  9.1  1.4  0.039  1.7  0.00066  1.2  0.090  0.94  0.65 
Xanthurenic acid  206.0448  11.7  0.86  0.011  0.96  0.47  0.70  0.001  0.80  0.0011   105 
L-Kynurenine  209.0922  13.4  0.71  0.00088  0.69  0.012  0.62  0.0019  0.41  0.0019 
3-Hydroxy-L-
kynurenine 
225.0868  15.1  0.90  0.15  0.83  0.027  0.85  0.0006
9 
0.63  0.0006
9 
N-Formylkynurenin  237.0871  13.9  1.1  0.58  0.45  0.30  0.23  0.0027  0.53  0.0027 
Miscellaneous 
L-Tyrosine  182.0812  15.7  0.73  0.024  0.87  0.043  0.61  0.0069  0.75  0.0069 
AHMDHP  196.0831  11.1  5.6  0.029  23.9  0.21  199  0.025  4.0  0.025 
5-Hydroxy-L-
tryptophan 
221.092  13.6  0.41  0.0043  0.18  0.00021  0.19  0.0023  0.32  0.0023 
Linolelyl carnitine  424.3421  10.1  0.66  0.003  0.95  0.5  0.63  0.0023  0.57  0.0013 
oleylcarnitine  426.3576  10.1  0.81  0.0088  1.1  0.21  0.75  0.0084  0.73  0.0020 
 
ND; metabolite not detected in sample group. AHMDHP; 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-
dihydropteridine 
 
3.4.4  Conclusion  
Allopurinol is one of the best inhibitors of XOR and is rapidly converted to oxypurinol 
by oxidation process: both allopurinol and its oxidized metabolite oxypurinol inhibit 
XOR  activity  (Spector,  1988).  Accordingly,  as  in  humans,  oral  administration  of 
allopurinol induced a blockade of the purine pathway in Drosophila. Interestingly, the 
data  provide  dynamic  data  on  the  relative  mobility  of  different  pools  of  purine 
metabolites in the fly; it would be interesting to test the resulting model (that there is a 
dynamic pool of urate and allantoin in the tubules, independent of the insoluble urate 
crystals). It is reasonable to posit a key role for tubules, because –as will be discussed 
later- the enzyme urate oxidase is expressed absolutely specifically in tubules, so this is 
where allantoin formation will occur. 
Inconveniently, oxypurinol has precisely the same molecular weight as xanthine, and so 
the  rise  in  xanthine  levels  could  be  attributed  to  an  accumulation  of  oxypurinol. 
However,  the  dietary  concentration  of  allopurinol  (at  110  µg/ml)  is  so  low  that  in 
practice, the peak is likely to represent endogenous xanthine. 
Allopurinol  use  as  an  inhibitor  of  XO  ramifies  into  several  branches  that  result  in 
several impacts on different biochemical pathways, for following the metabonomic field 
requires a full understanding of biochemistry as well as an open mind.   106 
Indeed, the present study is the first to utilize the technique of HILIC-LC-ESI-MS for 
the analysis of allopurinol. 
3.5  General Discussion 
 
The rosy mutation is a triumph of the Drosophila paradigm. It is the second mutation 
ever discovered in Drosophila (almost a hundred years ago) (Dow, 2007), and yet the 
original mutant stocks still exist today. Although many workers in the Drosophila field 
are  presently  energetically  pursuing  even  tenuous  models  for  human  disease,  rosy 
recapitulates rather precisely its corresponding human genetic disease (Chintapalli et al., 
2007)  .  It  is  even  possible  to  phenocopy  the  rosy  mutations  in  flies    (Keller  and 
Glassman, 1965), and the xanthinuria symptoms in humans (Gok et al., 2003), with the 
XOR inhibitor allopurinol. 
•  In this chapter, the Orbitrap technology was brought to bear on Drosophila, and 
there were several key findings: 
•  Orbitrap and flies are compatible: a simple homogenate allows the identification 
of hundreds of metabolites in a single experiment 
•  The Orbitrap is sufficiently sensitive to allow metabolomes of single fly tissues 
to be measured 
•  Single gene mutations have significant impact on the organismal metabolome 
•  The Orbitrap not just reproduces findings from years of classical, painstaking 
biochemistry in  a single experiment, but its amazing sensitivity allows these 
classical findings to be greatly extended. 
•  The  Orbitrap  also  allows  the  pharmacological  impact  of  drugs  on  the 
metabolome to be followed. 
As  a  result  of  this  work,  there  are  several  intriguing  lines  of  further  investigation 
suggested. How does XDH knockdown impact on osmolyte biosynthesis? How about 
oxidative stress- is this a result of urate deficiency? And are there separate labile and 
stable pools of urate in specific tissues, like the tubules? Although time did not allow 
the study of these new theories, it is hoped that it will one day be possible to follow 
them up. 
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Chapter 4  Maroon-like (mal)   108 
4.1  Introduction 
4.1.1  History 
Similarities among Drosophila mutants have long drawn the attention of Drosophilists. 
Similarities like body size and shape or eye colour, could result from either different 
alleles for the same locus or different genes in the same pathway. There has thus been a 
long tradition of crossing together mutants with similar phenotypes, to test for allelism 
(two mutants in the same gene) or for epistasis (the effects of one gene are modified by 
one or several other genes upstream in an enzyme series). Until the advent of DNA 
sequencing, such complementation analysis and epistatic analysis was a cornerstone of 
experimental genetics (Ashburner, 1990).  
In 1959, it was noted that several Drosophila melanogaster mutants shared a dull red 
eye colour. Those mutants are ry (Forrest et al., 1956), mal (Hadorn and Schwinck, 
1956)   and later cinnamon (cin) (Baker, 1973). 
Similarities between rosy and maroon-like are remarkable. Both of them have the same 
dull red eye colour; and both, also, are deficient in uric acid and have excesses  of 
hypoxanthine  and  xanthine.  Mutants  in  either  are  unable  to  convert  2-amino-4-
hydroxypterdine to isoxanthopterin, or to oxidise hypoxanthine to xanthine then to uric 
acid, reactions catalyzed by the xanthine oxidase. This is due to the absence of the 
enzyme. However, the genetic lesion is different, as the ry gene is located on the third 
chromosome, while mal is on the X chromosome (Glassman and Mitchell, 1959). The 
mal  mutant,  in  addition  to  the  malfunction  of  XDH,  is  also  defective  in  aldehyde 
oxidase  (Courtright,  1967)  and  pyridoxal  oxidase  (Forrest  et  al.,  1961).  Thus,  this 
suggested a link between the previous two enzymes and XDH, namely that mal was 
essential for the activity of all three different enzymes. As mal is epistatic to those three 
enzymes, it is likely to play a common role in their synthesis or function.     109 
 
It is known that conversion of 4-hydroxypteridine to 2,4-dihydroxypteridine needs an 
oxidative-type  reaction.  The  same  reaction  type  occurs  in  both  wild  type  and  rosy 
mutant flies, but not in the mal. This implies that mal is different from ry by the activity 
of the oxidases, which are suggested to be absent in the mal (Forrest et al., 1961). 
Furthermore, specific antibodies for xanthine dehydrogenase showed that the protein 
was  found  in  higher  levels  in  extracts  from  mal  than  ry,  which  implicates  that  the 
enzyme  in  ry  is  either  absent  or  reduced, 
while  in  mal  it  is  present  but  is  inactive 
(Glassman  and  Mitchell,  1959).  This  was 
subsequently found to be because ROSY is 
one of a small group of enzymes which use 
molybdenum at their active site, and Mal is 
the enzyme which inserts the molybdopterin 
prosthetic  group  into  the  maturing  XO 
enzyme (Ichida et al., 2001).  
Molybdenum  cofactor  biosynthesis  is  a 
conserved  pathway  among  bacteria,  fungi 
and  humans  (Schwarz  and  Mendel,  2006). 
This  synthesis  pathway  consists  of  five 
important steps summarized in (Figure   4-1), 
starting with guanosine triphosphate (GTP). 
The  GTP  is  converted  to  compound 
originally known as precursor Z, later called 
cyclic  pyranopterin  monophosphate  cPMP. 
Then  the  latter  is  converted  to 
molybdopterin  (MPT)  and  finally  to  the 
mature  molybdenum  cofactor,  MoCo 
(Figure   4-1).  
Figure   4-1 Molybdenum cofactor biosynthesis. After  
(Schwarz and Mendel, 2006). 
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4.1.2  Molybdenum- containing enzymes of Drosophila and their 
synthesis 
The main molybdenum-containing enzymes; XDH, AD and SO in Drosophila are all 
dependent on MoCo synthesis for their activity. Thus any defects in MoCo production 
leads  to  multiple  Drosophila  mutant  phenotypes  (Kamdar  et  al.,  1997).  This  is 
summarized in (Figure   4-2). The ry mutant is mutated in the XDH gene, consequently 
no enzyme produced to oxidize hypoxanthine to xanthine and then to uric acid. This in 
human, is called xanthinuria type I. Second, mal mutants suffer from dual enzyme loss; 
in addition to XDH, an AO is also absent. However the XDH enzyme is still present, 
but in inactive form. This is due to failure of an enzyme called sulphurase to add a 
sulphur  to  the  prosthetic  site  of  the  MoCo.  This  enzyme  also  affect  the  purine 
metabolism pathway in Drosophila as well as in human and are causing a disease called 
xanthinuria type II. Lastly, cin mutants suffer from the complete absence of the MoCo 
production, thus affecting not only XDH and AO, but also SO. This in human causes 
the MoCo deficiency disease which leads to neurological effects.  
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Figure   4-2 MoCo containing enzymes in Drosophila. This figure was drawn by me. 
GTP;  Guanosine  triphosphate, MPT;  molybdopterin,  MoCo;  molybdenum cofactor , 
SO;  sulphite  oxidase,  XDH;  xanthine  dehydrogenase,  AO;  aldehyde  oxidase,  cin; 
cinnamon, ry; rosy, mal; maroon-like. This figure was drawn by me. 
 
Because of their similarities in the chemical structures , both XDH as well as AO are 
classified in the same sub-group. Both, in order to be in the active form, are require 
post-translational sulphuration of the MoCo. On the other hand this post-translational 
sulphuration is not necessary for the other molybdoenzymes,, i.e. SO. This important 
reaction is carried out by an enzyme called sulphurase, which substitutes one of the oxo- 
groups of the MoCo with a sulpho double bond (Figure   4-3).   112 
Failure in this  sulphuration with sulphurase enzymes leads to defects in both enzymes , 
XDH and AO that leads to the rare inborn error of metabolism, xanthinuria type II 
(Garattini et al., 2008).  
 
 
 
 
 
 
Figure   4-3. The effect of the 
sulfurase  enzyme. 
substitution of an oxo group 
of  MoCo  with  sulpho-  
double bond (red). 
 
  Figure    4-4.  Instead  of 
sulphuration, a Cys is added. 
 
So deficiencies in any of the molybdopterin biosynthetic enzymes should produce a 
maroon-like  phenotype,  which  is  a  super  set  of  the  rosy  phenotype  as  all 
molybdoenzymes will be defective. 
So in flies, mal should produce a phenotype more severe than ry because more than one 
metabolic pathway is impacted.  
 
4.1.3  Links to human molybdoenzyme deficiency 
The molybdenum cofactor (MoCo) is an essential component of molybdoenzymes. So 
deficiency in MoCo is known, but rare in humans. It is autosomal recessive inborn error 
of metabolism, caused by defects in the biosynthesis of molybdenum-complexed pterin 
cofactor (Ichida et al., 2001).  
This  defects  lead  to  deficiency  of  the  previously  mentioned  three  molybdenum-
requiring enzymes: sulphite oxidase (SO), xanthine dehydrogenase (XDH) and aldehyde 
oxidase (AO). Affected individuals typically display severe neurological dysfunction in 
the newborn period or at early infancy along with renal impairment and high plasma 
concentration of xanthine.    113 
 
 
 
Figure   4-5. This chart show the metabolic pathways affected by molybdenum deficiency 
in human. SO; sulphate oxidase, XO; xanthine oxidase, MoCo; molybdenum cofactor 
deficiency. Due to absence of the MoCo, activity of XO and SO will be decreased. 
Figure after (Ngu et al., 2009) 
 
Affected  individuals  typically  display  intractable  seizures,  metabolic  acidosis, 
intracranial  haemorrhage,  feeding  difficulties,  dysmorphic  facial  features,  profound 
developmental  delay,  alterations  in  muscle  tone,  microcephaly,  lens  dislocation  and 
renal stones. Because of these varied features and the very rare occurrence, the disease 
can be easily misdiagnosed. The prognosis is poor: most of the infants die in the first 
days or weeks of their lives, and this could be the reason why it is rarely diagnosed: not 
because it is rare but because the it shares many of the clinical features with other 
diseases and its onset  is in the early infancy period and it is also fatal, so newborn 
babies die before proper diagnosis. 
As mal is a clear homologue of the human sulphurase, it is likely that it recapitulates to 
some extent the human disease. It may thus provide (as rosy does for xanthinuria type 
I), a model for xanthinuria type II. This chapter seeks to study the closeness of the 
model using metabolomics to profile the broader metabolic impact of the mutation.  
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4.2  Aims 
So, we selected mal for metabolomic analysis study because, we wanted to have better 
understanding of this mutant as human homolog xanthinuria type II animal model.  
In humans, xanthinuria type II produces additional defects and is more severe than type 
I. Would additional metabolic pathways also affected in Drosophila? 
All previous studies and research indicated that the molybdenum cofactor is deficient, 
thus all molybdoenzymes are present but are not functioning. Could this investigation 
lead to discovery of novel effects of the molybdenum co-factor deficiency?  
In addition in this chapter, I compare two different major wild type strains to compare 
inter-strain differences with mutant phenotypes.  
 
4.3  Results 
We conducted another comprehensive metabolic analysis profiling for mal using the 
methods described in the previous chapter. The investigation took place between the 
maroon-like mutant as a sample and as a control we used the wild type flies, Oregon R 
(OR). The impact of the mal mutation can be seen summarized in (Table   4-1).  
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Table   4-1. Major metabolomic differences between mal and OR. Reduced metabolites 
are in red coloure while blue colour indecates the incresed metabolite level. The test 
was  repeated  twice,  separated  by  five  months  and  with  N=5  biological  replicates. . 
Analyzed by Student’s t-test two tailed. 
Compound  m/z  Ratio 1  P value  Ratio 2  P value 2 
I. Purine metabolism pathway 
GABA  104.0707  0.53  0.00000030  0.731  0.00963 
Adenine  136.0759  3.7  0.00045  5.138  0.0019 
Hypoxanthine  137.0459  6.4  0.000014  21.816  0.079634 
Guanine  152.057  0.43  0.0019  0.656  0.086113 
Xanthine  153.041  75.0  0.000032  18.051  0.016686 
Allantoin  159.0516  0.027  0.00026  0.134  0.071928 
Uric acid  169.0358  0.0010  0.00028  0.021  0.001168 
Guanidine  284.0993  0.57  0.025  0.262  0.000145 
II. Eye pigmentation pathway 
Drosopterin  369.1531  0.22  0.000280  0.466  0.002149 
Xanthopterin  180.0518  0.0030  0.0030  0.021  0.018049 
Xanthommatin (met of 
Drosopterin)  424.0648  12  0.0057  2.165  0.000374 
Pterin (Benzene ring) 
the cofactor  164.0568  6.2  0.011  6.911  0.030468 
III Melanin pigments 
Tyrosine (is a precursor 
of melanin pigments)  182.0814  3.2  0.00056  11.586  0.006997 
Dihydrobiopterin  236.0783  2.0  0.058  3.330  0.001336 
IV Arginine and proline metabolism 
Proline betaine  144.1022  0.12  0.000034  0.572  0.0346 
Acetyl arginine  217.1297  2.8  0.0035  3.658  0.020833 
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4.3.1  Purine metabolism pathway  
As with rosy (and with allopurinol treatment), changes are observed in the purine 
metabolism pathway, consistent with the inhibition of XDH (Figure   4-6) not (Fig. 4-7). 
 
 
Figure    4-6.  Major  metabolite  changes  in  purine  metabolism  pathway  using  the  mal 
mutant. 
 
Accordingly,  mal  behaves  as  expected,  and  the  Orbitrap  technique  is  implicitly 
validated for identifying common metabolic fingerprints between mutants  of related 
genes. But are there further, or more severe, changes, consistent with the pathology of 
human xanthinuria type II? 
 
4.3.2  Eye pigmentation 
 The  normal  Drosophila  eye  pigments  are  composed  of  two  important  pathways, 
ommochrome  and  pteridines.  The  ommochromes,  which  are  synthesized  from  the 
tryptophan pathway, give rise to the brown pigments. By contrast, the pteridines are 
synthesized from guanine and produce the red pigments. Thus, any mutation to the 
ommochrome  pathway  will  affect  the  Drosophila  eye  colour,  and  by  reducing  the 
amount  of  brown  pigments,  make  the  eye  appear  redder.  Conversely,  mutations 
affecting the pteridine pathway will make the brown colour in the eye predominant so 
the eye will appear darker.   
The ommochrome biosynthesis pathway is well understood, and is less complicated 
compared to the pteridine pathway. Three pteridine pigment types are present in the   117 
Drosophila  eye,  Drosopterin,  isoxanthopterin  and  sepiapterin    (Evans  and  Howells, 
1978). Drosopterin in particular is produced from two precursors; pyrimidodiazepine 
PDA and dihydropterin DHP (Wang et al., 2008).  
 
 
Figure   4-7. Visual pigment biosynthesis. (is the enzyme converting 7, 8 dihydropterin to 
Drosopterin is the same that converting  pterin to xanthopterin? And this could be why 
both Drosopterin and xanthopterin are reduced? Even though their precursors are high 
in concentration?) 
   118 
4.3.3  Major metabolites differences between OR and CS wild types 
As a further control, two widely-used wild type lines, namely Oregon-R and Canton-S, 
were  compared  to  each  other.  The  full  list  of  metabolites  resolved  in  Oregon  R  is 
presented in (Table   4-2). 
 
Table   4-2 Metabolites in Drosophila OR strain observed by HILIC chromatography in 
combination with LC-MS 
Metabolite  Observed 
Mass 
Rt 
min 
Metabolite  Observed 
Mass 
Rt 
min 
Linoleamide  280.264  5  Oleoamide  282.28  5.4 
Hydroxy phenylacetic 
acid 
151.04  6.3  *Pyruvic acid  87.0088  6.9 
*Hydroxyketoglutaric 
acid 
161.009  6.4  Niacin  124.039  7.4 
*Lactic acid  89.0244  6.8  Succinic acid*  117.019  7.6 
Pantothenic acid  220.118  6.8  Fumaric acid*  115.004  7.7 
N-acetylglutamate  190.071  6.9  Ketobutyric acid*  101.025  8.1 
Aminohexadecanediol  274.274  7.7  Pyroglutamic acid  130.05  8.3 
* Ascorbic acid  175.025  7.8  Dihydrobiopterin 1  236.078  8.4 
Dopa quinone  196.061  8  Kynurenic acid  190.05  8.5 
Diacetyl ornithine  217.118  8  Formyl val-gly  203.103  8.7 
Hydroxybutyric acid*  103.04  8.1  Deoxyadenosine  252.109  8.9 
4-amino-4-
deoxychorismate 
226.071  8.8  Myristamide  230.248  9 
*Ribose  133.051  9.1  N-acetylaspartate  176.056  9.1 
Pyridoxate  184.06  9.3  Riboflavin  377.146  9.4 
Xanthurenate  206.045  9.5  Linolenylcarnitine  424.343  9.8 
Linolylcarnitine  426.359  9.8  Oleoylcarnitine  428.374  9.8 
Pyrimidodiazopterin  222.099  9.9  Dihydrobiopterin 1  240.109  9.9 
Dihydrobiopterin 2  236.078  9.9  Biopterin 1  238.094  10.2 
Histidine lipid  338.244  10.6  Xanthine  153.041  10.3 
Hypoxanthine  137.046  10.7  Hydromethyldeoxyhydrop
terin 
196.047  10.5 
Succinyladenosine  384.115  10.7  Uridine  245.077  10.5 
Xanthosine 1  285.083  10.8  Uracil  113.035  10.6   119 
Metabolite  Observed 
Mass 
Rt 
min 
Metabolite  Observed 
Mass 
Rt 
min 
Butoctamide 
semisuccinate 
316.212  10.9  Histidine lipid  362.244  10.6 
Acetylcholine 1  146.118  11.6  Histidine lipid  364.26  10.6 
Inosine  269.088  11.6  C12 sphinganine  218.212  10.7 
Pterin  164.057  11.9  Glycolic acid*  105.019  10.8 
Leucineproline isomer 1  229.155  11.9  Methylguanosine  298.115  10.8 
Ethyl n-acetylarginate  245.161  11.9  Valineleucine  231.171  11.3 
*Malic acid  133.014  12  Leu-leu  245.186  11.3 
Xanthopterin  180.052  12.1  Xanthosine 2  285.083  11.8 
Dihydroxanthopterin  182.068  12.1  Methyl tyrosine  196.097  12 
§*Hexose isomer1  179.056  12.2  Guanine 1  152.057  12.2 
Propylcarnitine  218.139  12.2  Cyclothionine  206.048  12.2 
*Deoxyhexose  163.061  12.4  Narigenin  273.075  12.2 
Phenylalanine  166.086  12.4  *Hexitol  181.072  12.4 
Butanedione  87.0441  12.5  Indospicine  174.124  12.6 
Kynurenine  209.092  12.7  Glycyl-dopa  255.098  12.6 
Biopterin 2  238.094  12.7  Adenosine  268.104  12.6 
Xanthommatin  424.079  12.7  Hydroxyindole acetic acid  192.066  12.7 
Tetrahydrofolate  446.179  12.7  Hydroxytryptophan  221.092  12.7 
Leucine  132.102  12.8  Hydroxyketoglutaric  163.06  12.9 
Guanine 2  152.057  12.8  Leucineproline isomer 2  229.155  12.9 
*Ketoglutaric acid  145.014  12.9  Isoleucine  132.102  13 
Leu-ala  203.139  12.9  Tryptophan  205.098  13.1 
Uric acid  169.036  13  §*Hexose isomer 2  179.056  13.2 
Dihydromethylguanosine  300.13  13  N-succinyl-2,6-
diaminoheptanedioate 
291.119  13.6 
Acetyl carnitine  204.124  13.1  Acetyl choline 1  146.118  13.7 
Pyridoxal  168.066  13.3  Tetrahydrothiophene 
carboxylic acid 
133.032  13.8 
Dihydrobiopterin 2  240.109  13.3  Aminoadipic acid  162.076  13.8 
Guanosine 1  284.099  13.3  *Gluconolactone  177.04  13.9 
Methylproline 1  130.086  13.4  Allantoin  159.052  14 
Acetyl serine  148.097  13.4  N2-(d-1-carboxyethyl)-l-
lysine 
219.134  14   120 
Metabolite  Observed 
Mass 
Rt 
min 
Metabolite  Observed 
Mass 
Rt 
min 
Acetyllysine  189.124  13.5  Guanosine 2  284.099  14.1 
Methionine  150.059  13.8  * Erythrose  119.035  14.2 
N2-acetyl-l-aminoadipate  
semialdehyde 
188.092  13.8  Adenine  136.062  14.2 
Formylkynurenic acid  237.087  13.8  *Pentose  149.046  14.2 
Spermidic acid isomer 1  176.092  13.9  Hydroxy kynurenine  225.087  14.2 
Pro-val/dethiobiotin  215.139  14  Valine  118.086  14.4 
§*Hexose isomer 3  179.056  14.2  Thioproline  134.027  14.4 
Leucineproline isomer 3  229.155  14.2  Proline betaine  144.102  14.4 
Camp  1  330.06  14.4  Tyrosine  182.081  14.5 
Ectoine  143.082  14.5  Spermidic acid isomer 2  176.092  14.8 
Guanidine butanoate  146.093  14.6  Ala-pro  187.108  14.8 
Propionylarginine  231.146  14.6  Methylproline 2  130.087  14.9 
N-acetyl-l-glutamate 5-
semialdehyde 
174.076  14.7  Camp  330.06  15 
Oxidized biopterin  254.089  15.1  Methyladenine  150.078  15.1 
Ala-glu  219.098  15.2  Methionine s-oxide  166.053  15.1 
N-acetylhistamine  154.098  15.3  Thymine  127.05  15.2 
Octopine  247.14  15.3  Gsh  308.092  15.3 
Proline  116.071  15.4  N-acetylhistamine isomer  154.098  15.8 
Uridine monophosphate  325.043  15.4  Cgmp  346.055  15.8 
Glycine betaine  118.086  15.5  Imp  349.054  15.8 
Carnitine  162.113  15.5  N6-(1,2-dicarboxyethyl)-
amp 
464.082  15.9 
Methylphosphate  113  15.6  Carnitine isomer  162.113  16 
Dihydrothymine  129.066  16.1  Acetylarginine  217.13  16 
Hydroxyproline 1  132.066  16.1  Ornithine acetate  175.108  16.2 
Taurine  126.022  16.3  Methyl adenosine 1  282.12  16.2 
Alanine  90.0549  16.4  Glutamic acid  148.061  16.3 
Meso-2,6-
diaminoheptanedioate 
191.102  16.5  4-
hydroxyphenylacetylglyci
ne 
210.076  16.3 
Acetylhydroxylysine  205.119  16.5  GABA  104.071  16.4 
Threonine  120.066  16.6  Glu-gln  276.119  16.7   121 
Metabolite  Observed 
Mass 
Rt 
min 
Metabolite  Observed 
Mass 
Rt 
min 
Amp  348.071  16.6  Hydroxyproline 2  132.066  16.8 
* Gluconic acid  195.051  16.7  Glucosamine phosphate  260.053  16.8 
Aspartic acid  134.045  16.8  Phosphoethanolamine  216.064  16.9 
Dopa  198.076  16.8  Glutamine  147.077  17 
Phosphoric acid  98.9843  16.9  Beta-alanine  90.055  17.1 
Aminopentanamide  117.102  17.1  Methylguanidino inositol  236.125  17.1 
Asparagine  133.061  17.4  Diaminocyclohexane 
tetraol 
179.103  17.2 
Nicotinate d 
ribonucleotide 
335.064  17.4  Guanidino inositol  222.109  17.3 
Glycine  76.0393  17.5  *Pentose-hexose  311.098  17.3 
Choline  104.107  17.5  Cytosine  112.051  17.6 
Serine  106.05  17.5  Hydroxyguanine  168.049  17.7 
Cytidine  244.093  17.6  Tyrosine phosphate  262.048  17.9 
Methyl adenosine 2  282.12  17.6  Phosphoethanolamine  142.026  18.2 
Citrulline  176.092  17.7  Cytidine monophosphate  324.059  18.4 
*Methoxyhydroxyphenyle
thyleneglycol 
185.08  17.7  Glutathione disulphide  615.13  18.8 
Arginylglycine  232.141  17.7  Methylhydroxyproline  146.081  18.9 
Drosopterin  369.153  17.7  *Citric acid  191.02  19.6 
Nad  664.117  17.8  Cysteine  241.031  20 
Glucose phosphate  261.037  17.9  Phosphocholine  184.073  20.1 
Gmp  364.065  18.1  *Tetrahexose  665.212  20.4 
Glycerophosphocholine  258.11  18.3  Acetylhydroxylysine  205.119  20.8 
* Trihexose  503.162  19.6  Arginine related  229.13  21 
Cystathione  223.075  20.2  Dimethylarginine  203.15  21.3 
Methyldihydroinosine  285.12  20.6  Histidine related 
compound 
168.077  22 
*Pentahexose  863.242  20.6  Methylhistidine  170.092  22 
Phosphoarginine  255.086  20.8  Aminobutyraldehyde  88.0756  22.7 
Argininosuccinate  291.13  21  Ornithine  133.097  23 
Histidine  156.077  22  Galactosylhydroxylysine  325.161  23.3 
Arginine  175.119  22.7  S-adenosylmethionine  399.145  24.3 
Lysine  147.113  22.9  N-acetylspermidine  188.176  25.2   122 
Metabolite  Observed 
Mass 
Rt 
min 
Metabolite  Observed 
Mass 
Rt 
min 
Fructosyl lysine  309.165  23  Putrescine  89.1072  26.2 
Thiamine  265.112  24.5  Phenol phosphate  171.992  28 
Histamine  112.087  25.9       
Glyceraldehyde 
phosphate 
171.006  28         
 
* Observed in negative ion mode 
 
These data, reflecting increased resolution as our skill in analysis increased, shows that 
the Orbitrap is clearly a very powerful machine for global metabolomic analysis. 
Investigations showed that both strains are fairly similar, however a few metabolites 
showed differences (Table   4-3).  
 
Table   4-3. Significant metabolite differences between OR and CS wild type flies.   
The  test  was  repeated  twice,  separated  by  five  months  and  with  N=5  biological 
replicates. 
Metabolite  m/z  Ratio 1  P value 1  Ratio 2  P value 2 
aminooxopentanoate  132.0656  3.5  0.0000048  9.3  0.067221 
ornithine  133.0972  1.6  0.0002134  3.3  0.037372 
Indospicine isomer  174.1239  12  0.0000033  10  0.000749 
N-acetylornithine  175.1079  23  0.0000706  87  0.000807 
Arginine  175.1191  0.77  0.0067336  0.59  0.000039 
Spermidic acid ?  176.0919  2.4  0.0000778  0.4  0.014783 
Spermidic acid?  176.0919  185  0.0000224  ND   
citrulline  176.1031  3.8  0.0005660  14.8  0.005540 
Hydroxyindole acetic acid  192.0657  0.62  0.0082408  0.22  0.000725 
Kynurenine  209.0923  0.62  0.0088140  0.17  0.000245 
Dihydrobiopterin  240.1094  0.59  0.0180132  0.48  0.001517 
AMP  348.0707  0.55  0.0034903  0.83  0.032279   123 
The  results  are  spread  fairly  broadly  across  the  metabolic  map,  and  there  does  not 
appear to be a particular concentration of metabolic changes within a particular part of 
the map. It is thus possible that some of these changes are false positives; at P<0.05, one 
would expect one false positive per 20 metabolites, and with more than 250 metabolites 
determined in each run, there is scope for most of these to be false positives. This is 
why in our earlier analysis, it was important to look for more than one change in a 
particular metabolic pathway. 
In principle, further experimentation and more replicates could resolve the issue, and 
increase  confidence  in  the  changes  observed.  One  change,  however,  that  did  seem 
consistent,  and  that  survived  repeated  sampling,  was  in  the  arginine  metabolism 
pathway (Figure   4-8). 
 
Figure   4-8 Metabolic signatures of OR and CS showing variations in the extracted ion 
chromatograms  representing  compounds  in  the  arginine/ornithine  pathway.  A, 13C 
isotope peak of ornithine acetate; SA, spermidic acid. After (Kamleh et al., 2009). 
 
Arginine levels  are slightly lower in CS. Assuming that  the  urea  cycle is not fully 
functional in Drosophila, in that conversion of arginine to ornithine via the loss of urea 
does not occur, citrulline and ornithine function as the precursors of arginine. Ornithine, 
ornithine acetate and citrulline are all elevated in CS. In addition to functioning as a 
precursor of arginine, ornithine enters the polyamine pathway, and two compounds, 
which are isomers of the spermidine metabolite spermidic acid (Kawase et al., 1994) are   124 
present in high abundance in CS. Only one of these compounds could correspond to 
spermidic acid; the other would have to be a compound such as aminoheptadioic acid. 
Neither  of  these  compounds  appears  in  the  Metlin  or  KEGG  databases,  although 
spermidic acid has been reported as a metabolite of spermine (Kawase et al., 1994). 
Although further experimentation would be required to validate this theory, the data 
show that the Orbitrap has the potential to resolve and identify entirely new metabolites. 
 
4.4   Discussion and conclusion 
4.4.1  How similar are different wild-type strains of Drosophila? 
All previously carried out experiments were done along with control samples. The fly 
wild type lines are the OR and CS. These fly lines are considered as the wild type flies 
and  are  used  extensively,  world  wide.  Despite  all  the  years,  no  studies  have  been 
conducted to investigate the deference or the similarities between them. 
It has been observed from the previous ry experiment that the Orbitrap is a powerful 
analyser  in  which  can  be  applied  to  generate  new  hypothesis  in  investigating  new 
mutants or even wild types. As it has not been reported before, a comparison between 
the two wild type strains are not exactly the same. This dose not mean they are both not 
wild types. The differences among the OR and CS are much fewer than comparing any 
of them to ry  or any other mutant. Furthermore, the significant difference in metabolites 
are not consistently in the same pathway which suggested the increase in false positive 
results. In any dataset with hundreds of data points, their will be some false positives. 
However, changes that occur in nearby metabolites are more likely to represent real 
changes than false positives. 
 
4.4.2  How similar are the metabolomic footprints of lesions in ry 
and mal? 
Similarities  between  ry  and  mal  are  not  only  in  the  phenotypes,  but  also  in  some 
metabolites. The main affected pathway is in the purine metabolism pathway, where the 
impact  of  XDH  is  clearly  revealed.    This  is  reflected  in  the  excessive  levels  of 
hypoxanthine and xanthine and their precursors, like adenine and inosine. By contrast, 
downstream  metabolites  such  as  urate  and  allantoin  are  both  sharply  reduced  or 
sometimes even not detected.  While the ry mutant mimics the xanthinuria type I inborn   125 
error  of  metabolism,  mal  mimics  the  xanthinuria  type  II.  Although  ry  and  mal  are 
phenotypically  similar,  they  are  genetically  very  different;  the  lesion  in  ry  is  in 
chromosome 3 whereas in mal it is in the X chromosome. In rosy only one enzyme is 
defective namely, XDH. While in mal the lesion is due to deficiency in both XDH and 
AO. This is attributed to a defect in sulphurase enzyme which adds a sulphur atom to 
the cofactor binding site.   
What was interestingly different from the ry mutant is on the tyrosine levels.  
The cause of defect in the purine pathway in mal mutant is that the lesion is not because 
the absence of the XDH enzyme, it is rather present, but the molybdopterin co-factor, 
which is require for the XDH functioning is defective. This co-factor is required not by 
the XDH only, but by a wide range of enzymes like aldehyde oxidase and sulphite 
oxidase.  And this may explain the secondary effects on the tyrosine metabolism.  
Also,  the  aldehyde  oxidase  enzyme  oxidises  pyridoxal  to  pyridoxate.  Accordingly, 
pyridoxate was seen in both OR and ry, but not in mal  (Figure   4-9).  Thus this is clear 
indication that this must be due to the molybdopterin co-factor defect.  
 
Figure   4-9 This diagram shows the electrogram of the traces of pyridoxate in OR, ry and 
mal. After  (Kamleh et al., 2009). 
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4.4.3  Maroon-like as a model for xanthinuria type II 
This work also allows the comparison of the models offered by Drosophila mutants ry 
and mal, for the human diseases xanthinuria type I and type II, respectively. Both types 
are characterised by lower plasma uric acid concentrations, and higher plasma xanthine 
concentrations; whereas urinary excretion of uric acid is low or undetectable, and that of 
xanthine is elevated. As discsussed above, both fly mutants recapitulate these symptoms 
rather closely.  
 
 
Figure   4-10 This picture shows darker eye colour in mal mutant compared with WT. 
This picture was taken by me. 
 
 
Although both types of hereditary xanthinuria in human are clinically similar, but there 
are  some  differences.  Whereas  patients  with  type  I  can  metabolise  allopurinol  to 
oxypurinol, those with type II cannot. Unfortunately, we did not test this finding in 
maroon-like flies. 
 
4.4.4  How consistent are metabolomes over time? 
The wild-type flies OR and CS were compared at two time points, 5 months apart. On 
both occasions, there were a number of differences in the metabolites listed in (Table 
  4-3); however, the differences were not the same on each occasion. Thus, variation in 
time must be a criterion for establishing stable differences. In addition, there is variation 
mal 
WT   127 
which  occurs  on  extraction,  as  it  is  virtually  impossible  to  stop  biologically  labile 
metabolites altering, because metabolism cannot be stopped instantaneously. There are 
of course some instrumental variations, but analysis of batches, e.g. 5 × OR against 5 × 
CS, in randomized order eliminates these. Biological variations are a difficult area and 
represent a major challenge in the extraction of useful metabonomic data. At best, all 
that is possible at the moment is to state that significant differences must be observed on 
at least two occasions to be considered significant. 
 
4.4.5  Conclusions 
•  The Orbitrap is capable of resolving over 250 metabolites in even a small sample, 
and of identifying potentially novel metabolites. 
•  The  two  wild-type  strains,  Oregon  R  and  Canton  S,  show  highly  similar 
metabolomes, but with consistent differences in arginine metabolism. 
•  Metabolomes are very labile, and repeated biological replicates need to be taken 
over an extended period to minimise variation. 
•  The rosy and the maroon-like are both excellent models of xanthinuria types I and 
II,  respectively.  Maroon-like  shows  changes  in  a  wider  range  of  metabolites, 
reflecting the impact on more than one enzyme.  
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Chapter 5  Urate oxidase (uro)   129 
5.1  Introduction 
As any living organism nitrogenous waste products can be highly toxic and need to be 
eliminated immediately either in the form of UA or other forms of metabolic forms 
(Vogels and Van der Drift, 1976). To do so these wastes are must be metabolized to 
lesser toxic products, like uric acid in Drosophila. Uric acid is also water insoluble, so 
its excretion wastes less water volume.  Such uricotelic excretory systems are found in 
terrestrial insects and birds. Excretion of urea or ammonia is found in large animals and 
water living animals.  
In some cases the wastes are metabolized to water soluble metabolites, thus they must 
be  diluted  to  reduce  its  toxicity  until  they  excreted.  Consequently,  excessive  water 
volume is highly demanded in this process. 
Uro  encodes  a  structural  gene  for  urate  oxidase  enzyme  (URO);  this  enzyme  is 
important in oxidation of urate to 5-hydroxyisourate (5HIU) or allantoin in Drosophila 
melanogaster  (Kral  et  al.,  1986).  It  is  exclusively  expressed  in  the  Drosophila 
Malpighian tubules, and only in the third-instar larvae and adults (Friedman, 1973) and 
(Chintapalli et al., 2007). Its activity is rapidly reduced in the late period of the third-
instar larvae and disappears in the pupal stage; then it regains its activity again at the 
early  adult  stage  as  shown  in  (Figure    5-2)  (Friedman,  1973).  This  disappearance  is 
controlled by an intercellular clock-like mechanism which at specific life period stops 
the expression of uro (Friedman and Johnson, 1977). Although others have different 
opinion (Jackson, 1978), this remarkable disappearance of the enzyme activity does not 
apply  to  all  Drosophila  species.  For  example  the  uro  gene  in  Drosophila  virilis  is 
expressed only in the MT and the enzyme activity is shown in the third-instar larvae 
only. Whereas in Drosophila pseudoobscura the mRNA abundant is also in the MT but 
the enzyme activity is shown only during the adult stage (Figure   5-1) (Wallrath and 
Friedman, 1991).    130 
 
Figure   5-1 Comparison between three different species of Drosophila showing the URO 
enzyme  activity  during  different  life  span.  Dark  circles  represents  males,  whereas 
opened circles represent females (Wallrath and Friedman, 1991). 
 
 It is puzzling that this gene should be controlled so precisely, and so differently, in 
three closely related species. The reason is not known; but it could be because the need 
for the protective antioxidant properties of urate differs between the species. 
The  end  product  of  purine  metabolism  varies  between  human  and  Drosophila.  In 
Drosophila, like other insects, the final purine product is a mixture of uric acid and 
allantoin, depending on expression levels of urate oxidase. On the other hand, urate 
oxidase is absent in human; and as a result, urate is not metabolized into allantoin (as in 
Drosophila) as the end product of purine metabolism. The absence of this enzyme has 
some beneficial effect on mammals (Chapman and Chapman, 1998), as UA, plays an 
important role as an antioxidant of ROS in plasma and excreted through urine as urate. 
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5.2  Urate and oxidative stress 
Several  diseases  have  been  suggested  to  be  caused  by  toxicity  due  to  free  oxygen 
radicals, like cancer, heart diseases and aging.  
It has been shown that an increased lipid peroxidation is found in heavy exercise and is 
accompanied by increased levels of urate. Free oxygen radicals rise as a result of the 
aerobic  metabolism  of  metabolic  reactions.  Consequently,  exposure  to  these  active 
oxygen  species  will  react  with  electrons  from  lipids  in  cell  membrane,  varieties  of 
important molecules like DNA, RNA, proteins and leading to cell damage. Ultimately, 
such  products  will  lead  to  products  that  are  able  to  be  cytotoxic,  mutagenic,  and 
carcinogenic and may be lethal to the organism.  
Antioxidants  are  thus  important  defences  against  oxidative  stress,  and  have  been 
asserted to protect against cancer and ageing. Urate is a potent free radical scavenger 
(Ames et al., 1981), which binds to these radicals and keeps them in a more stable form 
and causing less cellular damage (Hilliker et al., 1992).  
 
5.3  Urate and gout 
Although  urate  plays  a  vital  role  in  detoxification  and  free  radicals  scavenging  in 
disease and normal status (Ames et al., 1981), high levels of uric acid, by contrast can 
be damaging and lead to inflammatory disease. Gout is an inflammatory human disease 
that arises due to excessive uric acid levels in blood, and also due to the lack of urate 
oxidase  enzyme  to  further  metabolise  uric  acid  to  5HIU  (Maloley  and  R.Westfall, 
2000). 
The levels of circulating urate are thus a compromise between two opposing needs. As 
humans lack a urate oxidase enzyme, they are predisposed to higher levels of urate. By 
contrast, in Drosophila melanogaster, uric acid, is not always not end product of purine 
metabolism,  and  can  be  further  metabolized  to  5-hydroxyisourate  (5HIU),  by  urate 
oxidase,  and  then  to  allantoin  by  5-hydroxyisourate  hydrolase  (Figure    5-3). 
Nonetheless,  a  potential  role  for  urate  as  a  protection  against  oxidative  stress  in 
Drosophila can be inferred from the discovery that rosy mutants are hypersensitive to 
oxidative  stress,  induced  by  the  weed  killer  paraquat.  Paraquat  is  a  redox  cycling 
compound,  it  is  reduced  by  NADPH  to  form  a  relatively  stable  radical  species 
(Pq
+)which then racts with O2 to generat ROS (Hilliker et al., 1992), it is also inhibites 
microchnodrial electron transport (Franco et al., 2010).   132 
 
5.4  Control of urate oxidase expression 
Unlike microorganisms, uric acid oxidase enzyme in Drosophila melanogaster is not 
induced by uric acid, since ry and mal mutants have higher URO enzyme concentration 
higher than the Oregon-R wild type mutant. This interest, in both ry and mal mutants, 
came  from  the  fact  that  both  of  them  lack  detectable  levels  of  the  xanthine 
dehydrogenase enzyme, which is responsible for hypoxanthine to xanthine then to uric 
acid conversion (Friedman and Johnson, 1977). 
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Figure   5-2 The uro activity pattern in wild-type mal and ry in Drosophila. Modified 
after (Friedman, 1973). 
 
Urate oxidase activity is not detected in the first, second instar larvae and pupal stages. 
However, it is present in third instar larvae and adults. So it seems there is a temporal 
control  of  the  enzyme  activity  during  different  fly  stages.  However,  molecular 
mechanism  of  reactivation  of  the  uro  gene  in  the  adults  Drosophila  is  poorly 
understood. However, (Friedman and Johnson, 1977) have proposed two phenomena for 
urate oxidase activity. First an inducing factor, closely located to the gene that stimulate 
the production of enzyme, suggested to be found in the haemolymph. The second is that 
an  autonomous  intracellular  clock-like  mechanism,  found  in  the  adult  Malpighian 
 
Ore-R 
mal 
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tubules, may be responsible for controlling the time of changes to take place (Friedman 
and Johnson, 1977).  
The inducing factor was found in ry and mal 5-10 times higher than uro -mRNA and 
uro  proteins  than  in  wild  type  adult.  (Wallrath  et  al.,  1990).  However,  studies  by 
(Ramazzina et al., 2006) and (Tipton, 2006) suggested that urate oxidase is converting 
UA to 5HIU but not allantoin, as it was thought.  
 
 
Figure    5-3  Part  of  purine  metabolism  pathway,  emphasising  the  downstream 
metabolism of urate. 
 
5.4.1  Principle of Polarizing microscope assay for uric acid crystals 
As well as using metabolomic approaches, it is possible to visualize urate directly, as it 
is birefringent (Ainsworth et al., 2000). The polarized light microscope is designed to 
observe  and  capture  specimens  that  are  visible  primarily  due  to  their  optically 
anisotropic character. In order to accomplish this task, the microscope must be equipped 
with both a polarizer, positioned in the light path somewhere before the specimen, and 
an analyser (a second polarizer; Figure   5-4), placed in the optical pathway between the 
objective rear aperture and the observation tubes or camera port.    134 
 
Figure   5-4. The light polarizing microscope. 
http://www.microscopyu.com/articles/polarized/polarizedintro.html  
 
 
This polarizing effect depends on the properties of the specimen, including the thickness 
difference  between  the  refractive  index  and  the  birefringence  of  the  two  mutually 
perpendicular beams, which has a maximum value dependent on the specimen and on 
the direction of light propagation through the specimen. 
As the analyzer plate is rotated, the intensity of the polarization light varies cyclically, 
from zero (extinction; Figure   5-5 (d)) up to a maximum brightness at 45 degrees (Figure 
  5-4 (a), and then back down to zero after a further 90-degree rotation.  
That is why rotating the plate is crucial in polarized light microscope for determining of 
the specimen.  
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Figure   5-5. Principle of polarizing imaging of birefringent crystals. From: 
http://www.microscopyu.com/articles/polarized/polarizedintro.html  
One of the most common medical applications for polarized light microscopy is the 
identification  of  gout  crystals  (monosodium  urate).  Thus,  shiny  urate  crystals  are 
indicated as high levels of crystals under polarizing microscope (e.g. Figure   5-6). 
 
5.5  Aims 
We  aimed  to  perturb  the  uro  in  the  Drosophila  melanogaster  specifically  in  the 
Malpighian tubules in order to investigate the effects of this gene. As the uro is involved 
in complex biological activities in the human as well as in the Drosophila, we wanted to 
see  the  effects  on  longevity,  response  to  oxidative  stress  and  changes  in  the 
metabolome. Another interesting point is to investigate whether the nitrogen was being 
shunted to other pathway, for example proline and glutamine pathways.   
   136 
5.6  Results 
5.6.1  RNAi 
The RNAi is a method widely used as a powerful tool for reverse genetics in gene 
silencing.  The  method  first  was  used  in  C.  elegans,  was  quickly  adopted  for  gene 
silencing in Drosophila melanogaster (Kennerdell and Carthew, 2000).  
In  order  to  intervene  a  specific  gene  in  the  Drosophila,  an  inverted  repeat  DNA 
sequence must be constructed to target a specific gene, in our case, uro, and to be placed 
under the control of the UAS promoter. This was carried out with help of the pRISE II 
transgenic vector (Kondo et al., 2006). Then this construct was sent to be injected into 
white background fly embryos, w
1118 and was balanced over the homozygous lethal 
CyO on the second chromosome.  
 
5.6.2  Testing the effectiveness of RNAi against urate oxidase 
UAS-uro (RNAi) flies were crossed to uro -GAL4 virgin flies. Then 5 to 7 day old adult 
progeny were dissected in a Petri dish containing Schneider’s medium. Once the MT 
were separated, they were carefully transferred with a glass rod to be screened for both, 
uric acid crystals precipitation using the polarizing microscope (Figure   5-6) and gene 
expression  knockdown  with  both  quantitative  expression  analysis  (Figure    5-7)  and 
Orbitrap metabolomics (Figure   5-8).  
 
5.6.3  Polarizing microscope assay  
5-7 days old adult progeny of a cross between UAS-uro RNAi line and uro -GAL4 
driver, were selected for the analysis. Dissected MT were immediately transferred using 
a glass rod onto a microscope slide which also containing a few drops of Schneider’s 
medium. A coverslip was applied, using four dots of high vacuum grease to maintain a 
gap. This slide was then immediately inspected under the polarizing filter microscope.  
As a result of knocking down uro, UA crystals would be expected to accumulate in the 
Drosophila MTs. These crystals should be visible as birefringent under the polarizing 
filter.  
In (Figure   5-6), two pictures are shown for the same tubule. The one in the left, used as 
control  as  it  was  taken  under  the  classical  light  microscope.  It  was  shown  the   137 
background  is  lighter  than  the  object  and  it  is  not  signs  for  crystals  precipitations. 
Whereas  in the right side picture, the background was dark  as well as parts  of the 
tubules as they do not contain crystals. However, the main segments were full of the 
uric acid crystals; thus they were seen as shining under the polarizing filter.  
This  provides  us  with  a  clear  indication  that  polarizing  microscopy  is  capable  of 
visualizing urate crystals effectively.  
 
A    B   
   
 
Figure    5-6.  Demonstration  of  uric  acid  accumulation  in  tubules.  The  same  picture  is 
shown  what  it  looks  like  the  uric  acid  crystals  under  the  polarizing  microscopy. 
Transmitted  (A)  and  polarizing  (B)  views  of  uro  knockdown  tubules.  White  arrows 
denotes uric acid crystals precipitations, while red arrows pointing to areas where no 
crystals were seen.  Wild type  vs mutant comparison pictures are shown in Figure   5-9. 
 
5.6.4  Validation by qPCR 
As  the  polarization  test  suggested  that  the  uro  knockdown  was  working,  gene 
expression  validation  was  taken  place  in  order  to  measure  the  efficiency  of  the 
knockdown. For this MT from parents and the progeny were dissected in a Petri dish 
containing Schneider’s medium. Then the MT were immediately transferred by a glass 
rod into RLT buffer in preparation for RNA extraction. In the case when the extraction 
was not going to be immediate, RLT buffer containing the MT were preserved at the -80 
ºC. After mRNA extraction, quality and quantity of mRNA were measured. Then after,   138 
cDNA were  generated, using the mRNA as  a template, and again were  checked to 
quality and quantity.  
As  a  statistical  control,  four  technical  replicates  were  applied  for  each  of  three 
biological  replicates.  Each  tube  contained  12.5  µl  SYBR  green,  2  µl  primer  set, 
approximately 500 ng cDNA template and finally made up to 25 µl of nuclease-free 
water.  
As can be seen (Figure   5-7) there is a substantial decrease in the amount of expressed 
uro gene in knockdowns when compared with the other two parents. Approximately 
80% gene expression reduction was seen in the dissected MT as compared to the same 
number of parental tubules dissected. It must thus be concluded that this is a relatively 
successful knockdown. 
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Figure   5-7 This figure shows uro RNAi knockdown validated by qPCR. It shows uro 
gene knockdown expression dissected from the MT compared to uro GAL4 and uro 
UAS-RNAi parental lines. Approximately eighty per cent uro lower expression was 
seen as determined by Student’s t-test. Data are expressed as a percentage, compared 
with the average parental expression levels. 
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5.6.5  Validation by Orbitrap 
Further studies  were performed  to determine key metabolites  as a  result  of the uro 
knockdown on MT using the Orbitrap. The UAS-uro RNAi lines with their parents 
were used. Around 20 adult flies aged between 5 to 7 days old were used for the MT to 
be dissected. Fly dissection took place in a Petri dish containing Schneider’s medium. 
After the desired number of tubules was dissected, they were immediately transferred 
into ice-cold 50% methanol/ 50% water solvent. Samples were kept at -20 ºC for short-
term less than one week, or at -80 ºC for longer periods, until the day of analyses. Each 
fly line was repeated in three biological replicates.  
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Figure   5-8. Impact of uro knockdown on purine metabolite levels in tubule using the 
Orbitrap.  Data are shown as mean +/- SEM of three biological replicates.  A) Plotted by 
genotype.  B)  The  same  data  plotted  by  metabolite.  UAS  may  show  some  leaky 
expression even when not driven. This would explain why the UAS-uro resembles uro-
GAL4 x UAS uro.   
A) 
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It is nice to note that these results also show the ability to produce good metabolic data 
from isolated single tissues, rather than whole flies. 
 
 
5.6.6  Crystals under the polarizing microscope 
As  another  validation  method  in  the  uro  knockdown  we  used  the  polarizing  filter 
microscope. Usually uric acid crystals shine when seen under crossed polarizing filters, 
allowing  their  rapid  visual  identification  in  the  MT.  The  MT  from  the  uro  -RNAi 
progenies and their parental lines were dissected under the light microscope in a Petri 
dish containing Schneider’s medium. After dissection, a glass slide was marked with the 
designated line’s name and one drop of Schneider’s medium added; then with a glass 
rod the whole tubules were carefully transferred to the slide. As the eye view field was 
limited, and the whole MT was relatively wide, several pictures were taken then were 
merged together to form composite pictures showing the whole tubules (Figure   5-9). 
In this figure tubules in A and B were for uro -GAL4 parent and UAS-uro RNAi parent 
respectively; consistent with normal expression of uro, only sparse uric acid crystals 
were  seen.  Whereas  in  C,  the  UAS-uro  RNAi  progeny,  an  obvious  and  aberrant 
accumulation of uric acid crystals was seen.  
 
Although there was no significant difference in the levels of urate between the three 
lines in the metabolomic analysis, it was clear in the polarizing microscope and in the 
quantitative PCR. The results from the three techniques are thus slightly contradictory, 
but could be explained if most of the uric acid crystals were spun down into the pellet 
during methanol/water extraction for metabolomic sampling. The protocol used would 
favour sampling of the soluble urate.  
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Figure   5-9. Impact of uro knockdown on uric acid accumulation in adult tubules. Uro -
GAL4  parent  (A),  UAS-uro  (RNAi)  parent  (B)  and  progeny  of  uro  -GAL4>uro 
(RNAi) (C). The RNAi knockdown of uro  was functionally effective, and resulted in an 
abnormal accumulation of uric acid. 
A 
B 
C   142 
 
5.7  Survival assay 
Furthermore, this line was used to determine the effects on the fly survival and see the 
effects on aging and longevity.  
 
5.7.1  No additive to the fly food 
Longevity has been linked directly to urate concentration. Thus the Malpighian tubule 
specific gene, uro, was tested to see if it has an effect on fly survival. So experiments 
involved several fly lines were conducted including both the uro -GAL4 and UAS-uro 
(RNAi) parents and their progeny. Adult flies were collected and transferred to newly 
prepared fly food vials, and kept under medium crowding (10 males +10 females per 
vial). The number of dead flies were recorded twice a week. Flies were tipped weekly 
into newly-prepared vials. As seen in (Figure   5-10), survivorship curves were plotted. 
The UAS-uro RNAi cross fly line showed a slight improved in longevity compared to 
both  parents,  which  differed  markedly  in  their  survivorship.  The  UAS-uro  (RNAi) 
parent line was the fastest to die, while the other parent, uro -GAL4, was very similar to 
the progeny.  
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Figure   5-10 Survival assay for uro RNAi lines under normal conditions. When uro is 
knockdown  it  shows  more  urate,  which  is  antioxidant,  this  means  the  fly  is  better 
protected, this suggested the flies are healthier. Significant changes were seen P-value 
0.0018, Log-Rank (Mantel-test). 
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5.7.2  Survival assay under oxidative stress 
Unfortunately, our UAS-uro RNAi line was lost, so the oxidative stress experiments 
were  performed  with  the  uro  insertional  knockdown  line  from  Bloomington  
w
1118; {w
+mC=WH}PBac uro
f04888 (Mamer et al., 1971).  
 
 
It is important to increase the efficiency of transposon mutagenesis in D. melanogaster, 
to  emphasis  on  generating  stronger  loss-of-function  alleles.   In  this  line  the  most 
promising, pBac transposon was used for more effective gene disruption.  When this 
technique was discovered  by (Thibault et al. 2004) eighty-nine percent of the lines 
yielded unique flanking sequence by inverse PCR. In addition, 97 of 100 pBac lines 
analyzed  by  genomic  Southern  blotting  had  single  insertions.  And  the  unlinked 
background mutations screens of pBac stocks contained only 0.3 -0.5 %. Finally, they 
also found the insertion and transposase strains have been stable for 4 years with no 
observed breakdown. Taken together, these data support the conclusion that pBac acts 
as an effective mutagen and that the mutations observed are directly caused by the 
transposon insertion.  
 
The uro gene contain only one small intron (60 bp) in the middle of the gene, and the 
pBac is 7.2 kb is large enough  which was landed in the middle of the gene, and so is 
highly likely have disrupted the gene reducing the transcription of the normal mRNA as 
seen in Figure   5-11.     144 
 
Figure   5-11 The pBac transgenic insertion site on the uro gene. 
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Figure   5-12 Survival assay showing the effects of parquat on male specific into three 
different mutants. Three tubes of 10 flies. 
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Figure   5-13 Survival assay showing the effects of parquat on female specific into three 
different mutants. Three tubes of 10 flies. 
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Figure   5-14 A survival assay showing the effects of 20mM parquat on three different 
lines w
1118; {w
+mC=WH}PBac uro
f04888 , rosy
506 and w
1118. No significant changes were 
seen, P-value 0.25, Log-Rank (Mantel-test). 
 
5.8  Discussion 
From the  interfering  RNA  work  (Figure   5-7),  it can be seen  that a significant <  0.001 
knockdown, of approximately 80% of the uro expression, was achieved. This can be also 
confirmed  by  the  condensation  of  the  uric  acid crystals  in  the  MT  of  the  organism  as 
compared to the other parents (Figure   5-9). This gave enough confidence that it worked.   146 
However, when applying metabolomics, the results were a puzzling and confusing (Figure 
  5-8 A and B). The explanation to this could be that although there were an approximately 
80% knockdown, the other 20% perhaps was enough to produce enough UA to be seen by 
the Orbitrap. This small percentage (20%) is the residual expression, or what is sometimes 
called  leaky  expression,  would  be  capable  of  producing  some  protein.    An  alternative 
explanation for the UA crystals seen in the MT, are that these are of insoluble urate. This 
insoluble urate was pulled down in the sample preparation for the metabolomic experiment. 
So, even if urate production had ceased entirely, carry-over of insoluble urate would result 
in a relatively slow depletion of urate levels, much as was observed.  
Then the effects of uro on the Drosophila lifespan was also needed to be investigated, thus a 
survival assays were important to be carried out. 
Thus a survival assay was conducted to investigate the uro effects on Drosophila’s lifespan 
in comparisons with uro-GAL4 parental line and UAS-uro RNAi parental line as it can be 
seen in (Figure   5-10). Lifespan was significantly increased, P-value 0.0018 in the progenies 
of the uro-RNAi line crossed with the uroGAL4. 
Moreover, these interesting results have encouraged us to further survival testing using an 
oxidative stress agent. Sadly, the UAS-uro parental line were lost and this rendered us from 
carrying out the experiments. However, a Bloomington stock of uro knockdown insertional 
line were used (w1118; {w+mC=WH}PBac urof04888). 
This time survival assay under the 20 mM oxidative stress parquat was conducted. Beside 
the  uro    w1118; {w+mC=WH}PBac  urof04888    line,  rosy506  and  w  1118  were  also 
compared. (check if there is Oregon-R) 
The limited time during my PhD and the family bereavement happened have prevented me 
to test the uro w1118; {w+mC=WH}PBac urof04888  line to validate the gene knockdown 
by qPCR or to visualize the uric acid crystals under the polarizing microscopy. 
If the time allowed, it would be nice to continue these experiments in order to get insights in 
the future for the effect of parquat on the Drosophila lifespan. 
In particular, it would have wanted to confirm these exciting results by : 
•  Re-transforming Drosophila with my RNAi construct. 
•  Validating knockdown of w1118; {w+mC=WH}PBac urof04888  line by QPCR. 
•  Validating  knockdown  of  the    w1118; {w+mC=WH}PBac  urof04888  line  by 
visualising uric acid crystal accumulation (as seen in Figure   5-9); and perhaps 
•  Validating  knockdown  of  the    w1118; {w+mC=WH}PBac  urof04888      line  by 
Orbitrap analysis.   147 
In addition, it would be interesting to test the hypothesis that there are both soluble and 
insoluble pools of urate in tubule.   
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Chapter 6  Drosophila microarray analysis 
investigation   149 
6.1  Introduction 
Gene-expression  microarrays  have  become  widely  used  as  measurement  tools  in 
biological research (Lamy et al., 2011). Designing the experiment has a direct impact on 
the efficiency of the results interpretations and test validity (Leung and Cavalieri, 2003). 
From the experimental and technical point also, the biological replicates of samples are 
another important point must be carefully considered. In microarray analysis, two types 
of replication can be carried out: the technical replication, is when mRNA sample is 
used on multiple microarrays, and the biological replication, is when measurements are 
taken from multiple sample (Kerr et al., 2000).  
However, data analysis is considered the most challenging part of it. A wide range of 
methods for microarray data analysis have been used . 
 
Microarrays are considered among the most attractive techniques for high-throughput 
transcriptional profiling with metabolomics. This technique draws its power from the 
simultaneous detection of  tens of thousands of genes at the same time. The cost  is 
dropping constantly and it is not only being used exclusively in the research field, but in 
screening  for  cancers,  and  for  disease  diagnosis  and  monitoring.  In  time,  next 
generation  sequencing  (NGS)  technologies  are  likely  to  supplant  microarrays  for 
expression profiling; but at present microarrays are the mature platform of choice.  
 
6.1.1  General principle  
 
Generally in any microarrays, probes are fixed to a surface, usually glass. Each probe is 
complementary to a particular cognate mRNA. From each biological sample, mRNA is 
used to generate cRNA in order to hybridize to the probes. These cRNAs are usually 
labelled with fluorescent dyes for hybridization.  
 
After  hybridization,  laser  light  is  used  to  excite  the  fluorescent  dye;  the amount  of 
florescence  is  proportional  to  the  intensity  of  the  hybridization,  thus  reflects  the 
abundance of transcript (Figure   6-1).  
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Figure    6-1  Schematic  overview  of  the  Affymetrix  GeneChip,  taken  from 
www.affymetrix.com. 
 
 
 
6.1.2  Affymetrix 
Affymetrix one of the most popular microarray platforms used (Figure 1.21). In only a 
small square (1.28 cm
2) glass, more than 1,000,000 different probes are synthetically 
attached (Lipshutz et al., 1999).  
Each probe is 25 nucleotide long, between 16-20 probe pairs representing one particular 
gene. These probes are synthesized in a basis of perfect match (PM) and mismatch 
(MM) basis.  The PM is designed to complementary hybridized to cRNA, while the 
MM is the same sequence as the PM except that only one single base in the middle is 
changed. 
Drosophila GeneChip 
array 
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The probe lengths should not be exceeded 25 nucleotides as problem of  non specific 
hybridization are expected to be found (Fodor et al., 1991) and (McGall et al., 1996).  
 
 
6.1.3  RNA quality control 
All RNA extracted samples should meet the highest quality standards to ensure the best 
hybridization on the gene-chip array to be achieved. In order to inspect the RNA quality 
a small amount of  each sample must be assessed by the RNA 6000 Nano assay on the 
Agilent  Bioanalyzer  (Agilent  Technology  UK.  Ltd)  to  examine  the  ribosomal RNA 
bands. The more intact the ribosomal RNA, the less RNA degradation has occurred.  
Sample absorbance should also be read at 260/280: acceptable readings are between 1.8 
to 2.1 for RNA. Readings below 1.8 indicate possible protein contaminations while 
readings above 2.1 indicate likely RNA degradation.  
 
6.2   Affymetrix microarray experiment  
Total 2 µg of RNA was reverse-transcribed and in vitro transcribed according to the 
standard  Affymetrix  protocol  to  produce  biotinylated complementary  RNA  (cRNA). 
Prior  to  the  reverse  transcription,  poly-A  RNA  controls  were  added  into  the  RNA 
samples before target labeling. Poly-A controls (lys, phe, thr and dap) function is to 
monitor the target labeling process from the beginning of the experiment to finish. They 
act as indicators of target preparation and labeling efficiency.  The cRNA was then 
purified  and  checked  for  integrity  (see  section    6.1.3  RNA  quality  control)  and 
fragmented.  Fragmented  cRNA  was  hybridized  to  Drosophila  genome  2  expression 
arrays (4 biological replicates per tissue). Hybridized probes were then stained using 
streptavidin  phycoerythrin  conjugate  and  scanned  with  an  Affymetrix  GeneChip 
Scanner 3000 7G. The overview of the GeneChip 3’ IVT express kit labelling assay is 
shown in Figure   6-2. An additional amplification step was used as necessary for RNA 
samples less than 2 µg in the two-round amplification protocol; the starting amount of 
RNA for the two-round amplification was typically 100 ng. 
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Figure    6-2  Overview  of  the  GeneChip  3'  IVT  express  labelling  assay  (taken  from 
www.affymetrix.com). 
 
6.2.1  Statistical analysis 
Experimental trascriptomes compared against the relevant controls to obtain t-test P-
values for the statistical significance for differential expression.  
For the advanced analysis and annotation, GeneSpring GX10 (Agilent UK) was used. 
Raw data (signal intensity) CEL files were obtained from the Affymetrix GCOS and 
uploaded into the GeneSpring for further data processing and analysis. In GeneSpring, 
data was analyzed in several sequential steps which include data processing,   153 
normalization, grouping, interpretation, quality control, statistical analysis and 
functional annotation. 
6.2.2  Functional annotation 
The DAVID Gene Ontology (GO) package was used to represent the data on an 
intuitive heat map and to functionally annotate using ontology terms. 
6.2.3  Fold change (FC) analysis 
Fold Change Analysis was used to identify genes with expression ratios or differences 
between a treatment and a control that are outside of a given cut-off or threshold. Where 
Fold change was used, it was calculated between a condition (Condition 1) and one or 
more other conditions (Condition 2) treated as an aggregate. The ratio between 
Condition 2 and Condition 1 is calculated (Fold change = Condition 1/Condition 2). 
Fold change gives the absolute ratio of normalized intensities (no log scale) between the 
average intensities of the samples grouped. The entities satisfying the significance 
analysis are passed on for the fold change analysis. 
6.3  Allopurinol drug  
Allopurinol, was one  of the drugs discovered at Burroughs Wellcome  program  that 
started in 1940s and was awarded the Nobel Prize in Physiology and Medicine in 1988 
(Pacher et al., 2006). The drug discovery project was meant to find potential antitumor 
drugs. However, subsequent experiments showed effective control of serum and urinary 
uric acid by allopurinol; and its direct metabolite, oxypurinol, showed promise for the 
treatment of hyperuricemia. In 1966, allopurinol was Food and Drug Administration 
(FDA) approved as treatment for gout and until now it is an important cornerstone in 
primary and secondary hyperuricemia management (Pacher et al., 2006).  
Many researchers have also suggested additional important roles for that XO in different 
types of ischemic and tissue and vascular injuries, inflammatory diseases, and chronic 
heart failure. Beneficial effects on the previously mentioned conditions were seen not 
only due to allopurinol but also from its metabolite, oxypurinol. Reviewed in (Harrison, 
2002) , (Harrison, 2004) and  (Berry and Hare, 2004).  
 
 
6.3.1  Pharmacokinetics 
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When  administered  orally,  allopurinol  is  rapidly  absorbed  and  reaches  peak 
concentration in plasma within 30 to 60 min. On the other hand oxypurinol has lower 
oral bioavailability than allopurinol. 
In terms of half-life, allopurinol has relatively short time in plasma approximately (2–3 
h),  whereas  the  half-life  of  oxypurinol  is  much  longer  (14–30  h)  due  to  renal 
reabsorption (Pea, 2005). 
Gastrointestinal  pain,  hypersensitivity  reactions  as  well  as  skin  rash  are  the  most 
common  side  effects    of  allopurinol  and  it  may  vary  from  individual  to  individual 
(Pacher et al., 2006).  
 
6.3.2  Mechanism of action 
 
Allopurinol  is  known  inhibitor  for  the  enzyme  xanthine  oxidase,  which  blocks  the 
metabolism of hypoxanthine and xanthine to uric acid.  It acts by interfering with the 
catabolism of purines resulting in lowering  uric acid production.  
Also its metabolite, oxypurinol acts as in a competitive inhibitor as it is an isomer of 
xanthine.  Thus  preventing  the  conversion  of  xanthine  to  uric  acid.  Also  as  indirect 
inhibition , oxypurinol inhibits the purine biosynthesis by stimulating negative feedback 
(Pacher et al., 2006).  
 
6.4  Aim 
We  applied  the  Affymetrix  Gene-chip  array  in  a  way  to  identify  the  effects  of 
allopurinol drug on the MT of wild type OR Drosophila melanogaster in a time-course 
experiment.  
Allopurinol was intended used to phenocopy the rosy mutant and to test any metabolic 
effects on the Drosophila melanogaster tubular transcriptome.  
Furthermore, the classical rosy mutant MT was also analyzed in comparison with the 
WT OR tubules.  
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6.5  Results 
6.5.1  Microarray results for rosy compared to wild type 
The main purpose of the microarray experiment was to compare the transcriptome of 5-
7 day adult Drosophila melanogaster wild type against rosy Malpighian tubules. The 
total numbers of genes significantly (P-value 0.05) changed were 8720, where 3368 
were up regulated while 5352 genes were down regulated. In order to narrow down the 
list, only genes two times fold changed up and/or down were selected. This gave a list 
of  total  1189  on  both  directions.  To  focus  the  analysis  more  tightly,  only  genes 
significantly changed five times were only listed in ( Table   6-1 and Table   6-2). 
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Table   6-1 Genes significantly down regulated in rosy compared to wild type.  Genes 
shown  here  are  ranked  by  their  fold  changed  down  regulated  expression  in  MT 
compared to WT, P< 0.05. 
 
Gene Symbol  P-value 
FC 
Absolute  Gene ontology biological process 
ry  7.3E-20  160.1   Determination of adult life span 
CG13313  8.2E-18  159.4    
CG14957  3.4E-06  37.3   Chitin metabolic process  
CG2781  2.9E-16  30.4   Fatty acid elongation  
DnaJ-1  6.0E-07  29.3   Protein folding  
CG9981  3.7E-16  19.9   Atp biosynthetic process  
Hsp70Ba, Bb, bb and Bc  4.3E-02  18.4   Response to stress  
RFeSP  1.6E-12  18.3   Mitochondrial electron transport 
Map205  3.1E-10  17.6   Microtubule-based process  
Hsp27  2.3E-02  14.2   Response to stress  
CG10924  4.8E-12  12.6   Gluconeogenesis  
CG18673  4.6E-06  12.5   One-carbon compound metabolic process  
CG12910  9.4E-12  11.6    
Hsp26  3.5E-02  11.2   Response to stress  
 1636495_at  4.7E-08  10.7    
CG13397  3.2E-15  10.5   Metabolic process  
Pepck  2.8E-05  10.4   Gluconeogenesis  
ninaD  1.7E-03  10.3   Defense response  
CG9149  2.8E-21  9.8   Metabolic process  
CG4288  7.0E-11  9.7    
CG32103  2.9E-06  9.1   Transport  
CG7968  2.6E-04  8.9    
alpha-Est7  1.6E-09  8.6    
CanA1  1.1E-08  8.3   Protein amino acid dephosphorylation  
CG3292  4.9E-08  8.0   Metabolic process  
CG14688  4.8E-11  7.7    
CG10657  1.2E-06  7.2   Transport    157 
CG14872  1.1E-04  7.0   Transport  
CG9360   1.2E-09  7.0   Metabolic process  
 1624819_s_at  2.1E-13  6.9    
CG15202  1.5E-13  6.6    
 1623349_x_at  1.4E-13  6.5    
CG14298   1.3E-11  6.4    
CG12734   2.0E-05  6.2    
CG14120  2.7E-07  6.1   Metabolic process  
 1639729_s_at  1.6E-13  5.9   RNA-dependent DNA replication  
Cyp4e1  8.3E-08  5.9   Oxidation reduction  
Ugt86Dd  3.7E-10  5.8   Metabolic process  
Hsp22  5.4E-03  5.7   Response to stress  
CG6495  5.0E-11  5.6    
CG32750  2.0E-06  5.5   Nitrogen compound metabolic process  
Lox  3.4E-06  5.4   Protein modification process  
Nha1  9.7E-05  5.4   Transport  
CG8147  4.6E-02  5.2   Metabolic process  
CG6448  3.5E-15  5.2    
mthl8  3.0E-11  5.0   Response to stress  
CG9989  2.9E-07  5.0    
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Table   6-2 Genes were up regulated in rosy compared to WT. 
 
Gene Symbol  p-value  FC  Gene Ontology Biological Process 
CG10140  3.8E-16  72.7  Chitin metabolic process  
Cht4  6.3E-10  60.0  Carbohydrate metabolic process  
AttD  2.4E-06  59.9  Antibacterial humoral response  
CG12009  1.6E-23  56.4  Chitin metabolic process  
CG30031   2.4E-07  55.3  Proteolysis  
Arc1  2.7E-07  38.4    
Adh   2.6E-15  36.1  Cellular alcohol metabolic process  
CG30090  9.7E-20  35.5  Proteolysis  
RpL35  1.1E-22  28.0  Mitotic spindle elongation  
TyrR  5.4E-25  27.8  Signal transduction  
regucalcin  2.3E-19  23.5    
CG6330  6.7E-13  22.4  Nucleoside metabolic process  
CG5091   3.5E-20  22.0  Protein amino acid N-linked glycosylation  
His4r  1.9E-20  20.0  Chromatin assembly or disassembly  
Act42A  3.6E-08  19.6  Cytokinesis  
Arc1   2.4E-19  18.9    
CG30154  6.3E-19  18.7    
CG14687  3.9E-11  17.5    
lectin-37Db  8.6E-06  17.0    
CG31997  8.1E-09  16.7    
CG9336  5.2E-10  16.4    
Rab40  1.0E-16  16.3  Intracellular signaling cascade  
CG9691  3.6E-09  15.2    
CG11671  6.0E-08  14.7      159 
cib  6.6E-14  14.5  Cytoskeleton organization  
CG15210  4.8E-07  14.0    
alpha-Man-I  2.1E-15  13.9    
yellow-d  7.5E-07  13.8  Protein amino acid N-linked glycosylation  
CG5541  1.6E-15  13.6    
CG8768  3.9E-13  12.9    
 1625050_s_at  5.6E-09  12.7  Metabolic process  
CG7191  9.3E-10  12.7    
CG6643  2.2E-06  12.6    
insc  2.0E-15  12.2  RNA localization  
unc-13  1.6E-16  12.2  Intracellular signaling cascade  
norpA  3.7E-23  11.7  Lipid metabolic process  
Tsp42Eh  2.7E-09  11.7    
 1627236_s_at  3.0E-16  11.6    
Mlp60A  2.4E-11  11.5  Multicellular organismal development  
CG7447  9.6E-19  11.4    
RpS29  3.4E-16  11.3  Translation  
CG9072  1.1E-22  11.0  Tubulin complex assembly  
CG7778  3.9E-06  10.6    
cib  7.4E-14  10.5  Cytoskeleton organization  
CG5011  2.3E-09  10.0    
Idgf1  4.9E-05  9.6  Carbohydrate metabolic process  
CG30026  6.3E-06  9.5    
fau  2.1E-13  9.5  Response to stress  
Pvf2  2.1E-07  9.0  Salivary gland morphogenesis  
CG13075  7.1E-07  9.0  Chitin metabolic process  
CG12780   1.1E-07  8.9    
CG5910  6.4E-05  8.7    
Sema-2a  1.5E-09  8.7  Multicellular organismal development    160 
Nrg  3.4E-11  8.4  Cell adhesion  
Bsg  4.2E-05  8.4  Spermatid development  
DptB  4.1E-04  8.4  Antibacterial humoral response  
Hsp60B   1.5E-16  8.2  Protein folding  
Cht8  3.4E-17  8.1  Carbohydrate metabolic process  
CG3973   4.8E-14  8.1  Cell cycle arrest  
CG7267  4.5E-15  8.1    
Mef2  8.3E-15  8.0  Transcription  
CG4757  4.3E-04  7.7    
fax  1.9E-08  7.6  Axonogenesis  
CG13117  5.2E-09  7.6    
CG12310  8.6E-06  7.5    
RpII215  2.1E-15  7.5  Transcription  
CG16743  9.3E-06  7.2    
Tsp42El  1.1E-09  7.1    
CG9784  5.3E-12  7.1  Dephosphorylation  
CG1077  1.4E-13  7.0    
CG1572  2.2E-07  7.0    
Akt1  2.0E-09  6.7  Protein amino acid phosphorylation  
CG1146  3.8E-07  6.5    
CG31158  6.9E-12  6.3  Regulation of ARF protein signal transduction  
PGRP-SA  1.9E-06  6.3  Defense response  
Sucb  9.0E-09  6.3  Tricarboxylic acid cycle  
Dcp2  5.2E-13  6.3  Nuclear-transcribed mRNA catabolic process 
trol  4.1E-12  6.2  DNA methylation  
Eip75B  3.7E-07  6.2  Transcription  
CG15347  2.0E-06  6.2    
lea  4.1E-10  6.1  Neuron migration  
smi35A  4.5E-14  6.1  Protein amino acid phosphorylation    161 
CG34104   3.5E-11  6.1  Chitin metabolic process  
HLHm3  3.6E-14  6.0  Negative regulation of transcription from RNA polymerase 
W  1.1E-10  6.0  Embryonic development via the syncytial blastoderm  
CG32687  4.9E-10  6.0    
CG9672  4.8E-12  6.0  Proteolysis  
Stlk  2.5E-14  6.0  Protein amino acid phosphorylation  
msn  2.5E-09  6.0  Activation of MAPKKK activity  
Ect4  5.2E-12  5.9  Immune response  
Ste12DOR   1.0E-14  5.9  Spermatogenesis  
Btd  5.4E-04  5.8  Nitrogen compound metabolic process  
CG12112  3.1E-13  5.8    
CG6959  4.6E-10  5.8    
CG9021  6.4E-16  5.8    
eIF-4B  1.1E-11  5.8  Translational initiation  
shi  1.1E-14  5.7  Cytokinesis  
sls  3.1E-07  5.7  Somitogenesis  
 1641367_at  7.9E-09  5.7    
 1635258_s_at  5.9E-10  5.7    
RpS30  1.3E-17  5.6  Mitotic spindle elongation  
CG5804  1.5E-05  5.5  Cellular acyl-coa homeostasis  
Pka-C1  2.4E-06  5.4  Protein amino acid phosphorylation  
Nrg  9.2E-12  5.4  Cell adhesion  
Tm1  3.3E-11  5.4  Muscle contraction  
Flo-2  2.7E-10  5.3  Cell adhesion  
 1625336_s_at  1.2E-15  5.3    
Imp  3.3E-12  5.2  Spermatogenesis  
CG32626  1.2E-10  5.2  Purine base metabolic process  
CG5630  7.0E-08  5.2    
MtnB  1.2E-11  5.2  Cellular metal ion homeostasis    162 
Eip93F  5.6E-06  5.1  Phagocytosis, engulfment  
CG7920  1.9E-09  5.1  Acetyl-coa metabolic process  
CG32512  5.0E-14  5.1    
Mctp  1.1E-10  5.1    
Scamp  7.5E-16  5.1  Protein transport  
CG42329  5.8E-15  5.1    
Sox100B  1.4E-18  5.1  Male gonad development  
CG31004  1.9E-10  5.0  Cell-matrix adhesion  
baz  3.1E-10  5.0  Cytokinesis  
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6.5.2  Reconciling array and metabolomic data for rosy 
 
Perhaps the key finding of the thesis is the attempt to reconcile these related, but distinct 
datasets. Metabolite changes were brought from the rosy chapter three, while genes 
annotations  and  pathway  were  from  the  KEGG  website  and  finally  the  microarray 
datasets from this chapter (Figure   6-3).  
The purine metabolic pathway is shown, along with changes occurring on the levels of 
metabolome and transcriptomic (Figure   6-3).  As it is known that rosy is defective in 
xanthine oxidase, its precursors accumulate, while urate is lowered. Consistent with the 
known  lesion  in  rosy,  the  array  data  show,  ry  was  down  regulated  160  times,  this 
allowed  to  xanthine  to  accumulate  25  times.  This  accumulation  has  a  concomitant 
impact on levels of xanthine precursors; hypoxanthine (15 times) and guanine (3 times).  
 
Upstream  expression  changes  ionclude  the  guanine  deaminase  (3.5.4.3)  was  found 
down regulated 2 and half times. Further above the CG16758 gene was found to be 
twice as normal indicating the perhaps as a result of urate low concentration, demanding 
for more urate. The CG11883 was lowered more than halved time as normal, and that 
could be hypothesized due to increased levels of adenine, hypoxanthine and guanine, 
the activation of the feedback inhibition of the enzyme by APRT and HGPRT (Figure 
  6-3) (Kamleh et al., 2008). 
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Figure   6-3 A combination of different datasets. This novel compined figure represents 
the  purine  metabolism  pathway  with  respect  to  integrated  metabolomic  as  well  as 
transcriptomic.  Triangl  shaped  denotes  or  represents  gene  affeted,  while  arrows 
represent metabolites changed. Red colour means reduced in level or downredulated and 
blue cloure means incresed in level or upregukated. The impact of rosy on the xanthine 
oxidase, urate is reduced, which proved by orbitrap. Consequently urate oxidase gene 
was 1.4 upregulated, this could be as a masage from allantoin ordering the the fly to 
produce more urate  in order  to be later  converted to  allantoin.  Futher effect  of the 
enzyme are accumulation of xanthine and hypoxanthine which shown by orbitrap to be 
25  and  15  fold  increased  repectevely.  The  effects  do  not  soley  on  xanthine  and 
hypoxanthine,  it  impacted  further  up  the  pathway  as  it  reaches  their  immediate 
precursers, for example adenine and guanin and futher up like adenosine, inosine and 
guanosine with a slightely leasser increas.  
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6.5.3  Microarray results for Allopurinol 
 
It has been thought phenocopying the rosy with allopurinol drug might have interesting 
effects  on  the  metabolomic  and/or  transcriptomic  levels.  Allopurinol  is  known  to 
phenocopy rosy (Keller and Glassman, 1965). 
In  the  microarray  dataset  for  allopurinol  experiment,  although  374  genes  showed 
changed expression, there was no clear pattern, and there were no significant effects on 
the key enzymes in the purine metabolic pathway Table   6-3.  
This may be because the effect of the drug was only transient on the metabolic level. By 
contrast,  the  rosy  mutant  is  lacking  xanthine  oxidase  enzyme  since  birth.  Thus  no 
beneficial effect found on the transcriptomic level when applying allopurinol on WT. 
 
Table   6-3 Significantly downregulated grouped genes in six hours allopurinol treated flies. 
Top changed groups   Group 
members  
Changed 
members  
P-value 
changed  
Percent 
changed  
Blood coagulation  3  2  8.9e-05  66.67 
Reduced folate carrier activity  3  2  7.4e-05  66.67 
Determination of adult lifespan  98  2  6.6e-05  2.04 
Response to stress  82  7  5.6e-12  8.54 
Response to unfolded protein  7  3  4.4e-08  42.86 
Heat shock-mediated polytene 
chromosome puffing 
7  3  4.4e-08  42.86 
Response to hypoxia  18  4  3.5e-09  22.22 
Protein refolding  7  2  2.3e-05  28.57 
Cell morphogenesis involved in 
neuron differentiation 
4  4  1.7e-04  100.00 
Folic acid binding  4  2  1.5e-04  50.00 
Response to heat  81  7  1.2e-11  8.64 
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WT vs 6h upregulated 
 
Top Changed Groups   Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
Immune response  98  7  9.7e-06  7.14 
RNA-directed DNA polymerase (reverse RT)  12  2  9.6e-05  16.67 
Regulation of protein import into nucleus  10  2  9.4e-06  20.00 
Eclosion rhythm  12  3  8.6e-07  25.00 
Innate immune response  98  8  7.9e-07  8.16 
Glutathione peroxidase activity  9  2  6.8e-05  22.22 
Circadian rhythm  42  4  6.0e-07  9.52 
Antibacterial humoral response  28  6  5.7e-08  21.43 
Gns1/sur4 membrane protein  3  2  5.3e-05  66.67 
Protein import into nucleus  23  2  5.2e-05  8.70 
Regulation of circadian sleep  20  3  4.4e-06  15.00 
Tata box binding protein associated factor  8  2  4.1e-05  25.00 
Negative regulation of oskar mRNA translation  9  3  4.0e-05  33.33 
Structural molecule activity  88  5  3.8e-05  5.68 
Locomotor rhythm  37  4  3.6e-07  10.81 
Rhythmic process  18  3  3.2e-06  16.67 
Vitellogenesis  9  3  3.1e-06  33.33 
Rhythmic behavior  20  4  2.7e-08  20.00 
Protein heterodimerization activity  58  4  2.2e-06  6.90 
Photoperiodism  2  2  2.1e-07  100.00 
Negative phototaxis  2  2  2.1e-07  100.00 
Circadian behavior  5  2  2.1e-06  40.00 
Mating behavior  15  3  1.8e-06  20.00 
Negative regulation of histone modification  2  2  1.5e-06  100.00 
Entrainment of circadian clock  14  3  1.4e-06  21.43 
Acyl carrier activity  9  2  1.4e-04  22.22 
Regulation of circadian sleep/wake cycle  4  2  1.3e-06  50.00 
Defense response to bacterium  20  3  1.3e-04  15.00 
L-phenylalanine catabolic process  4  2  1.3e-04  50.00 
Copulation  13  3  1.1e-06  23.08 
Perinuclear region of cytoplasm  27  3  1.1e-05  11.11 
Sleep  11  2  1.1e-05  18.18 
Sex differentiation  27  3  1.0e-04  11.11 
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6.6  Conclusion 
 
As it can be seen in this experiment, allopurinol did not elicit consistent significantally 
reliable  effects  on  the  wild  type  fly  in  the  microarray  experiment.  However,  when 
microarray data were analyzed using the MT of rosy mutant against the MT wild type , 
as expected the rosy gene came on the top of the list of the upregulated.  
 
What needs to be addressed here is the question why does allopurinol induce changes in 
the metabolome, but not in the transcriptome under the same conditions?. Experimental 
error  or  high  variability  in  analysis  are  possibilities.  Alternatively,  the  short-term 
blockade of the purine metabolism pathway may not induce the same transcriptomic 
changes as the lifelong knockdown associated with rosy
506 deletion. 
 
Several genes and metabolites were affected as a direct impact of rosy, both in the 
transcriptomic and on the metabolomic levels respectively. These changes are shown in 
Table   6-1, Table   6-1 and Table 3-2 and Figure   6-3. Pleasing, to my knowledge it was 
first time a mutant has been studied with both techniques. 
 
The ‘list of genes’ resulting from a microarray analysis should not be viewed as an end 
in itself; its real value increases only as that list moves through biological validation, 
ranging from the numerical verification of expression levels with alternative techniques. 
Sadly, time has limited us from further array analysis. 
 
   168 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7  Summary and discussion 
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7.1  Introduction 
IEMs are a group of diseases with a much higher incidence in some areas more than 
others,  due  to  factors  like consanguinity. Because  of  their  early  onset, severity  and 
frequently  devastating  consequences,  good  animal  models  are  highly  demanded. 
Investigations of IEMs in animal models might be very helpful in exploring insights in 
these types of diseases, mode of transmission and the way of tackling them and finding 
the  best  screening  and  /  or  efficient  diagnosis  methods.  However,  most  IEMs  have 
vanishingly  low  incidence  in  the  Western  world,  and  so  are  considered  ‘orphan 
diseases’ – the investments in mammalian models or in drug therapy research is not 
considered justified. Simpler models, and rapid and efficient development pipelines, are 
thus  highly  important  goals.  Drosophila  melanogaster is well known as  a powerful 
genetic model, and has excellent genetic tools - for example RNAi, UAS-GAL4 system. 
Other  key  benefits  include  its  small  size,  the  short  reproduction  time  and  fully 
sequenced genome.  
Another bottleneck is provided by screening technologies in humans, which historically 
have been ad hoc, and based on single disease diagnoses. The newly developed mass 
analyzer, the Orbitrap, has great potential in neonatal screening, because of its ability to 
identify 300-500 small metabolites in a single run from a single sample. This provides 
the opportunity both to streamline neonatal testing, and to expand the range of diseases 
that can be screened.  
In this thesis, I addressed both issues, by using the new Orbitrap to test Drosophila 
mutants homologous to IEM genetic loci in humans, for example xanthinuria type I.  
7.2  What was achieved? 
At the outset of the project, the Orbitrap was a brand-new instrument, and metabolomics 
was  almost  unknown in  Drosophila.  A  pilot  experiment  was  performed  on  extracts 
pooled from 10 flies, male and females using the ry
506 mutant. Initially we were testing 
the  validity  of  the  technology  by  looking  for  key  metabolite  changes  in  the  purine 
metabolic pathway which was a targeted rather than global metabolomic validation.  
As  expected,  the  rosy  mutant  revealed  what  was  historically  was  found.  Having 
obtained the expected results, the analyzer was challenged further, to see to what extent 
that it would be useful in specific fly tissues. Consequently, we carried out another 
experiment using different fly tissues, like heads and Malpighian tubules. Empirically, 
15-20 heads and tubules for 20-30 flies were found to give informative results.   170 
Findings were again consistent with microarray expression data, as ry is expressed in 
the whole fly, with higher levels particularly in MT.  
Then  we  decided  to  take  one  step  forward  in  the  analysis,  after  validating  the 
technology, the approach was extended to all metabolites that could be resolved in the 
Orbitrap. Thus, 
all  significantly changed metabolites detected were arranged into putative metabolic 
pathways. Changes shown in (Table 3-3) were very sensible. Significantly, changes in 
metabolite levels can be detected several metabolites further up from the genetic lesion 
than  had  been  detected  by  classical  analytical  biochemistry.  This  provided  that  the 
Orbitrap technology with great confidence has provided more information in a single 
experiment than could be obtained by classical techniques.  
Remarkably, some of significantly metabolic changes were quite unexpected, and not 
known from the extensive classical literature (over 500 papers) on rosy. For example, 
effects on the tryptophan pathway, which involved in Drosophila eye pigmentation, 
were  also  noticed.  This  explained  how  the  ry  eye  red-dull  colour  is  generated. 
Generally, the Drosophila eye colour is  constituted as a  result  of a mixture of  two 
pigment  colours.  Each  colour  is  generated  from  a  distinct  pathway.  Thus,  any 
disruptions in either pathway will impact on the Drosophila eye colour.  
 Another  unexpected  finding,  was  the  impact  on  osmolyte  biosynthesis.    This  was 
explained on the basis that ry mutants are unable to make uric acid in the absence of 
XDH, they excrete the nitrogen waste in other forms, perhaps as water-soluble xanthine. 
This process would be wasteful of water, leading to osmotic stress.  
These results were extended to a second mutant, maroon-like, which is necessary for the 
activation of both rosy and  other  molybdoenzymes. Maroon-like is  thus epistatic to 
rosy, and we accordingly observed a broader range of metabolic changes than in rosy. 
The work thus showed that it was possible not just to characterize a known mutant in 
Drosophila, but to extend the phenotypic description usefully, and to follow an epistatic 
series. 
We also applied the Orbitrap technology to characterise a genetic lesion for which the 
underlying gene was not known – the eye and tubule colour mutant chocolate. In the 
limited  time  available,  a  definitive  metabolomic  fingerprint  was  not  identified. 
However, with more work, it should be possible to perform such identifications more 
easily, and thus to provide a useful phenotype for reverse genetics of novel genetic loci.   171 
In summary, then, Drosophila is highly compatible with Orbitrap technology, and the 
results are highly informative for analysis of both known and novel loci. 
7.3  Drug action  
This technology was also challenged not only with mutants or specific tissues, but also 
to  follow  and  unravel  the  pharmacological  effects  of  drug  actions.  It  again  proved 
successful. We used the anti-gout drug allopurinol, which is considered to phenocopy 
the rosy mutant both in humans and flies. Confidently, effects on purine pathway were 
seen, however we also uncovered interference with  isomers -  an important issue in 
metabolic  analysis.    We  found  unexpected  behaviour  of  what  was  believed  to  be 
hypoxanthine and xanthine levels. However, later on we concluded these changes were 
as results of the hypoxanthine and xanthine isomers, the original drug allopurinol and its 
oxypurinol metabolite, respectively.  
7.4  Utility of Drosophila 
All of those experiments would not be conducted without the availability of an excellent 
genetic  animal  model  like  Drosophila  melanogaster.  It  has  clear  advantages  for 
studying  some  human  disease  genes,  based  on  the  rich  information  available  for 
researchers. For example, availability of the completed Drosophila genome sequence 
(Adams  MD,  2000),  the  tens  of  thousands  of  available  classical  mutants  in  stock 
centres, RNAi stocks for nearly every gene (Dietzl et al., 2007), and the FlyAtlas.org 
(Chintapalli et al., 2007) and Homophila (Reiter et al., 2001) websites. 
A transgenic fruit-fly line can be made for approximately $500 in only three months and 
costs $30 per year to maintain (Dow, 2007). It is also one of the best and powerful 
genetic  animal  models  being  used;  this  is  due  to  its  short  life  cycle,  which  allows 
multiple generations to be screened quickly. The small size of the insect makes it better 
than many other animal models in terms of space in the lab and food requirements.  
At the molecular level, balancers and P-elements provide powerful genetic tools for 
gene  transformation  and  phenotype  selection.  Interfering  RNA  is  also  one  of  the 
important  molecular  genetic  tools  which  helps  in  field  of  functional  genomics, 
specifically reverse genetics. 
Also, these findings have encouraged us to think of applying the technology to unlock 
the mysteries for thousands of Drosophila mutants in captivity in stock centres. Thus, 
we subjected the chocolate mutant to for further metabolic investigations. Moreover, the 
list could be expanded widely to other mutants in stock centres world wide.     172 
This new technology had helped us in addressing scientific questions fairly quickly and 
easily. It costs few dollars to run the samples which takes the technician less than 30 
minutes in sample preparations and analyzers set-up. Then the analyzer might be left 
overnight to carry the job. Then a few days of further analysis (depending on the depth 
of the needed detail) can finalize the results.  
The Drosophila, as genetic model, has its limitations as it is not mammalian; however 
with all the new technology and techniques continually emerging, the Orbitrap with 
great certainty will help in closing the phenotype gap between human and Drosophila. 
In  particular, this thesis  has shown  the usefulness  of Drosophila in  modelling  rare, 
Mendelian diseases of humans that might otherwise be considered too rare to attract 
major research funding. 
Moreover in the utility of this technology, one can integrate the wealth of Drosophila 
genetics and metabolomics in other branches that will be great impact to it. This is to 
measure the changes in development, drugs mode of actions and newly discovered drug 
usages and might also be used in insecticide and detoxifications studies.  
 
7.5  Utilization in humans 
 Certain inborn errors of metabolism (IEM) are far more common in some parts of the 
world  than  other  places  in  the  world,  and  neonatal  screening  must  thus  be  more 
comprehensive. These inborn errors of metabolism, which are recessively inherited, are 
attributed to the consanguineous marriages practiced in the Arab world, especially in a 
country like Saudi Arabia (Al-Odaib et al., 2003).  
In Saudi Arabia, in particular, consanguinity rates are about 50%, of which 60% are at a 
first-cousin level of consanguinity (El Mouzan et al., 2008); furthermore, the Kingdom 
is considered to have one of the highest birth rates in the Middle East and North Africa 
(Saadallah and Rashed, 2007). 
So premarital screening programmes for congenital diseases could help significantly to 
limit the incidence and impact of inborn errors of metabolism. 
Although premarital screening is an ideal solution, it is not always practical, socially 
acceptable  or  economic;  so  in  practice  both  diagnosis  and  treatment  must  also  be 
researched.  In  order  to  have  better  understanding,  and  to  improve  management  of 
human genetic disorders, good metabolic screening and fairly fast and reliable analyzer, 
like the Orbitrap, is desirable. Although we did not assay human samples in this project,   173 
we showed that the Orbitrap is ideal for detecting the metabolic changes associated with 
such mutations, and in samples far smaller than are likely to be available from human 
patients. 
 
The consanguinity has played an essential role which made the genetic diseases are 
certainly important, if not, the most important health problem in this part of the World. 
The  most  sensible  way  to  combat  this  problem  is  prevention.  Thus  we  found  the 
Orbitrap  is  very  sensitive,  quick,  and  cost-effective  when  applied  to  investigate 
Drosophila mutants in metabolic detections. So we concluded that the analyzer is a 
powerful technique that could be applied in the routine and as a screening for genetic 
diseases  preventions  in  the  Arab  world  where  consanguinity  constitutes  a  major 
problem  especially in  country  like Saudi Arabia where it reaches up to 50% of  all 
marriages.  
Usually, inborn errors of metabolism causing clinical manifestations in the neonatal 
period are severe and often lethal if early detection was not done and proper therapy is 
not initiated. Clinical findings in this period are usually non-specific and similar to those 
seen  in  infants  with  sepsis.  However,  it  has  been  shown  that  if  detected  early, 
complications  in  these  disorders  could  be  easily  prevented  with  restricted  dietary 
programmes or with early drug intervention.  
With the advanced mass spectrometer analyzers available today, like tandem MS and  
GC-MS , a proper diagnostic revolution may not be far away. The tandem MS alone can 
detect  35-40  metabolic  disorders  and  has  revolutionized  the  concept  of  newborn 
screening in the developed countries (Roa. et al, 2009). 
It is now possible to screen rapidly, simultaneously, and inexpensively for a number of 
very rare disorders with the use of tandem mass spectrometry, but some metaboloites 
would missed with such lower sensitivity when compaired to Orbitrap.  
For this reason, assessment for the diagnostic potential of this technology is required. 
To evaluate the technology fully, studies of the clinical effectiveness of screening and a 
detailed cost analysis will be necessary, compared with what already available  in the 
medical field. 
Recently, new techniques involving the IEM are creating many possibilities for clinical 
applications. Although theses techniques might still be years away from practical use, it 
certainly will join the field of expanding genetic applications. These technologies, will 
have a great impact on carrier screening, which is an integral part of preventive genetics   174 
programs. However, before commencing such programs, diseases should be carefully 
selected.  
For example, in Saudi Arabia ( Table   7-1 ) various rare metabolic diseases are screened 
at King Faisal Specialist Hospital and Research Centre, Riyadh, KSA (Al Odaib. et al 
2003). In the last year, standard Guthrie cards (heel prick blood samples) collected from 
every  newborn  in  Saudi  Arabia  (200  000+  annually),  are  sent  to  King  Faisal,  and 
subjected to a battery of tests (including two MS runs), specifically to identify IEMs. If 
the Orbitrap could simplify or streamline this testing, it could have a major impact. 
 
Table   7-1 Major IEMs seen at the King Faisal Specialist Hospital and Research Centre. Riyadh, Kingdom 
of Saudi Arabia (1998-2002) 
Disease category 
 
Disease name 
 
Organic acidemias 
(n= 294) 
 
Methylmalonic acidemia (n=72) 
Propionic acidemia (n= 56) 
Glutaric aciduria type 1 (n= 29) 
3-Hydroxy-3-Methyl Glutaryl CoA Lyase Deficiency (n=26) 
Other organic acidemias (n=111) 
 
Amino acid disorders 
(n= 223) 
 
Maple syrup urine disease (n=58) 
Classical phenylketonuria (n=33) 
Biopterin dependent phenylketonuria (n=29) 
Homocystinuria (n=33) 
Other amino acid disorders (n=70) 
 
Lysosomal storage 
disease (n=172) 
 
Niemann-Pick disease type B (n=36) 
Multiple sulfatase deficiency (n=30) 
Morquio’s disease (n=25) 
Sandhoff’s disease (n=19) 
Hurler-Scheie disease (n=18) 
Gaucher disease (norbottnian type) (n=8) 
Other lysosomal storage disease (n=36) 
 
The medications required for the management of certain inborn errors of metabolism are 
so costly that few can afford them. For example, the available injectable enzymes for 
Gaucher and Niemann-Pick diseases cost approximately $30,000 per year for an infant. 
Since the dose is according to body weight, it increases proportionally with growth. The   175 
same is true for the tetrahydrobiopterin cost for biopterin dependent PKU and for the 
Betaine required for homocystinuria (Al Odaib. et al 2003).  
Thus, the carrier screening for rare genetic screening with a powerful analyzer like the 
Orbitrap, should take the lead over others in the Arabian Peninsula, especially in society 
like Saudi Arabia. 
7.6  Metabolic modelling and systems biology 
Although the Orbitrap is important in diagnosis, the other aim is to improve treatment. 
How could Drosophila, and the easy availability of mutants, help here? Firstly, mutant 
flies could provide a sensitized background for a genetic screen to identify modifiers of 
the severity of the disease – this is a very standard Drosophila technique. Secondly, the 
same sensitized background could be used to screen for compounds which improve 
survival .Although this is not a high-throughput screen, it is much less expensive than 
working with mice or humans. Thirdly, our work in Drosophila could allow us to build 
systems  biology  metabolic  models  that  could  predict  the  impact  of  mutations,  and 
potentially predict possible therapies. 
This  lead  us  to  integrate  the  metabolites,  viewed  in  different  tissues  with  gene 
expression level in those individual tissues (Chintapalli et al., 2007), suggesting that it 
may ultimately be possible to build models linking transcriptome and metabolome. 
However, this is not easy as it sounds, as metabolomic analysis consists of different 
stages. The hardest part is the data analysis; it requires up-to-date speedy computers as 
well  as  continuously  cutting-edge  computational  skills  along  with  very  strong 
biochemistry background knowledge.  
7.7  Recommendations 
The metabolomic studies are very helpful and a powerful method, along with what is 
available from the transcriptomic datasets, in the biological fields, in the normal as well 
as in the disease status. There are tens of thousands of Drosophila mutants in stock 
centres all over the world. Many of these fly lines are kept for several years without 
knowing the genetic makeup or the metabolomic profiling.  
Thus we argue that using the power of the metabolic analysis (especially using the 
Orbitrap analyser) along with the transcriptomic data, scientists would be able to unlock 
the genetic mystery of many of the lines and perhaps human genetic diseases. 
Furthermore, there is a huge pressure for cost-effective programmes for rare but lethal 
genetic  diseases  (like  IEMs)  in  the  neonatal  and  perhaps  the  premarital  periods,   176 
especially in a society like the Kingdom of Saudi Arabia. For this we argue that the 
Orbitrap analyzer is sensitive, fast, cost effective and high throughput enough analyzer 
that could be applied both in diagnostics as well as in screening; it is not yet been used 
in the Kingdom.   177 
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8.1  Drosophila media 
Reagent  composition 
Standard fly food  Per 1 litre of water  
10 g agar 
15 g sucrose 
30 g glucose 
35 g dried yeast 
15 g maize meal 
10 g wheat germ 
30 g treacle 
10 g soya flour 
S.O.C Medium  2% Trypton 
0.5 % Yeast Extract 
10 mM NaCl 
10 mM Mg Cl2 
10 mM MgSO4 
20 mM glucose 
Schneider’s medium    
 
8.2  Plasmids and vectors 
Item  Conceteration 
pENTR/D TOPO vector  15-20 ng/µl linerized plasmid DNA in : 
50 % glycerol 
50 mM Tris-HCL, Ph 7.4 
1 mM EDTA 
2 Mm ddt 
0.1 % Triton x-100 
100 µl / ml BSA   179 
30 µM bromophenol blue    
dNTP Mix  12.5 mM dATP 
12.5 mM dCTP 
12.5 mM dGTP 
12.5 mM dTTP 
In water , pH 8 
TE buffer is a commonly used buffer solution in molecular biology, especially in 
procedures involving DNA or RNA. "TE" is derived from its components: Tris, a 
common pH buffer, and EDTA, a molecule chelating cations like Mg
2+. The purpose of 
TE buffer is to protect DNA or RNA from degradation.  
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8.3  Primers used in this thesis  
 
no 
Plasmid 
used 
Gene 
name 
F or R 
Primer name to 
paplo 
Full primer seqence incl res.t site  Restic. Enzyme used 
Ann. 
Temp 
Seg. 
Size 
1  pWIZ  ry  F  ROSY F1  GCATTCTAGACTACACAGATGACATTCCCCGC   Xba I 
2  pWIZ  ry  R  ROSY R1  GCATTCTAGAAAACGCTTGGCACGACAGAC  Xba I 
58.6  556 
3  pWIZ  ry  F  ROSY F2  GCATTCTAGATCGGAACTGATTCACATTTCGG  Xba I       
4  pWIZ  ry  R  ROSY R2  GCATTCTAGATTCACCCACTGCCTTGGAAGAG  Xba I       
5  pWIZ  uro  F  URO pWIZ F1  GCATTCTAGATCACAATGTTTGCCACGCCC   Xba I 
6  pWIZ  uro  R  URO pWIZ B1  GCATTCTAGATGAAGTCGCAGTTCCCTTGGAC  Xba I 
58.6  489 
7  pRISE  uro  F  URO pRISE F1  TCACAATGTTTGCCACGCCC    
8  pRISE  uro  R  URO pRISE B1  CACCTGAAGTCGCAGTTCCCTTGGAC    
58.6  489 
9  pWIZ  uro  F  URO pWIZ F2  GCATTCTAGAGCAAAAAGGATTACTACCAGGGC  Xba I       
10  pWIZ  uro  R  URO pWIZ B2  GCATTCTAGAACCACGGTGCTAAAGATGCG   Xba I       
11  pRISE  uro  F  URO pRISE B2  GCAAAAAGGATTACTACCAGGGC           
12  pRISE  uro  R  URO pRISE F3  CACCACCACGGTGCTAAAGATGCG           
13  pRISE  ry  F  ry_pRISE F1  CTACACAGATGACATTCCCCGC          
14  pRISE  ry  R  ry_pRISE B1  CACCAAACGCTTGGCACGACAGAC          
      F  M13 Forward   5’-GTAAAACGACGGCCAG-3’       
      R  M13 Reverse    5’-CAGGAAACAGCTATGAC-3’       
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8.4  Metabolomics of cho, an uncharacterized mutant 
The field of metabolomics has proven to give more insights in mutants for either novel 
or  unknown  metabolites  (Kamleh,  2008).  Previous  studies  have  been  done  on 
Drosophila  were  done  based  on  observational  analysis,  like  variation  in  eye  color 
pigmentation. This time we tried to use the metabolomic profiling in a way to reveal the 
cover  for  historically  known  mutants  without  exactly  knowing  what  is  the  genetic 
lesion, like the cho mutant fly. In this contest, we tested the cho mutant against the 
Oregon R to elucidate the genetic lesion causing this pigmentation variation.  
 
 
 
8.4.1  Cho Phenotypes 
 
 
Figure    8-1  Part  of  Malpighian  tubule  from  cho  mutant.This  picture  shows  the 
pigmentations in the MT in the cho mutant. 
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Figure   8-2 Four different flies showing different phenotypes. 
 
8.4.2  Metabolomic comparisons between cho  and Oregon R 
 
Table   8-1 The major metabolite differences between cho and OR. 
Sampled on two occasions (n=5) separated by five months (cho/OR). 
 
Compound  m/z  Ratio 1  P value 1  Ratio 2  P value 2 
Hydroxyproline  132.0656  1.92  0.010003  9.10  0.002113 
Proline betaine  144.102  0.17  0.000793  0.17  0.000094 
N-acetyl histamine  154.0976  0.42  0.011233  0.31  0.027323 
Xanthurenic acid  206.045  0.60  0.008469  0.43  0.000107 
Kynurenine  209.0923  0.49  0.001686  0.46  0.001774 
Hydroxytryptophan  221.0922  0.19  0.009653  0.28  0.000405 
Pyrimidodiazepine  222.0988  2.20  0.000021  1.50  0.024299 
Hydroxykyurenine  225.0872  0.27  0.000457  0.43  0.000116 
Dehydrobiopterin  236.078  3.06  0.000365  2.73  0.000104 
Formylkynurenine  237.087  0.34  0.007335  0.46  0.029471 
Biopterin 1  238.0937  1.72  0.013539  1.40  0.042726  
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Biopterin 2  238.0937  3.73  0.000013  2.68  0.001068 
Drosopterin  369.1533  0.37  0.002922  0.19  0.000215 
Xanthomattin  424.0647  1.61  0.157908  3.33  0.001808 
 
 
 
 
 
8.5  Metabolites List 
 
Formula  Compounds  MZ  Time  Ionization 
mode 
C2H3NO2  Iminoglycine  74.02365  19.47  positive 
C2H5NO2  Glycine  76.03931  19.92  positive 
C4H6O2  butanedione  87.04408  16.3  positive 
C4H6O2  butanedione  87.04409  18.82  positive 
C4H8O2  Butanoic acid  89.05979  8.299  positive 
C3H7NO2  Alanine  90.05495  19.85  positive 
C3H7NO2  Alanine  90.05498  18.84  positive 
C4H9NO2  GABA  104.0706  18.82  positive 
C5H14NO  Choline  104.107  19.4  positive 
C3H7NO3  L-Serine  106.0499  19.92  positive 
C4H11NO2  Diethanolamine  106.0863  20.91  positive 
C8H10  Ethylbenzene  107.0856  5.152  positive 
C6H4O2  p-Benzoquinone  109.0284  19.08  positive 
C4H5N3O  Cytosine  112.0506  20.22  positive 
C5H9N3  Histamine   112.087  29.12  positive 
CH5O4P  Hydroxymethylphosphonate  112.9999  17.44  positive 
C4H4N2O2  Uracil  113.0346  11.63  positive 
C6H8O2  cis-1,2-Dihydrobenzene-1,2-diol  113.0598  8.223  positive  
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C5H9NO2  L-Proline  116.0704  17.75  positive 
C8H7N  Indole  118.0652  14.67  positive 
C5H11NO2  valine  118.0862  18.03  positive 
C5H11NO2  glycine  betaine  118.0863  16.56  positive 
C4H9NO3  L-Threonine  120.0655  18.94  positive 
C8H9N  Indoline  120.0808  14.4  positive 
C3H7NO2S  L-Cysteine  122.0271  17.08  positive 
C8H11N  Phenethylamine  122.0966  14.86  positive 
C6H5NO2  Niacin/Nicotinate  124.0394  8.266  positive 
C2H7NO3S  Taurine  126.0218  18.28  positive 
C6H6O3  1,2,3-Trihydroxybenzene  127.039  20.34  positive 
C6H9NO2  2,3,4,5-Tetrahydropyridine-2-carboxylate  128.0708  6.455  positive 
C5H7NO3  Pyrroline-4-hydroxy-2-carboxylate  130.0499  18.49  positive 
C5H7NO3  Pyrroline-4-hydroxy-2-carboxylate  130.05  19.52  positive 
C6H11NO2  methylproline3  130.0863  25.43  positive 
C5H11N3O  guanidino butanal  130.0974  17.47  positive 
C6H10O3  beta-Ketoisocaproate  131.0703  8.223  positive 
C5H9NO3  Glutamate 5-semialdehyde  132.0656  18.42  positive 
C6H13NO2  L-Leucine  132.1018  14.92  positive 
C6H13NO2  L-Leucine  132.1019  15.96  positive 
C4H8N2O3  L-Asparagine  133.0608  19.92  positive 
C4H7NO4  L-Aspartate  134.0448  19.14  positive 
C4H7NO4  L-Aspartate  134.0449  5.472  positive 
C5H5N5  Adenine  136.0618  14.66  positive 
C5H4N4O  Hypoxanthine  137.0458  11.82  positive 
C5H4N4O  Hypoxanthine  137.0459  17.84  positive 
C8H8O2  Phenylacetic acid  137.0597  8.049  positive 
C10H16  alpha-Pinene  137.1326  5.028  positive 
C7H7NO2  4-Aminobenzoate  138.055  17.75  positive 
C6H6N2O2  Urocanate  139.0503  15.99  positive  
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C2H8NO4P  Ethanolamine phosphate  142.0264  21.28  positive 
C7H13NO2  Proline Betaine  144.1019  16.58  positive 
C8H16O2  Octanoic acid  145.1224  5.964  positive 
C6H11NO3  Amino-3-oxohexanoic acid  146.0812  25.45  positive 
C5H11N3O2  guanidino butyric acid  146.0923  17.17  positive 
C7H16NO2+  acetylcholine 1+  146.1176  17.28  positive 
C7H16NO2+  acetylcholine 1+  146.1177  16.27  positive 
C5H10N2O3  Glutamine  147.0764  19.48  positive 
C6H14N2O2  L-Lysine  147.1129  25.41  positive 
C5H9NO4  glutamate  148.0604  18.62  positive 
C5H9NO4  N-Acetyl-L-serine  148.0606  5.364  positive 
C6H12O4  (R)-Pantoate  149.0806  19.48  positive 
C8H7NO2  Indole-5,6-quinone  150.055  14.65  positive 
C5H11NO2S  L-Methionine  150.0583  15.82  positive 
C6H7N5  Methyladenine  150.0774  17.67  positive 
C6H6N4O  Methylhypoxanthine  151.0617  15.82  positive 
C5H5N5O  Guanine   152.0567  13.3  positive 
C8H9NO2  (Z)-4-Hydroxyphenylacetaldehyde-oxime  152.0706  16.19  positive 
C5H4N4O2  Xanthine  153.0407  11.23  positive 
C7H11N3O  N-acetylhistamine   154.0974  18.21  positive 
C6H9N3O2  L-Histidine  156.0766  24.7  positive 
C6H7NO4  2-Aminomuconate  158.0448  9.729  positive 
C6H12N3O2+  Guanidine proline+  158.0925  16.48  positive 
C4H6N4O3  (S)(+)-Allantoin  159.0513  15.31  positive 
C8H17NO2  2-amino octanoic acid 1  160.1332  16.56  positive 
C8H17NO2  2-amino octanoic  acid 2  160.1332  12.85  positive 
C9H7NO2  indole carboxylic acid1  162.055  10.01  positive 
C6H11NO4  O-Acetyl-L-homoserine  162.0762  15.9  positive 
C7H16NO3  Carnitine  162.1123  18.42  positive 
C6H10O3S  Dihydroxy-5-(methylthio)pent-1-en-3-one  163.0423  9.162  positive  
  186 
C6H10O5  3,3-Dimethylmalate  163.0601  18.29  positive 
C6H5N5O  pterin  164.0566  13.09  positive 
C5H11NO3S  L-Methionine S-oxide  166.0532  19.44  positive 
C9H11NO2  L-Phenylalanine  166.0863  14.38  positive 
C5H4N4O3  Urate  169.0356  14.33  positive 
C7H11N3O2  1-Methylhistidine  170.0925  24.9  positive 
C3H9O6P  Glycerolphosphate  173.0209  18  positive 
C10H8NO2  Quinaldic acid  174.0551  14.65  positive 
C6H14N4O2  L-Arginine  175.1187  25.47  positive 
C6H9NO5  N-Formyl-L-glutamate  176.0554  9.753  positive 
C7H13NO4  Spermidic acid  176.0918  15.85  positive 
C6H13N3O3  L-Citrulline  176.1029  20.19  positive 
C6H5N5O2  Isoxanthopterin  180.0517  13.16  positive 
C6H13NO5  D-Galactosamine  180.0867  20.39  positive 
C6H7N5O2  Dihydroxanthopterin  182.0673  13.25  positive 
C9H11NO3  L-Tyrosine  182.0811  16.61  positive 
C5H15NO4P+  Choline phosphate+  184.0734  24.33  positive 
C8H14N2O3  Ala-Pro  187.1078  19.08  positive 
C9H21N3O  N-acetylspermidine  188.1758  28.15  positive 
C8H16N2O3  N6-Acetyl-L-lysine  189.1233  15.62  positive 
C9H20N2O2  7,8-Diaminononanoate  189.1597  25.89  positive 
C10H7NO3  Kynurenic acid  190.0499  8.743  positive 
C7H11NO5  N-Acetyl-L-glutamate  190.0711  8.793  positive 
C7H14N2O4  meso-2,6-Diaminoheptanedioate  191.1027  19.15  positive 
C10H9NO3  5-Hydroxyindoleacetate  192.0656  14.73  positive 
C9H11NO4  DOPA  198.0761  18.94  positive 
C12H25NO  Dodecanamide  200.201  5.401  positive 
C12H25NO  Dodecanamide  200.201  12.9  positive 
C9H17NO4  O-Acetylcarnitine  204.1227  15.43  positive 
C11H12N2O2  L-Tryptophan  205.0973  15.07  positive  
  187 
C8H16N2O4  Val Ser  205.1183  19.04  positive 
C8H16N2O4  Val Ser  205.1184  23.99  positive 
C10H7NO4  Xanthurenic acid  206.0447  10.18  positive 
C10H12N2O3  L-Kynurenine  209.0921  14.73  positive 
C10H11NO4  4-Hydroxyphenylacetylglycine  210.0761  17.11  positive 
C13H10O3  Dihydroxyfluorene-9-one  215.0696  18.7  positive 
C2H8NO4P  phosphoethanolamine  216.0633  19.44  positive 
C9H16N2O4  gamma-Glutamyl-gamma-aminobutyraldehyde  217.1185  8.269  positive 
C8H16N4O3  Acetylarginine  217.1295  18.62  positive 
C10H19NO4  Propionyl carnitine  218.1388  14.43  positive 
C9H17NO5  Pantothenate  220.1177  8.169  positive 
C9H17NO5  Pantothenate  220.1181  6.523  positive 
C11H12N2O3  5-Hydroxy-L-tryptophan  221.0921  14.63  positive 
C8H15NO6  Pyrimidodiazopterin  222.0985  12.09  positive 
C7H14N2O4S  L-Cystathionine  223.0747  23.35  positive 
C10H12N2O4  3-Hydroxy-L-kynurenine  225.087  16.2  positive 
C13H20O3  Methyl jasmonate  225.1487  5.266  positive 
C14H29NO  Myristamide  228.2322  5.372  positive 
C11H20N2O3  Leu-Pro  229.1547  16.56  positive 
C11H20N2O3  Leu-Pro  229.1547  15.19  positive 
C11H20N2O3  Leu-Pro  229.1548  14.14  positive 
C14H31NO  Dodecyldimethylamine oxide   230.2479  11.62  positive 
C11H21NO4  Butyrylcarnitine  232.1544  13.72  positive 
C10H22N2O4  1,1,3-tris(ethoxymethyl)urea  235.1653  17.98  positive 
C9H9N5O3  dehydrosepiapterin  236.0777  10.75  positive 
C11H12N2O4  N-Formylkynurenine  237.087  14.86  positive 
C9H11N5O3  Biopterin1  238.0936  14.33  positive 
C9H11N5O3  Biopterin2  238.0936  11.21  positive 
C9H13N5O3  Dihydrobiopterin  240.1091  15.21  positive 
C12H20N2O3  Pirbuterol  241.1547  16.69  positive  
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C6H11O8P  Inositol cyclic phosphate  243.0265  19.14  positive 
C6H11O8P  Inositol cyclic phosphate  243.0265  20.32  positive 
C9H13N3O5  Cytidine  244.0929  20.28  positive 
C9H12N2O6  Uridine  245.0769  11.63  positive 
C10 H20O3 N4  Ethyl-Acetyl-Arginine  245.1609  16.45  positive 
C14H31NO2  N,N-bis(butoxymethyl)-2-methylpropan-2-
amine 
246.2429  12.64  positive 
C6H15N4O5P  phosphoarginine  255.0854  23.7  positive 
C11H14N2O5  glycyl-dopa  255.0977  19.86  positive 
C16H33NO  palmitamide  256.2632  5.315  positive 
C8H20NO6P  GPC  258.1098  21.35  positive 
C6H14NO8P  D-Glucosamine 6-phosphate  260.0531  19.17  positive 
C6H13O9P  Glucose phosphate  261.0371  19.22  positive 
C6H13O9P  Fructose phosphate  261.0371  20.29  positive 
C11H20N2O5  Glutamyl-leucine  261.1445  14.35  positive 
C9H12NO6P  Tyrosine phosphate  262.0475  20.68  positive 
C12H17N4OS+  thiamine(+) 2  265.1116  28.17  positive 
C10H13N5O4  Adenosine  268.104  14.59  positive 
C10H13N5O4  Deoxyguanosine  268.1041  13.59  positive 
C10H12N4O5  Inosine  269.0881  12.85  positive 
C15H12O5  narigenin  273.0752  18.45  positive 
C10H17N3O6  Glu-gln  276.1189  19.3  positive 
C18H28O2  Stearidonic acid  277.2161  5.057  positive 
C18H30O2  (9Z,12Z,15Z)-Octadecatrienoic acid  279.2322  5.031  positive 
C11H15N5O4  Methyl adenosine  282.1198  18.88  positive 
C18H35NO  Oleamide  282.2794  5.286  positive 
C10H13N5O5  Guanosine1  284.099  14.91  positive 
C10H13N5O5  Guanosine2  284.099  15.93  positive 
C17H37NO2  C17 sphinganine  288.2897  11.83  positive 
C18H30O3  17-Hydroxylinolenic acid  295.2271  5.031  positive 
C11H15N5O3S  5'-Methylthioadenosine  298.0967  11.92  positive  
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C18H37NO2  Dehydrosphinganine(Sphingosine)  300.2893  11.93  positive 
C10H17N3O6S  GSH  308.0908  17.55  positive 
C12H24N2O7  Fructosyllysine  309.1657  25.4  positive 
C12H18N6O4  2-aminodimethyladenosine  311.1465  24.85  positive 
C16H29NO5  Butoctamide semisuccinate  316.2113  12.99  positive 
C16H29NO5  Butoctamide semisuccinate  316.2119  14.01  positive 
C19 H43 O2 N  C19 sphinganine  316.3209  11.65  positive 
C9H14N3O8P  cytidine monophosphate  324.0593  21.01  positive 
C9H13N2O9P  uridine monophosphate  325.0434  17.15  positive 
C12H20O10  Difructose anhydride isomer  325.113  17.71  positive 
C12H20O10  Difructose anhydride isomer  325.1131  19.22  positive 
C10H12N5O6P  c AMP  330.0602  16.34  positive 
C11H15N2O8P  Nicotinamide D-ribonucleotide  335.0638  20  positive 
C10H15N4O7P  2'-Deoxyinosine 5'-phosphate  335.0738  19.09  positive 
C9H14N5O7P  Dihydroneopterin phosphate  336.0695  19.9  positive 
C18 H29O3 N3  Histidine lipid  336.2282  12.48  positive 
C11H19N3O7S  S-(Hydroxymethyl)glutathione  338.1016  18.08  positive 
C18 H29 O3 N3  Hisitidine lipid  338.2437  12.38  positive 
C22H44ON  Dodecamide  338.3414  5.152  positive 
C12H22O11  Sucrose  343.1234  18.3  positive 
C10H13O7N5P  cGMP  346.0547  16.2  positive 
C10H14N5O7P  AMP isomer 2  348.0703  20.14  positive 
C10H14N5O7P  AMP isomer 2  348.0703  19.11  positive 
C10H13N4O8P  IMP  349.0544  17.9  positive 
C19H34O5N  C19H34O5N  356.2432  5.434  positive 
C18H37N4O3  C18H37N4O3  358.2952  6.526  positive 
C20 H31 O3 N3  guanidinosphingolipid  362.2434  12.29  positive 
C10H14N5O8P  GMP  364.0654  19.66  positive 
C20 H33 O3 N3  C20-guanidino phytosphingolipid  364.2586  12.13  positive 
C15H16N10O2  drosopterin  369.1531  20.4  positive  
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C17H20N4O6  Riboflavin  377.1455  10.42  positive 
C12H21PN5O7  C12H20PN5O7  378.1159  19.71  positive 
C14H17N5O8  Succinyladenosine  384.1151  11.89  positive 
C28H42O  Ergosta-5,7,22,24(28)-tetraen-3beta-ol  395.3311  5.697  positive 
C23H45NO4  L-Palmitoylcarnitine  400.3422  11.6  positive 
C20H13N3O8  Xanthomattin  424.0776  14.57  positive 
C25H45NO4  Linolenylcarnitine  424.342  11.59  positive 
C25H47NO4  Linolylcarnitine  426.3575  11.56  positive 
C13H22N4O8S2  S-Glutathionyl-L-cysteine  427.0951  22.68  positive 
C10H15N5O10P2  ADP  428.0368  24.42  positive 
C25H49NO4  Oleoylcarnitine  428.3733  11.47  positive 
C11H20N4O11P2  CDP-ethanolamine  447.0678  22.04  positive 
C14H18N5O11P  N6-(1,2-Dicarboxyethyl)-AMP  464.0813  17.1  positive 
C21H41O7P  DHAP(18:0)  478.2923  10.85  positive 
C18H32O16  Raffinose  505.1765  18.32  positive 
C17H27N3O17P2  UDP-N-acetyl-D-glucosamine  608.0888  20.95  positive 
C21H28N7O14P2+  NAD+  664.1163  20.58  positive 
C24H42O21  Stachyose  667.229  18.32  positive 
C37H72NO8P  PE(18:0/14:1(9Z))  690.5064  9.469  positive 
C37H72NO8P  PE(18:0/14:1(9Z))  690.5067  6.503  positive 
C40H75O10P  PG(16:0/18:2(9Z,12Z))  747.5167  8.266  positive 
C30H52O26  Cellopentaose  829.2809  20.43  positive 
C3H4O3  pyruvic acid  87.00881  7.547  Negative 
C3H6O3  Lactic acid  89.02444  7.774  Negative 
C3H6O3  beta lactic acid   89.02446  6.755  Negative 
C3 H6 O4  Glycolic acid  105.0194  7.285  Negative 
C4H4O4  Fumaric acid   115.0038  7.513  Negative 
C4H6O4  Succinic acid   117.0193  8.096  Negative 
C4H8O4  Erythrose  119.0351  16.72  Negative 
C5H6O4  Glutaconic acid  129.0194  12  Negative  
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C5H8O4  pentanedioic acid  131.0351  6.239  Negative 
C4H7NO4  2-aminobutanedioic acid  132.0303  19.04  Negative 
C4H6O5  malic acid  133.0143  10.62  Negative 
C5H10O4  Deoxyribose  133.0507  8.16  Negative 
C4H8O5  Erythronic acid  135.03  6.829  Negative 
C5H6O5  Oxoglutaric acid  145.0143  8.493  Negative 
C6 H10O4  Adipic acid  145.0507  6.359  Negative 
C5H8O5  Citramalic acid  147.0299  9.055  Negative 
C6H12O4  Mevalonic acid  147.0663  8.158  Negative 
C5H10O5  pentose  149.0457  12.47  Negative 
C8H8O3  3,4-Dihydroxyphenylacetaldehyde   151.0401  5.445  Negative 
C5H12O5  D-Xylitol  151.0613  15.15  Negative 
C7H12N2O3  Glycylproline  153.067  6.378  Negative 
C5H4N2O4  Orotic acid  155.01  12.4  Negative 
C7H11NO3  Tiglylglycine  156.0667  24.82  Negative 
C5H4O3  Furoic acid  157.0143  9.632  Negative 
C6H8O5  Oxoadipic acid  159.03  11.92  Negative 
C8H16O3  (R)-2-Hydroxycaprylic acid  159.1027  5.557  Negative 
C5H6O6  Hydroxyoxoglutaric acid  161.0092  6.415  Negative 
C5H10O6  Arabinonic acid  165.0406  15.56  Negative 
C9H10O3  Homovanillin  165.0558  5.774  Negative 
C8H8O4  3,4-Dihydroxymandelaldehyde  167.035  5.686  Negative 
C3H6O6P  Glyceraldehyde phosphate  168.991  17.8  negative 
C3H9O6P  Glycerol 3-phosphate  171.0064  17.81  Negative 
C6H6O6  -Aconitic acid  173.00925  10.166  Negative 
C6H8O6  Ascorbic acid  175.0248  9.632  Negative 
C6H10O6  3-Keto-b-D-galactose  177.04051  11.915  Negative 
C6H12O6  hexose  179.05612  16.717  Negative 
C6H12N2O3  D-Alanyl-D-alanine  181.06035  16.717  Negative 
C6H14O6  hexitol  181.07184  15.92  Negative  
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C4H9NO5S  Homocysteic acid  182.01288  9.449  Negative 
C7H8O6  cis-2-Methylaconitate  187.02487  8.392  Negative 
C6H8O7  Isocitric acid  191.01979  12.073  Negative 
C7H12O6  Quinic acid  191.05626  13.916  Negative 
C6H12O7  Gluconic acid  195.05104  16.507  Negative 
C10H11NO  Tryptophanol  196.05437  16.378  Negative 
C8H15N3O4  N-a-Acetylcitrulline  198.08852  18.437  Negative 
C8H16N2O5  N-Acetyl-b-glucosaminylamine  201.08812  9.219  Negative 
C8H7NO4  2-Methyl-3-hydroxy-5-formylpyridine-4-
carboxylate 
202.01241  19.827  Negative 
C7H10O7  Homocitric acid  205.03539  10.442  Negative 
C13 H20 O2  4-heptoxyphenol  207.13905  5.244  Negative 
C6H13NO5  Fructosamine  214.04868  19.37  Negative 
C4H11O3PS  Diethylthiophosphate  215.01419  11.972  Negative 
C5 H13 O7 P  2-C-methyl-D-erythritol 4-phosphate  215.03276  16.147  Negative 
C5H14NO6P  Glycerylphosphorylethanolamine  215.05588  8.008  Negative 
C9H9NO4  3-Hydroxyhippuric acid  216.02798  19.049  Negative 
C3H9O6P  Glycerol 3-phosphate  217.01196  17.828  Negative 
C10H12O4  Homoveratric acid  217.04832  15.969  Negative 
C6H10N3O4P  4-Amino-2-methyl-5-phosphomethylpyrimidine  218.03294  16.147  Negative 
C9H17NO5  Pantothenic acid  218.10339  8.135  Negative 
C9H11N5O2  2'-Deoxysepiapterin  220.08405  10.98  Negative 
C11H13NO3  N-Acetyl-L-phenylalanine  228.06442  23.292  Negative 
C3H8NO8P  Glycero Phosphoserine  230.00722  19.04  Negative 
C4H10NO8P  Glycero Phosphothreonine  244.0229  18.604  Negative 
C15H22O3  2-Ethylhexyl 4-hydroxybenzoate  249.14967  5.123  Negative 
C10H14N2O6  3-Methyluridine  257.07813  7.862  Negative 
C15H14O6  Epicatechin  271.06067  18.41  Negative 
C12H15NO5  Acetylvanilalanine  274.06995  23.288  Negative 
C16H22O4  Alpha-CEHC  277.14453  4.688  Negative 
C7H15O10P  Sedoheptulose 7-phosphate  289.03314  19.235  Negative  
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C17H26O4  Gingerol  293.1759  5.266  Negative 
C10H16NO3PS  Aminoparathion  306.05798  11.504  Negative 
C9H19O11P  1-(sn-Glycero-3-phospho)-1D-myo-inositol  333.05933  18.967  Negative 
C11H16N2O8  N-Acetylaspartylglutamic acid  349.08893  9.445  Negative 
C15H20O10  3-Methoxy-4-hydroxyphenylglycol glucuronide  359.09836  8.14  Negative 
C12H23NO10  Lactosamine  376.1015  19.595  Negative 
C18H38NO5P  Sphingosine 1-phosphate  424.24701  11.056  Negative 
C20H30O5  15-Keto-prostaglandin E2  387.15781  8.115  Negative 
C21H18O8  7-Deoxyadriamycinone  397.09323  16.154  Negative 
C23H37NO5  Columbiananin  406.25998  5.311  Negative 
C22H37NO3  Leukotriene B4 dimethylamide  408.27533  5.255  Negative 
C28H42O2  (R)-gamma-Tocotrienol  409.31128  5.023  Negative 
C23H43NO6  Hexadecanedioic acid mono-L-carnitine ester  410.2908  5.216  Negative 
C30H44O2  Demethylphylloquinone  436.33414  3.995  Negative 
C21H42NO7P  LysoPE(16:1(9Z)/0:0)  450.26251  10.86  Negative 
C21H44NO7P  LysoPE(16:0/0:0)  452.27805  10.946  Negative 
C22H44NO7P  LysoPC(14:1(9Z))  464.27829  10.82  Negative 
C23H42NO7P  LysoPE(18:3(9Z,12Z,15Z)/0:0)  474.26263  10.86  Negative 
C23H46NO7P  LysoPE(18:1(9Z)/0:0)  478.29315  10.724  Negative 
C26H22Cl2N2O3  Doconazole  479.09366  18.953  Negative 
C29H42O4  Ubiquinone Q4  489.2774  3.742  Negative 
C12H23NO4  Isovalerylcarnitine  489.31845  13.843  Negative 
C18H32O16  trihexose  503.16193  19.143  Negative 
c ADP  C15H21N5O13P2  540.05359  20.522  Negative 
C36H71NO3  Ceramide (d18:1/18:0)  600.51221  5.124  Negative 
C30H60NO6P  CerP(d18:1/12:0)  606.41406  9.572  Negative 
C20H32N6O12S2  Oxidized glutathione  611.14362  21.851  Negative 
C33H66NO8P  PE(14:0/14:0)  634.44574  9.228  Negative 
C24H42O21  tetrahexose  665.21472  19.558  Negative 
C43 H44O19  pentahexose  863.2428  20.56  Negative  
  194 
C31 H50 O19 N7 
P3 S 
3-Isopropenylpimelyl-CoA  948.20209  19.01  Negative 
C43H83O13P  PI(16:0/18:0)  859.53168  8.212  Negative 
C41H75O13P  PI(16:2(9Z,12Z)/16:0)  805.48651  8.252  Negative 
C42H70NO10P  PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)  778.46576  8.324  Negative 
C42H74NO10P  PS(20:4(5Z,8Z,11Z,14Z)/16:0)  782.49701  8.324  Negative 
C45H76NO8P  PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))  788.52441  5.564  Negative 
C45H78NO8P  PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)  790.53967  5.557  Negative 
C45H76NO7P  PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:1(9Z))  808.5061  8.272  Negative 
C14H25NO11  N-Acetyllactosamine  811.284  19.439  Negative 
C44H78NO8P  PC(18:4(6Z,9Z,12Z,15Z)/18:1(9Z))  824.54431  11.238  Negative 
C43H81O13P  PI(18:1(9Z)/16:0)  857.51697  8.212  Negative 
C43H82O16P2  PIP(18:1(9Z)/16:0)  897.48956  10.044  Negative 
C45H82O16P2  PIP(18:3(6Z,9Z,12Z)/18:0)  921.48926  9.83  Negative 
C47H83O13P  PI(22:4(10Z,13Z,16Z,19Z)/16:0)  923.50531  10.061  Negative 
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